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Abstract 
 
Identification of mutations in the mismatch repair genes of hereditary non-polyposis colorectal 
cancer (HNPCC) families can lead to improved management and screening of affected family 
members. This study aimed to characterise the mutation profile of MLH1 and MSH2 in a South 
African colorectal cancer cohort. Twenty patient samples were screened for mutations in MLH1 and 
MSH2 using Sanger sequencing and Multiplex Ligation-dependent Probe Amplification (MLPA). Three 
previously reported pathogenic mutations were found using Sanger sequencing, two in MLH1 (c.454-
13A>G and c.731_734delGTTA) and one in MSH2 (c.2006-6T>C). Six novel variants were detected 
using Sanger sequencing, two in MLH1 and four in MSH2. Further investigation of the novel variants 
strongly suggests that one variant in MLH1 (c.885-1G>A) is pathogenic and two have an unknown 
contribution towards disease. Molecular diagnostic screening of mutations in MLH1 and MSH2 has 
the potential to improve surveillance and management of HNPCC in South Africa.  
 
 
 
 
 
 
 
  
v 
 
Acknowledgements 
 
I would like to acknowledge the following for their contributions towards this study: 
 
The funding sources that made this research possible: 
 NHLS Research Trust 
 Wits Faculty Research Committee 
 
The laboratories that provided valuable input: 
 Regional Molecular Genetics Service at Manchester Academic Health Science Centre, St 
Mary’s Hospital, Manchester  
 Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury 
 National Health Laboratory Service Molecular Genetics Laboratory, Department of Human 
Genetics, Braamfontein 
 National Health Laboratory Service Molecular Diagnostic Division, Department of Human 
Genetics, Braamfontein 
 
My supervisors: 
 Prof. Amanda Krause 
 Dr. Robyn Kerr 
 
Shelley Macaulay and the genetic counsellors at the NHLS, Braamfontein 
 
 
 
 
  
vi 
 
Contents 
Declaration .............................................................................................................................................. ii 
Dedication .............................................................................................................................................. iii 
Abstract .................................................................................................................................................. iv 
Acknowledgements ................................................................................................................................. v 
List of Tables .......................................................................................................................................... xi 
List of Figures ........................................................................................................................................ xii 
Abbreviations ........................................................................................................................................xiv 
1. Introduction .................................................................................................................................... 1 
1.1. Cancer ..................................................................................................................................... 1 
1.1.1. Multi-step Tumourigenesis ............................................................................................. 3 
1.2. Genetics of Cancer .................................................................................................................. 3 
1.2.1. Oncogenes....................................................................................................................... 3 
1.2.1.1. Oncogene Activation ................................................................................................... 3 
1.2.2. Tumour Suppressor Genes .............................................................................................. 4 
1.2.2.1. Silencing of TSGs ......................................................................................................... 4 
1.2.2.2. Knudson’s Two Hit Hypothesis .................................................................................... 4 
1.2.3. Stability Genes ................................................................................................................ 5 
1.3. Hereditary Cancer ................................................................................................................... 6 
1.3.1. Familial Adenomatous Polyposis .................................................................................... 7 
1.3.2. HNPCC ............................................................................................................................. 7 
1.3.2.1. Features of HNPCC ...................................................................................................... 8 
1.3.2.2. Variations o ............................................................................................................... 10 
1.3.2.3. Diagnostic Guidelines for HNPCC .............................................................................. 10 
1.3.2.3.1. Amsterdam Criteria ................................................................................................... 10 
1.3.2.3.2. Amsterdam II Criteria ................................................................................................ 11 
1.3.2.3.3. Bethesda Guidelines ................................................................................................. 12 
1.3.2.3.4. Revised Bethesda Criteria ......................................................................................... 13 
1.3.3. Nomenclature: HNPCC or Lynch Syndrome? ................................................................ 13 
1.4. Mismatch Repair Genes ........................................................................................................ 14 
1.4.1. MLH1 ............................................................................................................................. 14 
1.4.2. MSH2 ............................................................................................................................. 15 
1.4.3. MSH6 ............................................................................................................................. 15 
1.4.4. PMS2 ............................................................................................................................. 16 
vii 
 
1.4.5. Recurrent and Founder Mutations ............................................................................... 16 
1.4.6. Functions of the MMR Genes ....................................................................................... 17 
1.4.7. Mechanism of Tumourigenesis in HNPCC ..................................................................... 18 
1.4.7.1. Coding Microsatellites............................................................................................... 18 
1.4.7.2. Apoptosis .................................................................................................................. 19 
1.4.8. Tissue Specificity of HNPCC ........................................................................................... 19 
1.5. Ethnic Group Differences in CRC Compared to Caucasians .................................................. 20 
1.5.1. Asians ............................................................................................................................ 21 
1.5.2. African Americans ......................................................................................................... 21 
1.5.3. Africans ......................................................................................................................... 21 
1.5.3.1. South African Black Population ................................................................................. 22 
1.6. Genetic Testing for HNPCC ................................................................................................... 22 
1.6.1. MSI Testing .................................................................................................................... 22 
1.6.2. Immunohistochemistry ................................................................................................. 23 
1.6.3. Direct Sequencing and MLPA ........................................................................................ 24 
1.6.4. Improved Clinical Management .................................................................................... 25 
1.6.5. Diagnostic Services ........................................................................................................ 25 
1.7. Aims and Objectives .............................................................................................................. 26 
2. Subjects, Materials and Methods ................................................................................................. 27 
2.1. Subjects ................................................................................................................................. 29 
2.1.1. Samples Present in the Laboratory ............................................................................... 29 
2.1.2. Sample Collection through the Clinical Diagnostic Service ........................................... 29 
2.1.3. Summary of Samples Collected for Study ..................................................................... 30 
2.1.4. Control Samples ............................................................................................................ 31 
2.1.5. Ethics Approval ............................................................................................................. 31 
2.2. Materials and Methods ......................................................................................................... 31 
2.2.1. Multiplex Ligation-dependent Probe Amplification Analysis ........................................... 31 
2.2.2. Polymerase Chain Reaction............................................................................................... 33 
2.2.2.1. PCR Primers for PCR Reactions ................................................................................. 33 
2.2.2.2. PCR Conditions for DNA Amplification ...................................................................... 34 
2.2.2.3. Agarose Gel Electrophoresis of PCR Products .......................................................... 34 
2.2.2.4. PCR Product Clean Up ............................................................................................... 34 
2.2.3. Sanger Sequencing ............................................................................................................ 35 
2.2.3.1. Universal Primers for Sanger Sequencing ................................................................. 35 
viii 
 
2.2.3.2. Sanger Sequencing Product Clean Up ....................................................................... 36 
2.2.3.3. The 3130xl Genetic Analyser ..................................................................................... 37 
2.2.4. Mutation Analysis of Sequencing and MLPA Data ............................................................ 37 
2.2.4.1. Sanger Sequencing Data Analysis ............................................................................. 37 
2.2.4.2. MLPA Data Analysis ................................................................................................... 38 
2.2.4.3. Determining Reporting History of Variants .............................................................. 38 
2.2.5. Determining Pathogenicity of Novel Variants................................................................... 39 
2.2.5.1. Restriction Fragment Length Polymorphism Analysis .............................................. 40 
2.2.5.1.1. RFLP Conditions ......................................................................................................... 41 
2.2.5.1.2. RFLP for MLH1 Variants ............................................................................................ 41 
2.2.5.1.3. RFLP Analysis for MSH2 Variants .............................................................................. 41 
2.2.5.2. High Resolution Melt Analysis .................................................................................. 42 
2.2.5.3. FASTSNP .................................................................................................................... 44 
3. Results ........................................................................................................................................... 45 
3.1. MLPA Analysis for MLH1 and MSH2 ..................................................................................... 45 
3.2. Variants detected using Sanger Sequencing ......................................................................... 45 
3.2.1. Variants Detected in MLH1 ........................................................................................... 47 
3.2.1.1. Previously Reported Non-Pathogenic Variants in MLH1 .......................................... 47 
3.2.1.2. Previously Reported Pathogenic Variants in MLH1 .................................................. 47 
3.2.1.2.1. The MLH1 c.454-13A>G Splice Mutation .................................................................. 49 
3.2.1.2.2. The MLH1 c.731_734delGTTA Frameshift Mutation ................................................ 49 
3.2.1.3. Novel Variants Detected in MLH1 ............................................................................. 50 
3.2.2. Variants Detected in MSH2 ........................................................................................... 51 
3.2.2.1. Positive Control ......................................................................................................... 51 
3.2.2.2. Previously Reported Non-Pathogenic Variants in MSH2 .......................................... 52 
3.2.2.3. Previously Reported Pathogenic Variants in MSH2 .................................................. 53 
3.2.2.4. Novel Variants Detected in MSH2 ............................................................................. 53 
3.2.3. Summary of Variants Detected by Sanger Sequencing ................................................. 55 
3.3. Determining Pathogenicity of the Novel Variants ................................................................ 55 
3.3.1. Restriction Fragment Length Polymorphisms ............................................................... 55 
3.3.1.1. MLH1 c.885-1G>A variant ......................................................................................... 55 
3.3.1.2. MSH2 c.-185C>A variant ........................................................................................... 56 
3.3.1.3. MSH2 c.1662-43C>T variant ...................................................................................... 56 
3.3.1.4. MSH2 c.1662-10C>T variant ...................................................................................... 56 
ix 
 
3.3.2. High Resolution Melt Analysis ...................................................................................... 57 
3.3.2.1. MLH1 c.1732-19T>A variant...................................................................................... 57 
3.3.2.2. MSH2 c.367-16T>A variant ....................................................................................... 57 
3.3.3. FASTSNP Analysis .......................................................................................................... 58 
3.3.4. Summary of Investigation of Pathogenicity for Novel Variants .................................... 59 
3.4. Characterising the Mutation Spectrum ................................................................................ 59 
3.4.1.1. Variants Separated by Ethnicity ................................................................................ 59 
4. Discussion ...................................................................................................................................... 62 
4.1. Patients Fulfilling Inclusion Criteria ...................................................................................... 62 
4.1.1. Clinical Management of HNPCC Patients ...................................................................... 63 
4.2. MLPA Analysis ....................................................................................................................... 64 
4.3. Variants Detected using Sanger Sequencing ........................................................................ 64 
4.3.1. Number of Variants in Study Cohort ............................................................................. 65 
4.3.2. Previously Reported Variants in MLH1 ......................................................................... 66 
4.3.2.1. The MLH1 c.655A>G (pIle219Val) variant ................................................................. 66 
4.3.2.2. The MLH1 c.731_734delGTTA variant ...................................................................... 66 
4.3.3. Previously Reported Variants in MSH2 ......................................................................... 67 
4.3.3.1. The MSH2 c.1811C>A (p.Ala604Asp) variant ............................................................ 67 
4.3.3.2. The MSH2 c.2006-6T>C mutation ............................................................................. 67 
4.3.3.3. The MSH2 c.573C>T (p.Leu191Leu) variant .............................................................. 68 
4.4. Determining the Pathogenicity of the Novel Variants .......................................................... 68 
4.4.1. The MLH1 c.885-1G>A mutation .................................................................................. 68 
4.4.2. The MLH1 c.1732-19T>A variant ................................................................................... 69 
4.4.3. The MSH2 c.-185C>A variant ........................................................................................ 69 
4.4.4. The MSH2 c.367-16T>A variant .................................................................................... 69 
4.4.5. The MSH2 c.1662-10C>T variant ................................................................................... 70 
4.4.6. The MSH2 c.1662-43C>T variant ................................................................................... 70 
4.4.7. CRC in Patients with No Pathogenic Mutations ............................................................ 70 
4.4.8. Molecular Diagnostic Screening of HNPCC Patients ..................................................... 71 
4.5. Characterising the Mutation Spectrum ................................................................................ 72 
4.5.1. Mutation Spectrum of MLH1 ........................................................................................ 72 
4.5.2. Mutation Spectrum of MSH2 ........................................................................................ 72 
4.5.3. Mutation Spectrum with regard to Ethnicity ................................................................ 72 
4.5.4. Mutation Spectrum of Pathogenic Mutations .............................................................. 72 
x 
 
4.6. Limitations and Future Directions ......................................................................................... 73 
5. Conclusion ..................................................................................................................................... 76 
Appendix A: Cancer Statistics ............................................................................................................... 78 
Appendix B: Solutions ........................................................................................................................... 83 
Appendix C: Consent Forms .................................................................................................................. 85 
Appendix D: Ethics Clearance Certificate .............................................................................................. 90 
Appendix E: PCR Primers for MLH1 and MSH2 ..................................................................................... 91 
Appendix F: Protocols Used .................................................................................................................. 97 
F.1 MLPA Protocol ............................................................................................................................. 97 
F.2 Protocol for MLPA on the 3130xl Genetic Analyser .................................................................... 98 
F.3 PCR Reaction and cycling conditions ......................................................................................... 100 
F.4 Minelute 96 UF PCR Purification Kit Protocol ........................................................................... 101 
F.5 Nucleospin Extract II Clean-up Protocol:................................................................................... 101 
F.6 Sanger Sequencing .................................................................................................................... 101 
F.7 DyeEx 96 Dye-Terminator Removal Protocol ............................................................................ 102 
F.8 DyeEx 2.0 Dye-Terminator Removal Modified Protocol ........................................................... 102 
F.9 Protocol for Sanger Sequencing using the 3130xl Genetic Analyser ........................................ 103 
F.10 Retrieval of Data...................................................................................................................... 104 
F.11 Using the LOVD InSiGHT Database .......................................................................................... 105 
F.12 High Resolution Melt Procedure ............................................................................................. 106 
Appendix G: Patient Pedigrees ........................................................................................................... 107 
Appendix H: Suppliers of Equipment and Reagents ........................................................................... 109 
References: ......................................................................................................................................... 110 
Electronic References ......................................................................................................................... 116 
 
 
  
xi 
 
List of Tables 
Table 1.1: Lifetime Risk of Individual Cancers in Families with an Identified MMR Mutation ............... 8 
Table 1.2: Percentage of HNPCC cases caused by mutations in each MMR gene ................................ 14 
Table 1.3: Founder mutations of MLH1 and MSH2 found in different populations ............................. 17 
Table 2.1: Summary of the patients and their inclusion criteria .......................................................... 30 
Table 2.2: Restriction enzymes used to investigate the frequencies of the novel variants ................. 40 
Table 2.3: Summary of the RFLP reactions for all enzymes .................................................................. 41 
Table 3.1: Summary of all variants detected in each patient in MLH1 ................................................. 46 
Table 3.2: Summary all variants detected in each patient in MSH2 ..................................................... 46 
Table 3.3: Summary of the previously reported non-pathogenic variants in MLH1 that were detected 
in the South African cohort ................................................................................................................... 48 
Table 3.4: Summary of the previously reported pathogenic variants that were detected in MLH1 in 
the South African cohort ....................................................................................................................... 48 
Table 3.5: Summary of the novel variants detected in MLH1 in the South African cohort .................. 50 
Table 3.6: Summary of the previously reported non-pathogenic variants in MSH2 in the South African 
cohort .................................................................................................................................................... 52 
Table 3.7: Summary of the reporting history for the previously reported pathogenic mutation in 
MSH2 detected in this study ................................................................................................................. 53 
Table 3.8: Summary of the novel variants detected in MSH2 in this study .......................................... 53 
Table 3.9: Summary of the allele frequencies that were determined by RFLP for each variant .......... 55 
Table 3.10: Summary of allele frequencies for the two variants that were investigated using HRM .. 58 
Table 3.11: Adaptation of the FASTSNP results for the MSH2 c.-185C>A variant. ............................... 59 
Table 3.12: Summary of the pathogenic status for the seven novel variants detected in the South 
African cohort ....................................................................................................................................... 59 
Table 3.13: Summary of the variants and the ethnic groups they were detected in. .......................... 60 
Table 3.14: Summary of patients and the pathogenic mutations found in this study ......................... 61 
Table 4.1: Summary of mutation detection rates from previous studies which were investigating 
MLH1 and MSH2 ................................................................................................................................... 65 
Table A.1: Estimated global incidence of cancer for both genders of all ages ..................................... 78 
Table A.2: Estimated global cancer mortality for both sexes of all ages .............................................. 79 
Table A.3: Summary rates for top 5 cancers in South Africa by sex ..................................................... 81 
Table A.4: Summary statistics for colorectal cancer, 1998 and 1999 ................................................... 82 
Table E.1: PCR Primers for MLH1 and PCR Product Sizes ..................................................................... 91 
Table E.2: PCR primers for MSH2 and the PCR product sizes. .............................................................. 92 
Table E.3: DNA Sequence of MLH1 ....................................................................................................... 93 
Table E.4: DNA Sequence of MSH2 ....................................................................................................... 95 
Table F.1: Hybridisation Mix for MLPA Technique ................................................................................ 97 
Table F.2: Ligation mix for MLPA Technique ......................................................................................... 97 
Table F.3: Pre-PCR reaction mix for MLPA Technique .......................................................................... 97 
Table F.4: Polymerase Mix for MLPA Technique .................................................................................. 98 
Table F.5: PCR Conditions for MLPA Technique .................................................................................... 98 
Table F.6: PCR reaction mix used for amplification of all exons for 1X reaction ................................ 100 
Table F.7: PCR conditions for amplification of all reactions ............................................................... 100 
Table F.8: Sanger Sequencing PCR Reaction mix ................................................................................ 102 
Table F.9: Cycle Sequencing PCR Protocol .......................................................................................... 102 
xii 
 
Table F.10: HRM master mix that was used for all HRM reactions .................................................... 106 
Table H.1: Table of Suppliers of Equipment and Reagents ................................................................. 109 
 
 
List of Figures 
Figure 1.1: Phenotypic Features of HNPCC ............................................................................................. 9 
Figure 1.2: Amsterdam Criteria for the Clinical Diagnosis of HNPCC .................................................... 11 
Figure 1.3: Amsterdam II Criteria used for the Clinical Diagnosis of HNPCC ........................................ 11 
Figure 1.4: Bethesda Guidelines for Genetic Testing of MMR Genes ................................................... 12 
Figure 1.5: Revised Bethesda Guidelines for Genetic Testing of MMR Genes ..................................... 13 
Figure 1.6: Diagram showing how the MMR proteins interact to repair mismatches in the DNA ....... 19 
Figure 2.1: Flow Diagram outlining the approach and actions taken in this study .............................. 28 
Figure 2.2: The MLPA reaction. ............................................................................................................. 32 
Figure 2.3: Schematic representation of PCR and sequencing reactions in this study ......................... 36 
Figure 2.4: Diagram of the expected RFLP analysis using HpyCH4III to screen for the MLH1 c.885-
1G>A variant ......................................................................................................................................... 41 
Figure 2.5: Diagram showing the expected RFLP fragments when TaqI is used to investigate the 
MSH2 c.1662-10C>T variant ................................................................................................................. 42 
Figure 2.6: Diagram showing the expected RFLP fragments when RsaI is used to investigate the 
MSH2 c.1662-43C>T variant ................................................................................................................. 42 
Figure 2.7: The expected RFLP fragments when MluI is used to investigate the MSH2 c.-185C>A 
variant located within the regulatory region ........................................................................................ 43 
Figure 2.8: The HRM normalised melting curve obtained from control samples................................. 43 
Figure 3.1: The MLPA result generated using the spread sheet from NGRL. ....................................... 45 
Figure 3.2: The MLH1 c.655A>G variant (p.I219V), which leads to a missense mutation, in exon 8 ... 47 
Figure 3.3: The MLH1 c.454-13A>G variant of intron 5 found in Patient 104 ...................................... 49 
Figure 3.4: The variant data obtained from LOVD for the MLH1 c.731_734delGTTA variant .............. 49 
Figure 3.5: The MLH1 c.731_734delGTTA mutation in exon 9 ............................................................. 50 
Figure 3.6: The MLH1 c.885-1G>A novel variant located within splice acceptor site of intron 10. ..... 50 
Figure 3.7: The MLH1 c.1732-19T>A novel variant that was detected in intron 15 ............................. 51 
Figure 3.8: The MSH2 c.1811C>A novel variant in exon 12. ................................................................. 52 
Figure 3.9: The MSH2 c.2006-6T>C pathogenic variant of intron 12 .................................................... 53 
Figure 3.10: The MSH2 -185C>A novel variant in the regulatory region .............................................. 54 
Figure 3.11: The MSH2 c.367-16T>A novel variant of intron 2. ............................................................ 54 
Figure 3.12: The MSH2 c.1662-43C>T novel variant located within intron 10 ..................................... 54 
Figure 3.13: The MSH2 c.1662-10C>T novel variant located within intron 10. .................................... 54 
Figure 3.14: RFLP analysis with HpyCH4III performed on patient 81 ................................................... 56 
Figure 3.15: RFLP gel picture from using TaqI to investigate the MSH2 c.1662-10C>T variants in 
patients 235 and 238. ........................................................................................................................... 57 
Figure 3.16: The HRM normalised melting curve for the assay of MLH1 c.1732-19T>A variant .......... 58 
Figure A.1: Percentage distribution of 10 most common cancers in South Africa by gender, 1998 and 
1999, all ages (NCR, 2004) .................................................................................................................... 80 
xiii 
 
Figure G.1: The pedigree for black patient 205 .................................................................................. 107 
Figure G.2: Pedigree for black patient 235. ........................................................................................ 107 
Figure G.3: Pedigree for black African patient 238 ............................................................................. 107 
Figure G.4: Pedigree for patient 136................................................................................................... 108 
Figure G.5: The pedigree for patient 150 where the MSH2 c.1811C>A variant was found ............... 108 
 
  
xiv 
 
Abbreviations 
 
5’      Five Prime  
3’      Three Prime  
%     Percentage  
α      Alpha 
µ     Micro 
µg     Microgram 
µl     Microlitre 
A     Adenosine 
APC     Adenomatous Polyposis Coli 
ASR     Age Standardized Rate 
bp     Base-Pair 
C     Cytosine 
cm     Centimetre 
CRC     Colorectal Cancer  
dATP      Deoxyadenosine-5’-Triphosphate  
dbSNP     Single Nucleotide Polymorphism Database 
dCTP      Deoxycytidine-5’-Triphosphate  
ddH2O     Double Distilled Water 
dGTP      Deoxyguanosine-5’-Triphosphate  
dNTP      Deoxyribonucleotide Triphosphate  
dTTP     Deoxythymidine-5’-Triphosphate 
DNA     Deoxyribonucleic Acid 
EDTA      Ethylenediaminetetra-Acetic Acid  
EtBr      Ethidium Bromide  
FAP     Familial Adenomatous Polyposis 
xv 
 
FASTSNP Functional Analysis and Selection Tool for Single Nucleotide 
Polymorphisms 
G     Guanine 
HNPCC     Hereditary Non-Polyposis Colorectal Cancer 
HRM     High Resolution Melt 
IARC     International Agency for Research on Cancer 
IHC     Immunohistochemistry 
kb      Kilobases  
LOVD     Leiden Open Variation Database 
M     Molar  
MgCl2      Magnesium Chloride  
MLH1     mutL Homolog 1 
MLPA     Multiplex Ligation-dependent Probe Amplification 
MMR     Mismatch Repair 
mRNA     Messenger RNA 
MSH2     mutS Homolog 2 
MSI     Microsatellite Instability 
MSI-H     High microsatellite instability 
MSI-L     Low microsatellite instability 
n     Nano 
NCR     National Cancer Registry 
ng      Nanograms 
NGRL     National Genetics Reference Laboratory 
NHLS      National Heath Laboratory Service  
PCR     Polymerase Chain Reaction 
PMS1     Postmeiotic Segregation 1 
PMS2     Postmeiotic Segregation 2 
RFLP     Restriction Fragment Length Polyorphism 
xvi 
 
RNA     Ribonucleic Acid 
Rpm     Revolutions per Minute 
SOP     Standard Operating Procedure 
T     Thymine 
Taq     Thermus aquaticus 
TBE     Tris, Boric Acid, EDTA 
TE     Tris-EDTA 
tRNA     Transfer RNA 
U     Units 
V     Volts 
WHO     World Health Organization 
 
1 
 
1. Introduction 
Cancer generally affects older people, as internal and external risk factors accumulate over a period 
of time that lead to a cell growth advantage (Vogelstein and Kinzler, 2004). However, there are 
cancer syndromes that co-segregate within families that affect younger individuals. A clear pattern 
of inheritance has been described for colorectal cancer (CRC) and many cancers (Garber and Offit, 
2005).  One such cancer syndrome is hereditary non-polyposis colorectal cancer (HNPCC), which is 
the focus of this study.  
 
Section 1.1 will provide a description of cancer and the processes that lead to tumourigenesis before 
briefly describing the incidence and mortality rates of cancer. The genetic basis of cancer and the 
role of specific classes of genes in tumourigenesis will be covered in Section 1.2. Section 1.3 will then 
focus on hereditary cancer before leading into hereditary CRC. HNPCC and the features of the 
disease will be described in Section 1.3 as well as the variations of HNPCC, the clinical criteria for the 
diagnosis and nomenclature for the disease.  
 
HNPCC is caused by defects in the mismatch repair (MMR) genes. The MMR genes, their functions 
and role in cancer predisposition will be described in Section 1.4. Because there are different ethnic 
groups that are included in this study, the differences among the ethnic groups relative to CRC in 
Caucasians will be described in Section 1.5. The methods for molecular detection of HNPCC by will 
be described in Section 1.6. Finally, this study was established to characterise the mutation spectrum 
of HNPCC in South Africa since it has not been well characterised in South Africa. Characterisation of 
the mutation spectrum will allow for the establishment of molecular diagnostic testing in South 
Africa, which will be necessary to provide a better healthcare service to South Africans. Since MLH1 
and MSH2 account for approximately 90% of HNPCC mutations, these genes were chosen to be 
screened first for mutations. The aims and objectives of this study are stated in Section 1.7. 
 
1.1. Cancer 
Cancer is a disease characterized by the uncontrolled growth of cells within the body, usually leading 
to the formation of a tumour. These ‘rogue’ cells are also able to spread to other parts of the body 
where they invade other tissues in a process known as metastasis. It is the two characteristics of 
uncontrolled growth and the ability to spread throughout the body that define a cell as cancerous 
(Alberts et al., 2002).  
 
According to Ferlay et al. (2010), in 2008, there were approximately 12.7 million new cases of cancer 
and there were approximately 7.6 million deaths worldwide, 64% of which occurred in developing 
nations. The most common cancers worldwide are lung cancer, breast cancer, CRC and prostate 
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cancer. This information can be found at GLOBOCAN (http://globocan.iarc.fr). This study will focus 
on CRC which accounted for 1.2 million cases of all the cancer in 2008. The global incidence and 
mortality statistics for cancer can be seen in Appendix A, under Tables A.1 and A.2. 
 
CRC is the third most diagnosed cancer in males and the fourth most diagnosed cancer in females. In 
2008, there were approximately 609 000 deaths from CRC among both sexes at all ages. It is also 
indicated that more males develop CRC than females, perhaps due to differences in risk factors 
(Ferlay et al., 2010; Cunningham et al., 2010). There are several changing risk factors, such as diet 
and obesity that are leading to increasing incidence in many developing nations (Cunningham et al., 
2010; Jemal et al., 2011).  
 
As CRC is one of the most common cancers in the world, its early identification and management is 
important in order to lower mortality. Early detection strategies aim to identify a tumour before it 
grows too large and metastasises, which is vital for preventing mortality. Evidence of the success of 
this strategy can be seen by the lower mortality rate in developed countries where early detection 
and treatment is available (Etzioni et al., 2003; Cunningham et al., 2010; Jemal et al., 2011).  
 
Detecting a tumour before it grows too large is important, but how does a tumour grow? Tumour 
growth is not caused by one single factor but rather by a series of factors that interact with the cell 
that leads toward uncontrolled growth. These contributing factors are internal (DNA mutations, 
hormones and immune responses) and external (UV light, tobacco, and infectious organisms) to the 
cell (Strachan and Read, 2004). When these factors interact they lead to mutations in the DNA of a 
cell. As mutations accumulate in the cell, normal functioning becomes disrupted in the proliferation, 
apoptosis or repair pathways (Vogelstein and Kinzler, 2004).  
 
A cell colony that grows uncontrollably will lead to the development of a neoplasm, which comes 
from the Greek for ‘new growth’. A neoplasm that does not invade surrounding cells but is still 
dividing rapidly is considered to be a benign tumour. Benign tumours can be removed easily with 
surgery depending on the tumour position and the patient has a vastly improved prognosis if a 
benign tumour is recognised and removed before it becomes malignant (Alberts et al., 2002; Etzioni 
et al., 2003). 
 
However, the prognosis for a patient decreases as the cell colony progresses from a benign tumour 
to a malignant tumour. A malignant tumour is one that is localised but has invaded the surrounding 
tissues (Alberts et al., 2002; Etzioni et al., 2003). It is often the metastasic effect of a tumour on the 
body that leads to death (Nguyen et al., 2009). The progression from a normal cell, to a benign 
neoplasm and finally to a malignant tumour is a feature of cancer known as multi-step 
tumourigenesis. 
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1.1.1. Multi-step Tumourigenesis 
Multi-step tumourigenesis can be described using observations from the colorectal tract in a process 
known as the adenoma-carcinoma sequence. An adenoma, which is a benign tumour, can develop 
after several mutations have accumulated in different genes. However, the adenoma may never 
acquire the further mutations necessary to develop into a carcinoma (malignant tumour). 
Conversely, the adenoma could develop into a carcinoma very quickly if the necessary mutations are 
acquired in a short space of time (Cunningham et al., 2010).  
 
In this way, CRC exemplifies the theory that cancer requires many different processes and mutations 
to occur before a tumour becomes malignant. Hence, multiple steps are required for a neoplasm to 
develop into a malignant tumour (de la Chapelle, 2004). However, once a tumour becomes 
malignant it is able to metastasise. 
 
1.2. Genetics of Cancer 
There are three main classes of genes involved in cancer development: oncogenes, tumour 
suppressor genes and stability genes.  
 
1.2.1. Oncogenes 
The oncogenes are genes that increase the number of cells by stimulating cell growth. The genes 
involved in normal promotion of cell proliferation are referred to as proto-oncogenes in the cell. 
However, the term oncogene is ascribed to these genes when they acquire mutations that lead to 
activation (Strachan and Read, 2004; Vogelstein and Kinzler, 2004). 
 
Oncogenes’ role in cancer development is through control of proliferation pathways, including the 
secretion and reception of growth factors, signal transduction systems, transcription factor and cell 
cycle regulators (Strachan and Read, 2004; Vogelstein and Kinzler, 2004; Croce, 2008; Boland and 
Goel, 2010). There are over 100 known oncogenes vital for normal growth and development. A lack 
of function of these genes would prevent a group of cells from growing (Alberts et al., 2002; 
Vogelstein and Kinzler, 2004). The activation of these genes can lead to excessive gene products or 
production of modified/novel products. Since oncogenes exhibit dominant effects, the activation of 
one allele is necessary for tumourigenesis (Strachan and Read, 2004; Vogelstein and Kinzler, 2004).  
 
1.2.1.1. Oncogene Activation 
There are three means by which oncogenes can be activated within the cell. Amplification may result 
in excessive amounts of gene products, which leads to an increase in cell growth (Vogelstein and 
Kinzler, 2004; Albertson, 2006; Croce, 2008). Proto-oncogenes can also translocate to 
transcriptionally active regions where they are overexpressed,  or fuse with other genes to create 
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novel chimeric genes whose products leads to excess cell proliferation (Mitelman, Johansson and 
Mertens, 2007; Croce, 2008).  
 
Point mutations can occur when mistakes in DNA replication are not corrected. Mutations can occur 
in regulatory regions which can lead to overexpression of a gene, or they can affect protein and 
enzyme activity in a way that enhances their activity. Furthermore, genes coding for cell surface 
receptors may be rendered constitutively active via point mutations (Albertson, 2006; Croce, 2008).  
 
1.2.2. Tumour Suppressor Genes 
Tumour Suppressor Genes (TSGs) are genes that function in inhibiting cell growth or provide check 
points to ensure fidelity of replication. TSGs act in an autosomal recessive fashion, which is different 
from the autosomal dominant pattern seen in proto-oncogenes. The homozygous loss-of-function of 
a TSG will lead to increased growth of cells (Alberts et al., 2002; Vogelstein and Kinzler, 2004).  
 
1.2.2.1. Silencing of TSGs 
Point mutations in crucial regions can lead to the silencing of a TSG through loss of expression, 
mRNA or protein degradation or truncated proteins (Strachan and Read, 2004; Vogelstein and 
Kinzler, 2004). TSGs can also be silenced by insertions or deletions in a chromosome, which can 
eliminate an entire gene or alter the gene sequence dramatically (Strachan and Read, 2004; 
Vogelstein and Kinzler, 2004). Epigenetic silencing occurs through methylation of a regulatory region 
and has been implicated in many cases of cancer. Methylation occurs frequently throughout the 
genome but aberrant methylation has been implicated in disease (Strachan and Read, 2004; 
Vogelstein and Kinzler, 2004; Hitchins et al., 2009).  
 
Generally, TSGs are able to function adequately even if one copy is non-functional and the other 
allele is functional. This is when there is heterozygosity of a gene. The loss of heterozygosity is one 
manner by which TSG lead to tumourigenesis. When the one functional copy is eliminated, the 
functions of the TSG are abolished in the cell. It has been found that individuals can be predisposed 
to cancer syndromes if they inherit one non-functional copy of a TSG; this phenomenon has been 
described as Knudson’s Two Hit Hypothesis. 
 
1.2.2.2. Knudson’s Two Hit Hypothesis 
Alfred Knudson proposed his ‘two hit’ hypothesis based on evidence from various cancer studies. 
Knudson was investigating how many ‘hits’ were required for a detectable cancer to develop. To do 
this, he studied cancers that were specific to children (Knudson, 1971).  
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Knudson (1971) reasoned that cancers require somatic mutations, thus the longer you live, the more 
mutations you develop and hence older people are more likely to be affected. However, cancers in 
children have had relatively little time to develop multiple somatic mutations. Knudson (1971) 
determined that two ‘hits’ were required for cancer development. One allele was inherited as non-
functional and the other allele acquired a loss-of-function somatic mutation.  
 
The two-hit hypothesis can be applied to many hereditary cancers where abolition of the TSG, or the 
stability gene, leads to the development of the cancer. Both TSG and stability gene classes act in an 
autosomal recessive manner. Since a cancer-causing mutation is already present in every cell of the 
body, the person carrying the mutation is at a higher risk of developing cancer (Knudson, 2001; 
Vogelstein and Kinzler, 2004). Predisposition to cancer syndromes will be described in more detail in 
Section 1.3. 
 
1.2.3. Stability Genes 
The third class of genes implicated in carcinogenesis are the stability genes, also known as ‘caretaker 
genes’ and these genes are responsible for genomic stability (Vogelstein and Kinzler, 2004). The 
MMR genes are a subclass of the stability genes and are the focus of this study. The basic function of 
the stability genes, and the MMR genes, will be described before a brief description of their 
involvement in cancer development will be given.  
 
Stability genes code for proteins that are responsible for repairing mistakes that are made by DNA 
polymerase during DNA synthesis. A DNA polymerase has a very low error rate when synthesising 
DNA. However, highly repetitive regions, such as microsatellites, are prone to errors during 
replication through polymerase slippage (Jiricny and Nyström-Lahti, 2000; Strachan and Read, 2004; 
Boland and Goel, 2010).  
 
Polymerase slippage occurs when there is incorrect pairing between the complementary strands of 
DNA and this leads to base/base mismatches, or the formation of insertions or deletions which 
create an insertion/deletion loop (Strachan and Read, 2004). Normally these errors are detected by 
the stability genes and corrected. If not corrected, a mutation will occur and remain in the genome, 
which in turn may lead to carcinogenesis after an accumulation of mutations (Jiricny and Nyström-
Lahti, 2000; Strachan and Read, 2004; Klug et al., 2006; da Silva et al., 2009; Cunningham et al., 
2010).  
 
The stability genes include the nucleotide-excision repair genes, base-excision repair genes and the 
MMR genes. Defects in the stability genes can lead to genomic instability, which is manifested in two 
forms. The first commonly seen form is chromosomal instability and the second form is 
microsatellite instability (MSI) (Strachan and Read, 2004; Cunningham et al., 2010). MSI is an 
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important aspect of mutations in the MMR genes, whereby MSI is a marker for tumourigenesis (see 
Section 1.4.7) and can be used as a preliminary screening test for HNPCC (described in Section 1.6.1).  
 
The stability genes are vital for correcting mutation errors and preventing them from being passed 
on through successive mitotic divisions. Generally, stability genes have been found to behave in an 
autosomal recessive fashion, indicating that both alleles need to be inactivated in order to achieve 
an increased mutation rate. When mutations occur in the stability genes that lead to their 
inactivation, much like the TSGs, a higher mutation rate is observed throughout the genome. This 
indicates that all genes in the genome will be affected by inactivation of the stability genes, including 
the oncogenes and TSGs (Vogelstein and Kinzler, 2004; Boland et al., 2008). The stability genes play 
an important, indirect role in cancer development.   
 
Vogelstein and Kinzler (2004) state that mutations, in any of the above three classes, can occur in 
the germ line. Germ line mutations can lead to cancer predispositions in individuals and their 
families. These predispositions increase the lifetime risk of developing a particular cancer (Frank, 
2004; Vogelstein and Kinzler, 2004).  
 
1.3. Hereditary Cancer 
It is estimated that about 20% of all CRC worldwide has a hereditary component. This is quite 
significant considering there are over 1.2 million new cases of CRC every year (de la Chapelle, 2004). 
Hereditary cancer syndromes are often the result of inheriting germ line mutations in genes that 
play a role in tumourigenesis. Some of these syndromes, such as HNPCC, are also known to have 
associated cancers that develop in other organs, such as the endometrium (Garber & Offit, 2005; 
Lynch et al., 2006; Cunningham et al., 2010).  
 
Genes that predispose individuals to cancer tend to affect cell death pathways, cell-cycle regulation 
pathways or DNA repair pathways. Germ line mutations in oncogenes are generally non-viable as the 
resultant phenotype is too severe. However, cancers involving inherited mutations in TSGs and 
stability genes are more common (Fletcher and Houlston, 2010). Cancer predisposing genes that are 
highly penetrant follow a single-gene Mendelian pattern of inheritance. Mutations in these genes 
tend to be physiologically recessive but they are inherited in a dominant fashion, via Knudson’s two 
hit hypothesis. A mutation will be inherited in one allele but the individual eventually acquires the 
mutation in the second allele. Only once both alleles are non-functional will cancer arise (Knudson, 
1971; Knudson, 2001; Frank, 2004, Fletcher and Houlston, 2010). 
 
The effect of the hereditary components in CRC is dependent on the penetrance of the particular 
genes that are involved (Cunningham et al., 2010, Fletcher and Houlston, 2010). CRC may seem 
familial but may be chance clustering since it is a common disease. A seemingly sporadic case may 
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be hereditary but may have been misclassified due to small family size, poor diagnostics or 
incomplete family history (de la Chapelle, 2004; Jasperson et al., 2010). 
 
CRC syndromes, such as Familial Adenomatous Polyposis (FAP) and HNPCC, have been vital to the 
understanding of CRC since several highly penetrant genes have been identified in these syndromes. 
These two CRC syndromes are the most common hereditary variants of CRC, accounting for 
approximately 1% and 5% of all CRC cases respectively. The genes implicated in these syndromes are 
also involved in sporadic cases of CRC and their identification has led to better understanding of 
sporadic and hereditary CRC (de la Chapelle, 2004; Jasperson et al., 2010).     
 
The following sections will describe both these diseases in more detail. Although FAP is caused by 
mutations in the APC tumour suppressor gene and HNPCC is caused by mutations in the MMR genes, 
both diseases follow the two-hit hypothesis. 
 
1.3.1. Familial Adenomatous Polyposis 
FAP is a hereditary CRC syndrome characterised by hundreds to thousands of adenomas that present 
in the colon of affected individuals. These adenomas usually develop in childhood and there is 
practically a 100% lifetime risk that at least one of the adenomas will develop into a carcinoma. Of all 
the CRC cases, FAP is estimated to account for about 0.2%-1% (de la Chapelle, 2004; Gryfe, 2009). 
 
FAP is caused by germ-line mutations in the tumour suppressor gene Adenomatous Polyposis Coli 
(APC) gene. FAP is inherited in an autosomal dominant manner via the two-hit hypothesis (de la 
Chapelle, 2004; Gryfe, 2009). Additionally, somatic mutations of the APC gene are known to be 
involved in sporadic CRC, leading to this gene being considered the ‘gatekeeper’ of neoplasia in the 
colorectal tract (Gryfe, 2009). It has also been noticed that APC mutations occurs early in 
carcinogenesis, often being the initiator of the adenomatous process (de la Chapelle, 2004)  
 
1.3.2. HNPCC 
HNPCC is a group of hereditary cancer syndromes that frequently manifest in the colorectal tract. 
HNPCC is the most common form of hereditary CRC, with an incidence estimated to be between 2% 
to 5% of all new CRC cases diagnosed annually (Lynch et al., 2006). When pathogenic mutations in 
the MMR genes are detected, HNPCC is reclassified as Lynch Syndrome (Vasen et al., 2007; 
Cunningham et al., 2010). 
 
Families with HNPCC are often identified by an increased number of cases of CRC, endometrial 
cancer and a number of other cancers that are associated with HNPCC (ovaries, small bowel, hepato-
biliary tract, pancreas, upper uro-epithelial tract, brain, kidney and stomach) as can be seen in Table 
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1.1. HNPCC is relatively common for a lethal, autosomal dominant disease. However, HNPCC 
generally does not affect the reproductive fitness of a carrier before they have children, leading to 
the mutations being transferred to children (Frank, 2004; Garber and Offit, 2005; Lynch et al., 2006). 
 
Table 1.1: Lifetime Risk of Individual Cancers in Families with an Identified MMR Mutation (Vasen et al., 
2007) 
Type of Cancer Lifetime Risk 
Colorectal Cancer (Men) 28-75% 
Colorectal Cancer 
(Women) 
24-52% 
Endometrial Cancer 27-71% 
Ovarian Cancer 3-13% 
Gastric Cancer 2-13% 
Urinary Tract Cancer 1-12% 
Brain Tumour 1-4% 
Small Bowel Cancer 4-7% 
 
 
1.3.2.1. Features of HNPCC 
HNPCC receives its name from the paucity of polyposis observed in patients. This is in contrast to the 
high number of polyps observed in other hereditary CRC syndromes such as FAP where hundreds to 
thousands of polyps are observed in the colon. Therefore, polyps (or adenomas) are observed in 
HNPCC but there are significantly fewer polyps, and the few that develop are more likely to develop 
into carcinomas (Jasperson et al., 2010). 
 
HNPCC has distinct features which allow it to be differentiated from other CRC syndromes and which 
can be seen in Figure 1.1. HNPCC follows an autosomal dominant inheritance pattern (Lynch et al., 
2006). It can also be noted that HNPCC is a highly penetrant disease, indicating that an MMR 
mutation carrier has a higher lifetime risk of developing colonic or extra-colonic tumours than the 
general population (Lynch et al., 2006). 
 
In the general Caucasian population, the average age for sporadic CRC development is about 65. 
However, the average age of cancer development is about 45 years in HNPCC patients (Lynch et al, 
2006). It is this feature which the Bethesda criteria (described in Section 1.3.2.3.3) uses to determine 
if an individual should be sent for further investigation. 
 
Between 70% and 85%, of colonic tumours develop in the proximal colon, with the estimated 
lifetime risk of CRC between 25% and 75% in carriers (de la Chapelle, 2004; Jasperson et al., 2010). 
The lifetime risk of developing colonic and extra-colonic tumours is given in Table 1.1. The risk of 
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developing the other extra-colonic cancers is not as high as CRC but identification of people with 
MMR mutations can allow those individuals to detect these cancers early (Vasen et al., 2007). In 
addition, the risk of developing an extra-colonic cancer increases with age (Watson et al., 2008).   
 
Autosomal dominant inheritance pattern 
Younger age of onset (<50) of CRC compared to average 
age of CRC in general population (≈65) 
Between 70% and 85% of tumours develop in the 
proximal colon 
Accelerated carcinogenesis  
High risk of synchronous and meta-chronous tumours  
Increased risk of malignancy at specific extra colonic 
locations  
Sebaceous adenomas, sebaceous carcinomas and 
keratoacanthomas  in Muir Torre Syndrome 
Pathology of tumour is poorly differentiated, mucinous, 
signet rings and excess of infiltrating lymphocytes within 
tumour 
Improved prognosis versus other CRC 
 
Figure 1.1: Phenotypic Features of HNPCC (Lynch et al., 2006) 
 
HNPCC is marked by a significant excess of synchronous and meta-chronous CRCs. Synchronous 
tumours are present at the same time whereas meta-chronous tumours are present within 10 years 
of each other. It is estimated that about 30% of patients will develop a second primary CRC within 10 
years of developing the first primary CRC (Lynch et al., 2006). It is also known that progression from 
adenoma to carcinoma is accelerated in HNPCC patients. An adenoma may develop into a carcinoma 
within 2 years of development whereas this process usually takes about 8 years in sporadic CRC 
(Lynch et al., 2006). This is a feature of HNPCC that makes identification and frequent screening of 
carriers very important.  
 
The tumours in HNPCC patients tend to be poorly differentiated and contain an excess of mucoid 
and signet-ring cells. The tumours also display an excess of infiltrating lymphocytes among the cells 
which has been linked to the improved prognosis in HNPCC due to the lymphocytes suspected of 
having cytotoxic effects (Lynch et al., 2006; Boland et al., 2008; Boland and Goel, 2010).  
 
MSI is an indicator that the MMR genes are non-functional; a feature that can be used in screening 
(described in Section 1.6.1). A tumour that is deficient of its MMR enzymes exhibit MSI as they are 
unable to correct the errors in the microsatellites. Since the errors are not corrected, the mutations 
accumulate within the cell. It is estimated that approximately 12% to 17% of all CRCs are deficient in 
the MMR proteins (Boland and Goel, 2010; Cunningham et al., 2010).   
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Interestingly, MSI in CRC has been found to be a good prognostic factor and molecular marker. 
Tumours that have a high frequency of MSI maintain their diploid state but also have certain other 
features. These features include a more proximal colon localization, poor differentiation, contain 
tumour infiltrating lymphocytes, are less likely to invade and are less likely to contain mutations in 
KRAS or p53 (Popat et al., 2005; Boland and Goel, 2010).  
 
1.3.2.2. Variations of HNPCC 
There have been variations of HNPCC reported in literature. These variations are related to HNPCC 
as the MMR genes are non-functional in patients, but they display characteristics that are not 
typically observed in HNPCC families. Muir-Torre syndrome is characterised by sebaceous gland 
tumours and individuals that present with these skin lesions should receive screening for MSI or 
Immunohistochemistry (Ponti and de Leon, 2005, Lynch et al., 2006, South et al., 2008). Turcot 
syndrome, a rare variant of HNPCC, is characterised by the occurrence of a primary malignancy in 
the central nervous system as well as a primary CRC (Hamilton et al., 1995, Lebrun et al., 2007). 
 
1.3.2.3. Diagnostic Guidelines for HNPCC 
Since HNPCC has specific features, it is possible to identify the disease and differentiate it from other 
cancers such as sporadic cancers and other hereditary cancer syndromes. The Amsterdam criteria 
and the Bethesda criteria, as well as the revisions for both criteria, were developed to aid both 
research and the diagnosis of families with HNPCC and their subsequent management.  
 
1.3.2.3.1. Amsterdam Criteria 
Prior to 1990, there were no formal guidelines used to identify HNPCC. This was a hindrance as it 
prevented many groups from performing uniform research on HNPCC. The International 
Collaborative Group on HNPCC (ICG-HNPCC) held a meeting in Amsterdam in 1990 and identified the 
need to perform collaborative research studies on uniformly selected cohorts and address various 
issues related to HNPCC. Minimum guidelines which could be used to identify families in a clinical 
setting were established, known as the Amsterdam criteria (seen in Figure 1.2) (Vasen et al., 1991; 
Vasen et al., 1999). This was particularly important as the genetic basis of HNPCC had not been 
established yet (Umar et al., 2004a). 
 
The establishment of the Amsterdam criteria had a significant effect as many researchers accepted 
and used the criteria to identify families with HNPCC. The Amsterdam criteria were instrumental in 
establishing the association between HNPCC and defects in the MMR genes (Vasen et al., 1999; 
Umar et al., 2004a). However, it was soon realized that the Amsterdam criteria were designed for 
specificity, and not sensitivity, as many families did not fulfil the Amsterdam criteria since it did not 
account for extra colonic tumours (Vasen et al., 1999; Umar et al., 2004a).  
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At least three relatives should have histologically verified CRC 
One of the three relatives should be a first degree relative of 
the two 
Familial Adenomatous Polyposis should have been excluded 
At least two successive generations should be affected 
At least one of the relatives should be diagnosed prior to the 
age of 50 
 
Figure 1.2: Amsterdam Criteria for the Clinical Diagnosis of HNPCC (Vasen et al., 1991) 
 
1.3.2.3.2. Amsterdam II Criteria 
ICG-HNPCC agreed to broaden the criteria to include extra colonic tumours but they also realised the 
need to not move too far away from the original criteria as many clinicians had adopted them. It was 
felt that the criteria needed to remain clinical as many families did not have access to DNA testing or 
mutation analysis (Vasen et al., 1999).  
 
The ICG-HNPCC decided that it would include the more ‘common’ extra colonic cancers from all 
populations. The group wanted to ensure specificity of the criteria and felt that including tumours 
that were common in only one population could lower the specificity of the criteria (Vasen et al., 
1999).  In 1999, the Amsterdam II criteria were finalised and accepted by the group. The Amsterdam 
II criteria, as well as the HNPCC associated cancers, are presented in Figure 1.3. 
 
There should be at least three relatives with an HNPCC associated 
cancer* 
One should be a first degree relative of the other two 
At least two successive generations should be affected 
At least one family member should be diagnosed before the age of 
50 
Familial Adenomatous Polyposis should be excluded in the CRC 
cases 
Tumours should be verified by pathological examination 
*HNPCC associated cancers: Endometrial, ovarian, gastric, renal pelvis/ureter, brain, hepatobiliary tract, skin and small 
bowel cancers 
 
Figure 1.3: Amsterdam II Criteria used for the Clinical Diagnosis of HNPCC (Vasen et al., 1999) 
 
The Amsterdam II criteria allowed for an expanded, yet simple, nomenclature that could be used to 
identify families to be included in studies across the globe (Vasen et al., 1999). With the 
implementation of the Amsterdam II criteria, it was possible to identify and characterise many more 
families with HNPCC. Additionally, all Amsterdam I positive families will still be positive under the 
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Amsterdam II criteria. The Amsterdam II criteria are particularly important for this study as any 
patient that fulfilled the Amsterdam II criteria was included in this study.  
 
1.3.2.3.3. Bethesda Guidelines 
A genetic diagnosis for HNPCC became necessary after the association between HNPCC and the 
MMR genes had been established (Umar et al., 2004a; Umar et al., 2004b). The National Cancer 
Institute (NCI) held a workshop in Bethesda in 1996 to discuss the role of genetics in the pathology 
of HNPCC. At the conclusion of the workshop, the NCI had developed criteria, known as the 
Bethesda guidelines, which could be used to identify which individuals should be sent for genetic 
testing for HNPCC. The Bethesda guidelines, included aspects of the Amsterdam criteria as well as 
pathological evaluations (Rodriguez-Bigas et al., 1997; Umar et al., 2004a).   
 
The Bethesda guidelines, which can be seen in Figure 1.4, are of particular significance as they 
recommend that individuals who meet any one of the seven criteria should be considered for 
genetic testing. The Amsterdam criteria require that all the criteria are met to make a diagnosis of 
HNPCC (Rodriguez-Bigas et al., 1997; Umar et al., 2004a). 
 
Individuals with cancer in families that meet the Amsterdam 
criteria 
Individuals with two HNPCC-related cancers, including 
synchronous and meta-chronous CRCs 
Individuals with CRC and a first degree relative with CRC or an 
HNPCC related tumour 
Individuals with CRC or endometrial cancer younger than 45 
Individuals with right-sided CRC and undifferentiated pattern 
diagnosed <45 years 
Individuals with signet-ring-cell type CRC diagnosed under the age 
of 45 
Individuals with adenomas diagnosed younger than 40 years of 
age 
 
Figure 1.4: Bethesda Guidelines for Genetic Testing of MMR Genes (Rodriguez-Bigas et al., 1997) 
 
Research on HNPCC had shown that about 90% of patients that fulfilled the Amsterdam criteria also 
showed MSI. Thus, the group felt that microsatellite testing would be an appropriate genetic 
screening test and then mutation detection in the MMR genes could be performed to find the 
pathogenic mutations. Identifying pathogenic mutations will allow other family members to be 
screened for the mutation, improving management and detection of CRC (Rodriguez-Bigas et al., 
1997; Umar et al., 2004a). 
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1.3.2.3.4. Revised Bethesda Criteria 
In 2003, the NCI met again with findings of additional research that was performed so that they 
could update the Bethesda Guidelines. It was found that the Bethesda criteria were very sensitive 
but not very specific when it came to determining patients with MSI in their tumours (Terdiman et 
al., 2001). It was also found that family history was important in the diagnosis of HNPCC, even when 
the diagnosis is made at a young age. Studies indicated that a poor family history may be due to non-
paternity, adoption, new or recurrent mutations, denial of a family history and even small family size 
(Terdiman et al., 2001; Umar et al., 2004a; Umar et al., 2004b). The NCI updated the Bethesda 
guidelines to account for some of the research findings, giving rise to the revised Bethesda 
guidelines, which can be seen in Table 1.6 (Umar et al., 2004b).  
 
The revised Bethesda guidelines place less emphasis on histology but they do keep the family history 
criteria. Genetic testing allows high risk individuals to be identified and screened regularly for 
disease (Umar et al., 2004a; Umar et al., 2004b; Vasen et al., 2007). For this study, the revised 
Bethesda criteria were used to identify patients who developed CRC under the age of 50 years. The 
selection criteria are discussed in more detail in Section 2.1. 
 
CRC diagnosed in a person younger than 50 years of age 
Presence of synchronous or meta-chronous CRC and HNPCC-related tumours 
CRC with MSI-H histology younger than 60 years of age 
CRC in one or more first degree relatives with an HNPCC related tumour, 
with one of the cancers being diagnosed under 50 years of age 
CRC diagnosed in two or more first or second degree relative with HNPCC 
related tumours, regardless of age 
 
Figure 1.5: Revised Bethesda Guidelines for Genetic Testing of MMR Genes (Umar et al., 2004b) 
 
Both the Amsterdam II criteria and the Bethesda guidelines are useful for detecting HNPCC but both 
do yield false positives and false negatives since they are both imperfect criteria (Lynch et al., 2006; 
Vasen et al., 2007). Screening of the MMR genes is used to confirm the diagnosis of HNPCC in 
individuals that fulfil either the Amsterdam II criteria or the Bethesda guidelines. Once a mutation in 
a family is found, targeted screening of other family members can be offered. 
 
1.3.3. Nomenclature: HNPCC or Lynch Syndrome? 
The name HNPCC was made a standard in 1989 at a meeting in Amsterdam in order to allow doctors 
to identify the disease more readily. By 2004, the NCI proposed that “Lynch Syndrome” should be 
used, as it was before the standardization to HNPCC. It was felt that HNPCC was inappropriate as it 
excluded the extra-colonic tumours observed in patients (Vasen et al., 1999; Vasen et al., 2007). It 
was then proposed that Lynch Syndrome should be used for patients who had an identified MMR 
mutation or had high microsatellite instability (MSI-H). A further proposal was that families fulfilling 
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the Amsterdam criteria but who lacked evidence of defective MMR should be referred to as having 
familial CRC (Vasen et al., 2007).  
 
For the current study, patients who fulfil the revised Bethesda criteria will be referred to as having 
suspected HNPCC. Patients who fulfil the Amsterdam II criteria are considered to have a clinical 
diagnosis of HNPCC and shall be referred to as such. Since Lynch Syndrome is the term given to 
patients with an identified mutation or MSI-H, it is not appropriate to use this term except in 
patients with known MMR mutations.   
 
1.4. Mismatch Repair Genes 
HNPCC is known to be caused by a loss of function in one of the MMR genes, also known as the 
‘mutator phenotype’. There are usually one of four genes that are commonly mutated in HNPCC and 
they are MutL homolog 1 (MLH1), MutS homolog 2 (MSH2), MutS homolog 6 (MSH6) or post-meiotic 
segregation increased 2 (PMS2). Of these four genes, MLH1 and MSH2 are the most commonly 
mutated genes in HNPCC, accounting for about 40% and 50% of all HNPCC cases, respectively (de la 
Chapelle, 2004; Peltomäki, 2005; Lynch et al.,2006; Jasperson et al., 2010). These two genes are the 
focus of this study because they are the most commonly mutated genes. A summary of the 
contribution towards HNPCC from each MMR gene can be seen in Table 1.2. 
 
Table 1.2: Percentage of HNPCC cases caused by mutations in each MMR gene (Peltomäki, 2005) 
Gene Percentage of 
HNPCC cases 
MLH1 40% 
MSH2 50% 
MSH6 ~10% 
PMS2 <1% 
 
1.4.1. MLH1 
The MLH1 locus had been known to be involved in HNPCC for many years through linkage studies 
and it is a highly penetrant gene (Nyström-Lahti et al., 1994, Kolodner et al., 1995). MLH1 is located 
at chromosome 3p21 and contains 19 exons that span over 58 kilobases, with the MLH1 protein 
containing 756 amino acids. Interestingly, each of the major genes in HNPCC has been found to be 
associated with specific tumours. Families with MLH1 mutations tend to have a higher incidence of 
CRC than families with mutations in the other genes (Kolodner et al., 1995; Peltomäki, 2005; da Silva 
et al., 2009) 
 
Characterization of MLH1 was an important step in understanding HNPCC as it gave further insights 
into the aetiology of HNPCC and allowed for enhanced mutation detection. After characterizing 
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MLH1, Kolodner et al. (1995) performed mutation screening in a large family who were shown to 
have possible MLH1 mutations by linkage analysis. Using direct DNA sequencing of the gene, it was 
found that an insertion led to a frame shift mutation which produced a truncated MLH1 protein and 
it was this mutation that was responsible for HNPCC in that family.  
 
MLH1 has also been found to be epigenetically silenced in cases of HNPCC. Gazzoli et al. (2002) 
reported a case of HNPCC where methylation of one allele was present in the blood, but both alleles 
were methylated in the tumour. The pathogenesis suggested a constitutional MLH1 epimutation. 
Hesson et al. (2010) indicate that many cases with a similar pathogenesis have been reported but 
that the epimutation may not be present in the germ line. However, those individuals are 
predisposed to HNPCC by way of methylation of the MLH1 locus in somatic tissue, proposed to be 
caused by cis-acting elements in the same region as MLH1. 
 
1.4.2. MSH2 
The MSH2 gene is located at chromosome 2p16 and contains 16 exons spanning over 73kb. The 
MSH2 protein has been found to contain 934 amino acids (Kolodner et al., 1994). Similarly to MLH1, 
MSH2 is highly penetrant, but mutations in MSH2 have been found to be more associated with 
extra-colonic tumours and Muir-Torre features (Kolodner et al., 1994; Peltomäki, 2005; Lynch et al., 
2006; da Silva et al., 2009).  
 
Germ line mutations in MSH2 tend to lead to abolition of the protein. These mutations include 
premature stop codons, altered splice sites or rearrangements (Boland et al., 2008). However, 
epimutations have also been discovered. Terminal mutations in the EPCAM gene, located upstream 
of MSH2, lead to an abnormal EPCAM-MSH2 fusion transcript and MSH2 promoter methylation 
(Hesson et al., 2010). This EPCAM mutation leads to reduced expression of the MSH2 gene. This 
EPCAM mutation confers the same risk of tumour development as MSH2 mutations in familial 
cancer (Hesson et al., 2010). 
 
1.4.3. MSH6 
The MSH6 gene is located at chromosome 2p15 and contains 10 exons and is approximately 20kb in 
size. The MSH6 protein, also known as GTBP, is a 153kDa protein consisting of 1360 amino acids 
(Acharya et al., 1996). The mean age of onset of CRC in families with MSH6 mutations is 56 years, as 
opposed to 45 years in classical HNPCC. This attenuated phenotype is the result of compensation 
provided by MutS homolog 3 (MSH3) in the cell (Acharya et al., 1996; da Silva et al., 2009; Talseth-
Palmer et al., 2010). In addition to later age of onset, women in families with MSH6 mutations tend 
to develop endometrial cancers more frequently, with a 71% lifetime risk by age 70 (Peltomäki, 
2005; da Silva et al., 2009; Talseth-Palmer et al., 2010). 
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Although MSH6 is responsible for roughly 10% of cases, it is estimated that many cases involving 
MSH6 are overlooked. One reason for under-representation in these families is due to lack of routine 
testing of MSH6 in many laboratories. Another reason for under-representation is that families with 
MSH6 mutations have an attenuated phenotype that does not fulfil the Amsterdam criteria, or the 
Bethesda guidelines. There are reports that there is a high incidence of MSH6 mutation carriers in 
Amsterdam negative families (Boland et al., 2008; da Silva et al., 2009; Sjursen et al., 2010; Talseth-
Palmer et al., 2010). 
   
1.4.4. PMS2 
The PMS2 locus at chromosome 7p22 contains 15 exons and is 16kb in size (Nicolaides et al., 1994). 
PMS2 has been found to be mutated in families with HNPCC but is reported in less than 1% of all 
HNPCC cases. PMS2 is however, also thought to be under-represented due to the attenuated 
phenotype of older age of onset and weak family history (Peltomäki, 2005; Lynch et al., 2006; Boland 
et al., 2008; da Silva et al., 2009). 
 
Paradoxically, PMS2 mutations are also thought to lead to childhood onset of tumours when two 
non-functional alleles are inherited. One challenge facing PMS2 management is the limited number 
of observed cases, which is one reason why there is no clear phenotype described for this gene. It 
has also been suggested that PMS2 is associated with variable (Peltomäki, 2005; Lynch et al., 2006; 
Boland et al., 2008; da Silva et al., 2009).  
 
1.4.5. Recurrent and Founder Mutations 
These above four MMR genes, MLH1, MSH2, MSH6 and PMS2, are the main genes involved in the 
aetiology of HNPCC. There is a wide range of mutations found in HNPCC families. However, it has 
been found that occasionally the same mutations occur in families that are unrelated. There are two 
explanations for these occurrences. The first explanation is that these mutations are recurrent 
mutations that occur within gene ‘hot spots’. These hot-spots are prone to mutations, which often 
appear de novo in individuals (de la Chapelle, 2004; Lynch et al., 2006).  
 
The second explanation is founder mutations, which are usually introduced into a population by one 
individual and retained through genetic drift. There are several factors that determine if a mutation 
will persist in a population, including rapid population growth, population bottlenecks, isolation and 
chance. Founder mutations can be observed in isolated populations that have grown from a small 
group of individuals (de la Chapelle and Wright, 1998; de la Chapelle, 2004; Strachan and Read, 
2004).  
 
Founder mutations have significant impact for individuals and molecular genetic diagnosis (Lynch et 
al., 2006). As a first step in molecular diagnosis, those individuals from that population can be tested 
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for the founder mutation as it provides a first line target for mutation detection, rather than whole 
gene sequencing. Targeted mutation analysis will save costs and facilitate better management 
(Lynch et al., 2006). 
 
Although there are many mutations reported for each of the MMR genes, there have been found to 
be several founder mutations in various populations. A summary of some of the known founder 
mutations can be seen in Table 1.3 below. A founder mutation has been detected in South African 
mixed ancestry individuals (Goldberg et al., 1998; Stupart et al., 2009).  
 
Table 1.3: Founder mutations of MLH1 and MSH2 found in different populations 
Population Gene Mutation References 
South African Mixed Ancestry MLH1 c.1528C>T in Exon 13  Goldberg et al., 1998 
Ashkenazi Jews MSH2 c.1906G>C Foulkes et al., 2002 
Chinese MSH2 c.1452-1455delAATG Chan et al., 2004 
Finnish MLH1 Deletion of Exon 16 Nyström-Lahti et al., 1995 
Italians MSH2 Deletion of Exons 1-6 Stella et al., 2007 
USA Caucasians 
(American Founder Mutation*) 
MSH2 Deletion of Exons 1-6 Clendenning et al., 2008 
*This mutation was traced back to a German that settled in the USA in the 18
th
 century (Clendenning et al., 2008) 
 
1.4.6. Functions of the MMR Genes 
The MMR gene products do not function independently of one another. Instead, they interact 
together in a complex pathway which is responsible for correcting errors and even play a role in 
apoptosis if damage is not repaired. The following section will describe how these gene products 
interact within the cell. 
 
The MMR system is responsible for detecting and correcting DNA replication errors that occur on the 
newly synthesized strand of DNA. As mentioned above, DNA polymerase occasionally makes a 
mistake when synthesising DNA and inserts an incorrect nucleotide. This can lead to a base 
mismatch or an insertion-deletion loop (Boland and Goel, 2010).  
 
Within the cell, the predominant heterodimer for detecting mismatches on the DNA strand is known 
as MutSα. The heterodimer MutSα is made up of MSH2 and MSH6 proteins. MutSα is able to bind to 
base/base mismatches as well as 1bp insertion-deletion loops and repair them (Peltomäki, 2005).  
 
A second mismatch recognition protein known as MutSβ consists of MSH2 and MSH3. The MutSβ 
complex functions to effectively eliminate 2-8bp unpaired nucleotides, which form an insertion-
deletion loop that the complex recognizes. The MutSα and MutSβ vary in their affinities due to the 
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MSH6 or MSH3 protein bound to MSH2, with the MSH3 complex being able to bind to larger 
insertion-deletions loops than the MSH6 complex (Peltomäki, 2005; Boland and Goel, 2010).   
      
The functions of the MutL complexes are not as well-known or understood as the MutS complexes. 
The MutLα complex, which consists of MLH1 and PMS2, is also vital to the functioning of the MMR 
system. This complex is considered important in bridging mismatch recognition with downstream 
repair processes, such as long-patch excision (Peltomäki, 2005; Boland and Goel, 2010). 
 
The MLH1 protein is also able to dimerize with PMS1, forming the MutLβ complex. This complex has 
been shown to suppress mutagenesis in Saccharomyces cerevisiae (yeast), but the function of this 
complex has not been fully elucidated in humans (Boland and Goel, 2010). Similarly, the MutLγ 
complex, composed of MLH1 and MLH3, suppresses insertion-deletion loops in yeast but has an 
unknown function in humans (Boland and Goel, 2010). A diagram of these protein interactions is 
given in Figure 1.1. 
 
1.4.7. Mechanism of Tumourigenesis in HNPCC 
If the MMR proteins do not identify and correct mismatches, the DNA synthesized subsequently will 
contain mutations. When MMR activity is eliminated, mutations occur at a higher rate as the cells 
proliferate. Point mutations that arise by single base mismatches could lead to changes in protein 
structure or function, premature stop codons or complete silencing of genes. The mutation of genes 
involved in cell proliferation can lead to the elimination of entire regulatory systems (Chao and 
Lipkin, 2006; Boland et al., 2008; Boland and Goel, 2010). 
 
1.4.7.1. Coding Microsatellites 
Coding microsatellites are microsatellite repeats that are located within exons. MSH2, MSH6 and 
PMS2 each contain mononucleotide repeats with at least seven adenines, which may be prone to 
insertions and deletions (Boland and Goel, 2010). It has been found that many genes involved in cell 
growth (including TGFBR2, BAX and CASP-5), contain coding microsatellites that are frequently 
mutated in cells with MSI (Chao and Lipkin, 2006, Boland et al., 2008).  
 
The above indicates that the MMR system is responsible for maintaining the functions of other 
genes by preventing frame-shift mutations in coding microsatellites. Additionally, the MMR system 
may become more defective as more repair components are abolished. The MMR components are 
also thought to be important in signalling apoptosis when DNA damage cannot be repaired (Chao 
and Lipkin, 2006; O’Brien and Brown, 2006; Boland and Goel, 2010).  
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1.4.7.2. Apoptosis 
This mechanism for apoptosis is not clear but it is thought that the MMR proteins may use direct 
signalling by recruiting additional proteins to the cell. Alternatively, indirect signalling through 
excessive double strand breaks could lead to toxicity, and subsequently apoptosis. An important step 
for tumourigenesis is the abolition of apoptosis pathways. The BAX gene has an important role in 
signalling apoptosis and is commonly abolished in MSI tumours, which leads to a growth advantage 
for a cell (Chao and Lipkin, 2006; O’Brien and Brown, 2006).  
 
1.4.8. Tissue Specificity of HNPCC 
HNPCC is characterised by tumours that develop predominantly in the colon, but that there are a 
number of extra-colonic tumours that are linked to MMR deficiency. This raises an important 
question, why does defective MMR predominantly lead to tumours in the colon? Models have been 
proposed to understand the tissue specificity involved in HNPCC.  
Figure 1.6: Diagram showing how the MMR proteins interact to repair mismatches in the DNA 
(Fishel, 2001). The MutSα heterodimer (hMSH2 and hMSH6) binds to the DNA and detects single base 
mismatches. The MutLα complex (hMLH1 and hPMS2) binds to the MutSα complex. The MutSβ 
heterodimer (hMSH2 and hMSH3) binds to insertion/ deletion loops in the DNA. The MutLβ complex 
binds to the MutSβ complex. In this figure, the ‘h’ in the protein name indicates a human protein.  
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One mechanism by which the tumours develop in the colorectal tract regards cell proliferation rates. 
The epithelial cells in the gastrointestinal tract have the highest proliferation rate of all cells in the 
body, being replaced every three to five days. Cells that proliferate at a higher rate are more 
susceptible to mutations when the MMR genes are mutated. This one factor can provide a very 
plausible reason for CRC development in HNPCC but does not account for cancers in slower 
proliferating cells like those of the urinary tract  or no tumours in tissues such as bone marrow or 
respiratory tract (Chao and Lipkin, 2006). 
 
Environmental factors such as tobacco smoking, diet and pharmaceuticals are considered to play 
important roles in carcinogenesis. Diets high in fat and low in folate and calcium (‘Western diets’) 
are associated with an increased incidence of CRC. These diets are also associated with increased 
Body Mass Indexes (BMIs), which may be an important factor in colorectal tumour development 
(Watson et al., 2004; Chao and Lipkin, 2006; Botma et al., 2010). 
 
Tumour development in the endometrium is not well understood. The endometrium undergoes 
monthly cycling in response to hormones, which starts with rapid proliferation of cells and ends with 
menstruation. After the phase of rapid proliferation, apoptosis occurs in the newly synthesised cells. 
The loss of apoptosis could lead to the cells not undergoing the regular cycling and persisting. It is 
believed that rapid changes in proliferation rates and loss of apoptosis could be an important factor 
in endometrial and ovarian cancer (Chao and Lipkin, 2006).    
 
Overall, there are many important factors that play a role in the tissue-specific tumourigenesis 
observed in HNPCC. These factors include mutations in genes, diet, hormones and exposure to 
mutagens.  
 
1.5. Ethnic Group Differences in CRC Compared to Caucasians 
This section will describe some of the differences in CRC, with regard to incidence and histology, 
seen among the different ethnic groups compared to Caucasians. This section is given to highlight 
that different populations show slightly different features for CRC and HNPCC, which may be seen in 
the South African population. The Asian population will be compared to Caucasians first, then the 
African Americans and finally the Africans. The tumour spectrum of families with CRC does vary 
between geographic locations. This is thought to be attributed to differences in risk factors in the 
different region’s each ethnic group inhabits. However, it has been found that an ethnic group that 
has migrated to a new region will adopt the same risk of CRC as that regions population because 
they are exposed to the similar risk factors (Anderson et al., 2003).  
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1.5.1. Asians 
For this literature review, Asians with Chinese and Japanese heritages have been compared to 
Caucasians as there have been a number of studies on these populations. It has been found that 
Japanese Americans have an increased risk (1.40) of developing CRC relative to Caucasians, even 
after accounting for various risk factors. The Japanese Americans had the highest rate of positive 
family history for CRC, which suggests that genetic factors may be important in the observed cases 
(Ollberding et al., 2011). Further studies indicate that the number of sporadic CRC patients under 50 
is increasing year on year in Asian populations (Chew et al., 2009).  
 
When directly observing HNPCC patients of Asian descent, their tumours are generally located in the 
distal colon. This localization of HNPCC tumours differs from Caucasians, as well as Africans, who 
present primarily with tumours in the proximal colon (Wei et al., 2011). With regard to the extra-
colonic tumours, stomach cancer is more predominant in Asian HNPCC families compared to 
Caucasian HNPCC families (Wei et al., 2011). Asian families with HNPCC also show an increased risk 
of developing endometrial cancer relative to Caucasian patients (Ollberding et al., 2011).  
 
1.5.2. African Americans 
It has been reported that there is a higher lifetime risk of CRC and that survival among African 
Americans with CRC is lower than in Caucasians. The higher incidence rate of CRC may be attributed 
to various environmental risk factors, including diet and screening rates (Agrawal et al., 2005). The 5 
year survival rate in African Americans (53%) is lower than the 5 year survival rate of Caucasians 
(63%) for all stages of cancer, probably due to a lack of early screening (Anderson et al., 2003; 
Agrawal et al., 2005). These numbers give more support to early screening and detection of CRC. 
 
The proportion of African Americans who present with CRC under the age of fifty (10.6%) is higher 
than the proportion of Caucasians (5.5%) that present under the age of 50 (Agrawal et al., 2005). 
African Americans also show a higher degree of proximal tumours but the rate of tumourigenesis is 
not as accelerated compared to Caucasians (Anderson et al., 2003; Agrawal et al., 2005). 
 
African American kindred’s with HNPCC have been reported. The average age of diagnosis is lower 
than the population average in HNPCC families (Agrawal et al., 2005). Agrawal et al. (2005) also 
highlight another study on African Americans which found that 43% of patients had MSI-H tumours 
and that 77% of these tumours were located in the proximal colon.   
 
1.5.3. Africans 
It is indicated that there is a higher prevalence of MSI in black African patients (10-30%) than in 
Caucasian patients (5-15%) with regard to sporadic CRC (Anderson et al., 2003). There is speculation 
that the increased prevalence of MSI CRC is the result of germ line mutations in the MMR genes. 
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HNPCC has been detected in African populations, with unique germ line mutations accounting for 
several cases (Anderson et al., 2003). Unfortunately, there is very little literature covering CRC in 
Africa and there is very little information about HNPCC in African populations (Anderson et al., 2003; 
Cronjé et al., 2009; Hitchins et al., 2011).  
 
1.5.3.1. South African Black Population 
In South Africa it is estimated that one in four men and one in five women, will develop cancer 
during their lifetime (National Cancer Registry (NCR), 2004). The latest cancer statistics in South 
Africa show that CRC is the sixth most common cancer (NCR, 2011). Interestingly, the Age 
Standardised Rate (ASR) figures indicate that CRC is more common in Caucasians under the age of 50 
than in the black and mixed ancestry population (NCR, 2011). More information on Cancer rates in 
South Africa can be seen in Appendix A under Figure A.1 as well as Tables A.3 and A.4. The incidence 
rate for CRC is predicted to increase every year in South Africa, partly due to the spread of the 
Western diet (Anderson et al., 2003; NCR, 2004). Interestingly, Wentink et al. (2010) found that CRC 
was rare in rural parts of South Africa, where the Western diet may not have penetrated. 
 
In South Africans, the black patients exhibit similar phenotypes to the African American patients, 
namely lower age of diagnosis and more proximal localisation of CRC (Anderson et al., 2003; Cronjé 
et al., 2009; Wentink et al., 2010).  It is indicated that about 26-41% of black patients in South Africa 
who presented with CRC were under the age of 50, which is a high proportion of patients that fulfil 
the Bethesda criteria (Cronjé et al., 2009; Wentink et al., 2010). Studies have found that younger 
patients show a tendency to develop proximal CRC with deficient MLH1, MSH2 or MSH6 proteins. 
They concluded that HNPCC could be a strong underlying factor for CRC in young black patients seen 
at local hospitals and that genetic testing should be offered (Cronjé et al., 2009).   
 
1.6. Genetic Testing for HNPCC 
Testing for MSI and loss of MMR proteins expression can be used to screen colorectal patients for 
HNPCC. However, the best strategy for identification of HNPCC is to screen for germ line mutations 
using complete sequencing and Multiplex Ligation-dependent Probe Amplification (MLPA) of the 
MMR genes (Boland and Goel, 2010). Once Lynch Syndrome is confirmed, the family members can 
be tested using targeted sequencing to determine if individuals are at an increased risk of 
developing cancer. This section will discuss the molecular genetic testing strategies for screening and 
diagnostic identification of HNPCC. 
  
1.6.1. MSI Testing 
MSI occurs in approximately 12-17% of all CRC’s. Cases of sporadic CRC with MSI tend to be in older 
patients who, additionally, do not show familial clustering of CRC. MSI in sporadic CRC is often the 
result of biallelic methylation of MMR genes, typically MLH1 (Boland and Goel, 2010). However, MSI 
is present in more than 90% of cases of HNPCC due to the deficiency of the MMR proteins, as 
described in Section 1.4.7.1 (Boland et al., 2008; Boland and Goel, 2010).  
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MSI testing allows one to determine whether a microsatellite has expanded and can be performed 
simply and cheaply using PCR techniques (Boland and Goel, 2010). The National Cancer Institute 
(NCI) has endorsed a panel of five microsatellite markers which include two mononucleotide 
microsatellites (BAT25 and BAT26) and three dinucleotide microsatellites (D2S123, D5S346 and 
D17S250) (Vasen et al., 2007; Pineda et al., 2009; Boland and Goel, 2010). The tumour DNA is 
compared to the blood DNA to determine if the microsatellites show expansions or deletions. If 
there are no differences among any microsatellites, then the tumour is microsatellite stable. If one 
marker shows a change in size, then the tumour has low MSI (MSI-L). If two or more markers are 
unstable, then the tumour is said to have high MSI (MSI-H) (Pineda et al., 2009; Boland and Goel, 
2010).  
 
MSI testing has been shown to be very sensitive for predicting the presence of MMR mutations. This 
testing can be very useful in families that have a high probability of having HNPCC, even when 
protein expression seems normal or in individuals who meet the Bethesda criteria to determine 
whether they should proceed to genetic analysis. The protein could be detected using IHC, but it 
may be non-functional due to missense mutations. MSI testing can be cost effective as it determines 
whether a tumour is caused by MMR deficiency before sequencing the MMR genes (Vasen et al., 
2007).  
 
MSI testing also has disadvantages for testing. MSI testing requires a high proportion of tumour 
tissue in order to get good results. MSI testing has also been regarded as not being useful for MSH6 
mutation carriers due to the lower level of MSI seen in their tumours. Furthermore, MSI may be 
acquired through somatic mutations in sporadic tumours, which would yield a false positive for 
inherited MMR gene testing (Pineda et al., 2010).    
 
1.6.2. Immunohistochemistry 
IHC is the process of using antibodies, prepared against specific proteins, to determine if the protein 
is present in tissue. This process is achieved by labelling an antibody, then allowing it to bind to 
proteins in tissue. If the protein is not present, the antibodies cannot bind and are washed away 
(Strachan and Read, 2004). IHC has been an important histological tool for the molecular diagnosis 
of HNPCC. 
 
When using IHC for the detection of loss of MMR, antibodies against MLH1 and MSH2 are usually 
used. However, to get a more complete result, antibodies against MSH6 and PMS2 should also be 
used (Vasen et al., 2007). Since MSH2 and MLH1 are obligatory components in the MMR system, 
absence of these proteins leads to instability of their protein partners. If the MLH1 protein is absent, 
the IHC shows the loss of staining for both MHL1 and PMS2 and similarly, if MSH2 is absent, for 
MSH2 and MSH6 (Peltomäki, 2005; Boland et al., 2008).  
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IHC has been shown to be very sensitive for detecting MMR expression but there is a higher rate of 
false negatives than with MSI testing. These false negatives are the result of detecting non-
functional proteins or protein fragments. However, IHC allows one to detect which proteins are 
abolished, which can be used to direct mutation testing. This has been thought to be particularly 
useful in MSH6 mutation carriers (Lynch et al., 2006; Vasen et al., 2007). IHC has a lower cost and is 
also widely available in many pathology laboratories (Pineda et al., 2010; Prof. A. Krause, University 
of the Witwatersrand, Johannesburg, Personal communication, 2011). Although there are 
laboratories that provide IHC testing in South Africa, the testing is not cheaply or easily available. IHC 
would have been an ideal inclusion in this study. The IHC status was only known in the positive 
control in this study (described in Section 2.1.1) 
 
IHC also has several limitations which can affect its usefulness. These limitations include a lower 
sensitivity for detecting MLH1 expression. IHC does not distinguish between germ line mutations or 
hyper-methylation as a mechanism for loss of expression. It can also be challenging to interpret the 
results from IHC staining, especially if there are no internal controls (Lynch et al., 2006; Pineda et al., 
2010).      
 
Both MSI testing and IHC have strengths and limitations but both have been shown to be very useful 
for detecting loss of MMR function in a tumour. Thus either test can be offered to patients as a first 
step to determine MMR status. However, there seems to be consensus that IHC is the more 
beneficial as it can direct mutation testing. Ultimately, the next step should be mutation detection 
using sequencing and MLPA if MSI or IHC is positive (Lynch et al., 2006; Vasen et al., 2007; Boland 
and Goel, 2010). 
 
1.6.3. Direct Sequencing and MLPA 
Individuals that fulfil the Bethesda criteria can be screened using MSI testing or IHC but the ideal 
course of action is to sequence their DNA and determine if they harbour any germ line mutations in 
the MMR genes. Sequencing the MMR genes is the gold standard method for mutation detection 
and can be complemented by MLPA analysis (Boland and Goel, 2010).  
 
Sequencing of the exons of these genes is most useful when using primers that include a portion of 
the intron/exon boundary. This allows the entire exon to be sequenced as well as the splice sites, 
where mutations are known to occur (Boland and Goel, 2010). However, some pathogenic 
mutations are small and may be missed by sequencing.  
 
MLPA allows for the detections of large mutations that include the deletion or duplication of whole 
exons. If an exon is deleted and the breakpoint occurs outside of the sequencing primer binding site, 
then the sequencing analysis will not show any mutation as only the wildtype allele is sequenced and 
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not the mutant allele. MLPA allows for the quantification of each exon, thus determining if an exon 
is missing or duplicated. Large deletions are not rare in HNPCC, with more than a third of mutations 
in MSH2 believed to be large exon deletions (Schouten et al., 2002; Boland and Goel, 2010). 
Furthermore, the mutations detected by MLPA are almost certainly pathogenic as they affect large 
portions of coding DNA (Lynch et al., 2006). 
 
1.6.4. Improved Clinical Management 
The most important reason for finding the pathogenic germ line mutation is that it can aid family 
members with clinical management. Morbidity and mortality of individuals can be lowered by 
lowering their risk factors and providing adequate surveillance for affected members. If one family 
member is found to harbour a pathogenic mutation, family members can have the same region 
tested for the presence of that mutation. Furthermore, members who are negative for mutations 
can avoid regular colon tumour screening (Lynch et al., 2006; Boland and Goel, 2010). 
 
The best process for surveillance of the colon is full colonoscopy, due to the tumours developing 
primarily in the proximal colon. Colonoscopy has been shown to have lifesaving benefits and can 
reduce the incidence of CRC by up to 90% (Anderson et al., 2003; Lynch et al., 2006). Unfortunately, 
this procedure can be uncomfortable as it is invasive. If an individual is found to be a mutation 
carrier, and thus have an increased risk of cancer, the recommendation is to undergo regular 
colonoscopy every 1-2 years. Alternatively, prophylactic colectomy can be performed to minimise 
the risk of developing CRC (Lynch et al., 2006). 
 
In addition to colonoscopy, women who carry a mutation are at an increased risk of endometrial 
cancer. Screening strategies for endometrial cancer are less well established than those for colon 
cancer. However, endometrial sampling and transvaginal ultrasound are found to detect 
endometrial cancers at an early stage, which is vital for effective treatment (Järvinen et al., 2009). 
Furthermore, prophylactic oophorectomy and hysterectomy can be performed on a carrier once 
they have had children to prevent the endometrial and ovarian cancers from developing (Järvinen et 
al., 2009).  
 
1.6.5. Diagnostic Services 
Early detection is shown to prevent mortality in cancer and awareness of risk can save lives. 
Unfortunately, early detection hinges very heavily on good diagnostic facilities to identify at risk 
individuals. This can be particularly important in South Africa where there are limited resources. 
Mutation screening can benefit the health system as it could allow resources to be directed to 
individuals that need them, thus providing a more efficient use of the resources (Goldberg et al., 
1998).  
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In South Africa, the ability to diagnose a mutation carrier within molecular genetic laboratories is 
very limited. Patients who present with clinical features suggestive of HNPCC do not have a 
molecular diagnostic facility in South Africa where they can be tested. Patients have to have their 
samples sent to overseas laboratories for testing, which can cost approximately £500 per gene 
(£1=R13.18, 2 June 2012). Unfortunately, this cost is one that many South Africans cannot afford 
(Prof. A. Krause, University of the Witwatersrand, Johannesburg, Personal communication, 2011).     
 
In order to look for disease-causing mutations in HNPCC, HNPCC testing needs to be set up locally. 
Testing for mutations, particularly recurrent and founder mutations, may considerably improve the 
molecular diagnosis of HNPCC in the South African population. Once individuals have been 
diagnosed as having an increased risk, they can be screened regularly, which will allow for early 
detection and surgery can be offered. 
 
1.7. Aims and Objectives 
The aim of this project is to establish the mutation profile for HNPCC in MLH1 and MSH2 in the 
South African population. The South African populations have not been extensively studied and may 
contain novel variants that have not been reported previously or founder mutations. This study will 
investigate the exons and intron/exon boundaries of MLH1 and MSH2 to determine the molecular 
aetiology of HNPCC. These two genes have been chosen for this study as they account for 
approximately 90% of HNPCC mutations in other populations. It is important to determine if 
mutations are common in a population to provide a cheap, effective diagnostic service. There may 
be possible founder mutations since there are studies to suggest that there is a higher than expected 
proportion of young black people with CRC, which may be attributable to HNPCC (Cronjé et al., 
2009).  
 
The objectives of the following study were: 
1. To collect samples from patients that fulfilled the inclusion criteria for this study. A DNA bank at 
the NHLS, Braamfontein, was used to identify previously banked samples. Patients were also 
collected prospectively through local hospitals. Any patient that fulfilled the Amsterdam II 
criteria was included in this study. Since no black patients were Amsterdam II positive, the age 
criterion from the revised Bethesda guidelines was also used. These criteria would allow patients 
to be selected from various ethnic groups within South Africa 
2. To perform MLPA of the MLH1 and MSH2 genes in the patients that were selected to determine 
if there are any large deletions or duplications present. 
3. To perform Sanger sequencing on all the exons and intron/exon boundaries of the MLH1 and 
MSH2 genes to determine the presence of any small insertions, deletions or single base changes. 
4. To determine the pathogenicity of variants detected in MLH1 and MSH2 by bio-informatic and 
lab-based methodology.  
5. To characterise the mutation spectrum in patients and determine if any common pathogenic 
mutations, or common variants, exist.  
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2. Subjects, Materials and Methods 
This chapter will describe all the subjects, materials and methods that were used during this study. 
Section 2.1 will describe patient identification and inclusion criteria for the study while Section 2.2 
will describe the MLPA method, which was used to determine whether large deletions or 
duplications were present in MLH1 or MSH2. Section 2.3 will describe how DNA was amplified using 
the polymerase chain reaction (PCR), which was necessary to perform Sanger sequencing, described 
in Section 2.4. This section will describe how sequencing of the exons and intron/exon boundaries of 
the genes MLH1 and MSH2 was performed using the PCR products as template DNA.  
 
The analysis of MLPA and Sanger sequencing data is given in Section 2.5. Additionally, this section 
will describe the methods used to correctly name the variants, and determine reporting history, 
using the LOVD database at the International Society for Gastrointestinal Hereditary Tumours 
(InSiGHT; www.InSiGHT-Group.org) and the UCSC Genome Browser and the BLAST-Like Alignment 
Tool (BLAT). Section 2.6 will describe the methods used to elucidate the frequencies of the novel 
variants that were found, using restriction fragment length polymorphisms and high resolution melt. 
A flow chart showing the materials and methods can be seen in Figure 2.1. All the solutions used in 
this study can be found in Appendix B.    
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Figure 2.1: Flow Diagram outlining the approach and actions taken in this study 
Sample Collection 
Sanger Sequencing  
Primers from SOP of 
Regional Genetics Service 
at Manchester Academic 
Health Science Centre 
Variant Detected 
Checked on Leiden Open 
Variation Database (LOVD) 
Amsterdam II Criteria: 
Patients with family history 
10 Whites, 1 mixed ancestry 
 
Revised Bethesda Guidelines: 
Patients with no family history 
7 Black, 1 mixed ancestry 
 
Positive control: 
Known mutation in MSH2 
 
MLPA 
P003 Salsa probe 
mix (MRC-Holland) 
Previously Reported 
Unknown Significance 
Non-pathogenic Pathogenic 
Novel variant 
Determine pathogenicity 
Bioinformatic 
analysis: 
FASTSNP 
Allele frequency: 
Restriction Fragment Length 
Polymorphism (RFLP) 
High Resolution Melt (HRM) 
Pathogenic/ non-pathogenic/ unknown significance 
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2.1. Subjects 
Twenty patient samples were included in this study.  The Amsterdam II criteria were used to select 
patients. However, the black patients available did not fulfil the Amsterdam II criteria, so it was 
decided to use the revised Bethesda criteria to increase the number of black and mixed ancestry 
patients in this study. A summary of the patients collected in this study can be seen in Table 2.1. 
Patient samples were ascertained in two ways:  
1) Samples already present in the laboratory from patients who fulfilled the clinical criteria for 
HNPCC  
2) Sample collection through the clinical diagnostic service 
 
2.1.1. Samples Present in the Laboratory 
Over the past 15 years, 25 patients who presented with CRC and had a positive family history of CRC 
were seen through the Genetic Counselling Service, NHLS, Braamfontein. At the time, genetic 
diagnostic testing was not available in South Africa and the DNA from these patients was stored in 
the DNA bank at the NHLS, Braamfontein. Both the collection of patient blood, and DNA extraction, 
were performed by the Clinical Diagnostic Service in the Department of Human Genetics, NHLS and 
the University of the Witwatersrand. These patients had previously given informed consent for 
inclusion in further CRC research. Thirteen of these 25 samples were patients that fulfilled inclusion 
criteria for this study.   
 
Of these 13 samples from the DNA bank, 11 patients fulfilled the Amsterdam II criteria. Ten were 
white patients and one was a mixed ancestry patient. Due to the higher number of white patients 
with family history in the DNA bank, it was possible to exclude white patients from the DNA bank 
who did not fulfil the Amsterdam II criteria. One black patient and one mixed ancestry patient from 
the DNA bank were included using the revised Bethesda guidelines as they developed CRC under the 
age of 50.  
 
One of the white patients (150) that fulfilled the Amsterdam II criteria had a known MSH2 mutation, 
which was identified by the Wessex Regional Genetics Laboratory in Salisbury. The mutation was 
identified using Sanger sequencing of the exons and intron/exon boundaries of MSH2. Previous IHC 
results on patient 150 showed a lack of staining for MSH2. Unfortunately, the IHC status of the other 
patients in this study was not known. Patient 150 was included as a positive control to validate the 
sequencing method.  
 
2.1.2. Sample Collection through the Clinical Diagnostic Service 
Samples were collected at Garden City Clinic, Chris Hani Baragwanath Hospital and Donald Gordon 
Medical Centre. Patients were identified through the Clinical Diagnostic Service and blood was 
collected once the patient had been counselled and informed consent for research was attained 
(Appendix C shows the information and consent forms that the patients signed).  
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Six black patients were identified through the clinical diagnostic service. These patients were 
diagnosed with CRC under the age of 50 and were included in the study. One white patient, who had 
a family history of CRC, was identified through the Clinical Diagnostic Service.  
 
Table 2.1: Summary of the patients and their inclusion criteria  
Ethnic 
Group 
Patient 
Number 
Age at 
Diagnosis 
Gender Location of Tumour Inclusion Criteria Met 
Black  104 49 Male Unknown (3rd recurrence) Revised Bethesda Guidelines 
Black  205 28 Male Sigmoid colon Revised Bethesda Guidelines 
Black  235 21 Male Rectum Revised Bethesda Guidelines 
Black  238 49 Male Rectum Revised Bethesda Guidelines 
Black  247 47 Male Rectum (Recurrence) Revised Bethesda Guidelines 
Black  267 47 Female Rectum Revised Bethesda Guidelines 
Black  290 48 Female Rectum Revised Bethesda Guidelines 
White  32 50 Male Sigmoid colon Amsterdam II Criteria  
White  42 64 Female Unspecified (colectomy) Amsterdam II Criteria  
White  52 37 Male Upper gastro-intestinal tract Amsterdam II Criteria  
White  61 67 Male Distal colon Amsterdam II Criteria  
White  81 29 Male Proximal colon Amsterdam II Criteria  
White  86 40 Female Transverse colon (recurrence) Amsterdam II Criteria  
White  89 49 Female Proximal colon Amsterdam II Criteria  
White  136 56 Female Transverse colon Amsterdam II Criteria  
White  150 44 Male Sigmoid colon Amsterdam II Criteria  
White  190 50 Male Duodenum Amsterdam II Criteria  
White  253 28 Female Rectum Amsterdam II Criteria  
Mixed 
Ancestry 
13 45 Male Unspecified (Colon) Amsterdam II Criteria  
Mixed 
Ancestry  
175 41 Female Rectum Revised Bethesda Guidelines 
Average Ages: Black=41.28; White=46.72; Mixed Ancestry=43.00 
2.1.3. Summary of Samples Collected for Study 
In total, 20 patients were identified for inclusion in this study. Twelve of the 20 patients fulfilled the 
Amsterdam II criteria (11 white, one mixed ancestry) and eight patients fulfilled the revised 
Bethesda guidelines (Seven black, one mixed ancestry). One of the Amsterdam II positive patients 
had a known mutation in MSH2 and was included as a positive control. 
 
Patient DNA was extracted using the salting out technique. However, this technique was performed 
by the Molecular Diagnostic Division in the Department of Human Genetics at the NHLS, 
Braamfontein as they needed to maintain quality control measures on the patient DNA. An aliquot 
of DNA was then given for this study and the DNA concentration was standardised for PCR and MLPA 
applications. The DNA concentration is particularly important in MLPA, which is a quantitative 
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technique. The DNA concentration was measured using a ND-1000 Nanodrop spectrophotometer 
(Thermo Scientific, USA) and then diluted to 50ng/ul of DNA in ddH2O. 
 
2.1.4. Control Samples 
Sanger sequencing detected seven novel variants in the study cohort (Section 3.2). These variants 
were investigated further using either RFLP or HRM which were performed on ethnically matched, 
random population control samples, collected under the “Genetic Diseases studies in Southern 
African populations: Control samples” (ethics approval: M050706) in the Department of Human 
Genetics, NHLS, Braamfontein. These samples were collected at the NHLS in Braamfontein. The 
people that gave these samples consented to their samples being used as population controls and 
their ethnicity was self-reported.  Forty five random white, unlabelled control samples and 45 
random black, unlabelled control samples were used. In addition, these control samples were also 
used in the MLPA reactions. 
 
2.1.5. Ethics Approval 
Ethics approval for this study was obtained from the Wits Human Research Ethics Committee 
(HREC), approval number M10612. The ethics clearance certificate can be seen in Appendix D. As 
stated previously, informed consent was required from all patients whose samples were included in 
this study. The samples were tested in the laboratory as anonymised aliquots using only the patient 
numbers. Due to the nature of the research and the utility of the information to a particular family, 
the supervisors of this study were able to identify the patients through their corresponding 
numbers, for the purposes of reporting results back. The results from this study will be given back to 
the patients or their families by clinicians or genetic counsellors of the Clinical Division. 
 
2.2. Materials and Methods 
2.2.1. Multiplex Ligation-dependent Probe Amplification Analysis 
MLPA is a relatively simple, high throughput and robust technique developed by the company MRC-
Holland. MLPA allows detection of DNA copy number changes of up to 50 probes in a single reaction. 
The technique is based on the semi-quantitative PCR principle and can be applied to detecting copy 
number changes (Schouten et al., 2002). In this way it is ideal for looking for large deletion or 
duplication mutations. For this study, the MLPA technique was used to determine if any exons were 
deleted or duplicated in MLH1 or MSH2.  
 
The MLPA technique uses a specific probe design to detect DNA copy number changes. Each probe 
consists of two oligonucleotides, which are ligated together during the MLPA reaction. The first, 
shorter, oligonucleotide contains a target specific, hybridisation sequence (20-40nt) and a universal 
sequence which is identical for all probes at the 5’ end. The longer oligonucleotide contains a target 
specific sequence (20-40nt), a stuffer sequence of variable length and the universal sequence at the 
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3’ end. The universal sequences at the 3’ and 5’ ends allow PCR amplification using only one PCR 
primer pair (Schouten et al., 2002). The MLPA reaction is shown in Figure 2.2.  
 
Figure 2.2: The MLPA reaction. This figure outlines the steps in an MLPA reaction. 
The hybridisation sequences bind to the target DNA and are then ligated together. The hybridised products are 
then amplified in a PCR reaction, with each amplicons having a unique length (Schouten et al., 2002) 
 
MLPA is particularly useful when trying to detect large deletions or duplications. Large deletions 
where the breakpoints occur outside of the PCR primer will not be detected by Sanger sequencing. If 
the PCR primers are unable to bind to an allele because the breakpoints fall outside of the primers, 
the electropherogram will not show any deletion since only a single allele is amplified. MLPA is a 
quantitative technique, therefore if an allele is not present, the probe will not bind and this lack-of-
binding will be detected through the quantitative PCR reaction. Similarly, an extra allele will be 
detected during quantification as an additional probe binds to that allele (Schouten et al., 2002).  
 
MLPA and Sanger sequencing complement each other during mutation detection. If a patient has a 
homozygous deletion of an exon, or more than one exon, Sanger sequencing would appear to fail as 
the alleles are not present. However, MLPA will detect these deletions as control probes will allow 
the operator to determine whether an exon is deleted, or if the MLPA reaction failed. The Sanger 
sequencing will detect the single base changes and small deletions or duplications that MLPA is 
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unable to detect (Schouten et al., 2002; Boland and Goel, 2010). Somatic mutations in cancer can be 
problematic due to the diversity of mutations in a cancer cell, but this study is aiming to detect 
germline mutations by investigating blood, which should not contain many somatic mutations.  
 
The P003-B2 Probe mix (SALSA MLPA Kit P003-B2 MLH1/MSH2) contains probes for the 19 exons of 
MLH1 and the 16 exons of MSH2. This kit contains two probes for the most 3’ exon of the EPCAM 
gene, which has been shown to be implicated in HNPCC (Ligtenberg, 2009). Furthermore, the P003-
B2 kit contains nine probes that bind to other chromosomal positions and are used as reference 
probes. The details of the probe mix can be found at www.mrc-holland.com. The MLPA technique 
was performed following the manufacturer’s instructions (given in Appendix F.1). Each reaction mix 
for the MLPA technique is given from Table F.1 to F.5.   
 
The MLPA technique requires control samples (5-10) to be run at the same time as the patient 
samples. This not only allows the results to be quantified, but also lowers the error rate. The 
genotype of these control samples was unknown, but they were subsequently confirmed to be wild 
types during MLPA analysis. The MLPA samples were collected into a 96-well plate and placed inside 
the 3130xl Genetic Analyser (Applied Biosystems, USA). The Foundation Data Collection v3.0 
software (Applied Biosystems, USA) was used to initiate the MLPA runs and collected the raw data 
(Appendix F.2).  
 
Nineteen of the 20 patient samples were included in the MLPA analysis. Patient 136 was not 
included in the MLPA analysis as this sample was included late in the study. MLPA for a single sample 
would be too expensive as it is necessary to run at least five control samples with the samples being 
analysed.   
 
2.2.2. Polymerase Chain Reaction 
PCR is a technique that allows for the amplification of a specific segment of DNA (Mullis and Faloona, 
1987). The following sections will describe the methods used for PCR amplification in this study.  
  
2.2.2.1. PCR Primers for PCR Reactions 
The primer sequences used for MLH1 and MSH2 were sent to us courtesy of the Regional Molecular 
Genetics Service at Manchester Academic Health Science Centre, St Mary’s Hospital, Manchester. 
The primer sequences and primer binding sites are given in Appendix E. These primers were used to 
amplify each exon as well as the intron/exon boundaries of both genes. The primers were checked 
for specificity of binding using the Primer-BLAST tool at the National Centre for Biotechnology 
Information (Rozen and Skaletsky, 2000; NCBI, 2011). The primers were synthesised by Inqaba Biotec 
(South Africa) originally and Whitehead Scientific (South Africa) synthesised the primers for exons 7 
and 8 of MLH1 after the original primers were found to be faulty.  
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The primers were designed to include universal tails at the 5’ and 3’ ends of the PCR products which 
allow for easier set up of the Sanger sequencing technique. This was facilitated by a single forward 
or reverse primer being used for the Sanger sequencing reaction. The utility of the universal primers 
is explained in more detail in Section 2.4.1.  
 
2.2.2.2. PCR Conditions for DNA Amplification 
The same PCR conditions were used for each primer pair in every reaction mix. The PCR reaction mix 
is shown in Appendix F (Table F.6). The annealing temperature for the primers (55°C) was given in 
the Standard Operating Procedure (SOP) from the Regional Molecular Genetics Service, Manchester. 
The PCR reaction mixes were placed into an Applied Biosystems 2720 Thermal Cycler (Applied 
Biosystems, USA) and the cycling conditions from the SOP were used (Appendix F, Table F.7). 
Negative controls were run with each batch of samples to check for contamination. The conditions 
for the thermo-cycling can be seen in Table F.7.  
 
Initially, a temperature gradient was used to determine the optimal annealing temperature. It was 
found that the 55°C from the SOP was the optimal temperature for annealing. During the gradient 
PCR, the PCR reaction for exon 7 and 8 of MLH1 did not produce a single band. Further 
troubleshooting involved MgCl2, temperature and primer gradient PCR. These did not resolve the 
problem and new primers were ordered from a different manufacturer (as mentioned in Section 
2.2.2.1). These new primers produced a single, correct sized band at 55°C. 
 
2.2.2.3. Agarose Gel Electrophoresis of PCR Products 
Amplification and band sizes of all the PCR reactions, as specified in Appendix E, were confirmed by 
visualising products on a 3% (w/v) agarose gel (Bioline, UK) containing 3% (v/v) Ethidium Bromide 
(Sigma-Aldrich, UK). For each PCR product, 2μl was mixed with 2μl of Ficoll dye before the mixture 
was loaded into the wells of the agarose gel with a multichannel pipette. The PCR product was 
electrophoresed for approximately one hour at 5V/cm. Finally, the product was visualized using a 
G:Box Vacutec Gel Documentation system with GeneSnap v.6.08 software (Syngene, UK). A 1KB+ 
DNA ladder (Invitrogen, USA) was used to size the bands in the gel. 
 
 
2.2.2.4. PCR Product Clean Up 
Following confirmation of the correctly sized PCR products, the PCR products were cleaned up to 
remove the unused primers as well as excess reagents. It is important to remove these primers and 
reagents before Sanger sequencing as they can interfere in the sequencing process. PCR clean-up 
was performed using either the Qiagen Minelute 96 UF PCR purification kit (Qiagen, Germany) or the 
Machery-Nagel Nucleospin Extract II column clean-up kit (Machery-Nagel, Germany), both of which 
filtered the PCR products through a membrane and an elution buffer was used to collect the purified 
PCR products. 
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The Minelute 96 UF PCR purification kit was primarily used due to the high-throughput efficiency of 
the 96-well plate system. This kit was used following the manufacturer’s instructions (Appendix F.4). 
The Nucleospin Extract II kit was used for individual samples or small batches. This kit was used 
following a protocol (Appendix F.5) that was modified to use a lower volume of reagents. The 
purified PCR products were placed into clean 96-well plates or strip tubes before being used in 
Sanger sequencing. 
 
2.2.3. Sanger Sequencing 
Sanger Sequencing was used to determine the nucleotide sequence of DNA. This sequencing method 
is based on the chain-termination method which utilises dideoxyribonucleotide triphosphates 
(ddNTPs). The ddNTPs are analogues of deoxyribonucleotide triphosphates (dNTPs) which are 
incorporated into the growing DNA chain by DNA polymerase. However, the ddNTPs lack a 3’ 
hydroxyl group, which prevents the next dNTP from joining the growing chain. Separating the 
fragments by size allows one to elucidate the sequence of the DNA (Sanger et al., 1977).   
 
The Sanger sequencing technique is useful for detecting base substitutions, small insertion or 
deletion mutations. Sanger sequencing was performed using the BigDye Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems, USA) for all the MLH1 and MSH2 amplicons. This process was 
performed using a modified reaction mix, which is given in Appendix F (Table F.8). This reaction has 
been modified to use only 4µl of BigDye v3.1 instead of the 8µl recommended by the manufacturer. 
This was found to be the lowest volume of BigDye v3.1 which would yield good quality results. This 
was performed to consume fewer reagents, and thus save costs. The reaction mix was placed in a 
GeneAmp 2720 Thermal Cycler (Applied Biosystems, USA) and a cycle sequencing protocol (given in 
Table F.9) was followed. 
 
2.2.3.1. Universal Primers for Sanger Sequencing 
A universal sequencing primer was used in the reaction mix to facilitate easier set up of sequencing. 
The universal primer was complementary to either the 5’ or 3’ tail that had been included in the 
design of every PCR primer. Inclusion of a universal primer sequence optimises the sequencing 
process as it allows the operator to use a single sequencing primer for all reactions. This is 
particularly useful when sequencing the 18 primer pairs of MLH1 and 16 primer pairs of MSH2. 
Without the universal primer, each exon to be sequenced would require an individual primer. Figure 
2.3 shows how the universal tail and primer is used during both PCR reactions.  
 
Generally, only the universal primer complementary to the 5’ tail (the forward sequencing primer) 
was used and was sufficient to generate good sequencing data. Due to a microsatellite within the 
exon 12 in MLH1, a second, internal forward sequencing primer was needed to obtain good 
sequencing data. Bidirectional sequencing using the reverse primer was undertaken if the forward 
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sequencing data was unclear, or to confirm the presence of a variant. This is the routine approach 
used by the Molecular Diagnostic Division in the Department of Human Genetics, NHLS, 
Braamfontein.  If the variant was still present after sequencing from both directions, it was 
considered to be a confirmed variant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.3.2. Sanger Sequencing Product Clean Up 
Once the Sanger sequencing reaction was completed, it was important to remove excess BigDye v3.1 
reagents from the sequencing products as they could interfere with the interpretation of the 
sequence in the Genetic Analyser. Sanger sequencing clean-up was performed using either the 
Qiagen DyeEx 96 or the Qiagen DyeEx 2.0 spin kits (Both from Qiagen, Germany). These kits use a gel 
bed to remove excess reagents in conjunction with a centrifugal force.  
 
The DyeEx 96 and DyeEx 2.0 kit were used following the manufacturer’s instructions. The DyeEx 96-
well plates allowed for high throughput clean-up while the DyeEx 2.0 could be used for smaller 
batches. The protocols for each kit are given in Appendix F.7 and Appendix F.8, respectively. The 
cleaned Sanger sequencing product was collected and vacuum dried in a Concentrator 5301 
(Eppendorf, Germany) before undiluted Hi-Di Formamide (Applied Biosystems, USA) was used to re-
suspend the DNA products in preparation for the 3130xl Genetic Analyser. 
 
PCR (35 Cycles) 
 
Sequencing PCR 
Figure 2.3: Schematic representation of PCR and sequencing reactions in this study. 
Universal primers (shown in blue) were included at the 5' and 3' ends of the primers (grey). 
The universal primers do not bind to the template DNA but are included in the amplicons. A 
universal sequencing primer (shown in green) can be used to sequence from either the 5’ or 3’ 
tail. 
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2.2.3.3. The 3130xl Genetic Analyser 
The Applied Biosystems 3130xl Genetic Analyser uses a gel matrix, located within the capillaries, to 
separate Sanger sequencing product fragments by size. The fragments then pass a laser which 
detects which fluorescent terminator is present on the particular fragment. Since they separate by 
size, the smallest fragments (those where the terminator is closest to the sequencing primer) pass 
the laser before larger fragments. The sequence of the DNA is then determined in the order that the 
fluorescent terminators pass the laser. This information is captured by the genetic analyser and 
processed by the Foundation Data Collection v3.0 software package. The 3130xl genetic analyser is 
able to process 16 samples in one run, with six runs needed to process a 96-well plate. 
 
Before initializing a sequencing run, the Sanger sequencing product in the 96-well plate was 
denatured at 95°C, for two minutes. The 1x buffer and ddH2O troughs were checked to ensure that 
they were at the correct level and the polymer was checked to make sure it was not empty or 
bubbles were present. The 96-well plate was loaded into the 3130xl Genetic Analyser and the 
Foundation Data Collection v3.0 software was used to create and start each run (given in Appendix 
F.9). Section 2.5 will describe the analysis of the Sanger sequencing and MLPA data. 
 
2.2.4. Mutation Analysis of Sequencing and MLPA Data 
Once Sanger sequencing and MLPA were completed, data analysis was undertaken to determine if 
there were any variants present. The MLPA and sequencing data were collected and analysed 
differently. 
 
2.2.4.1. Sanger Sequencing Data Analysis 
The Sequencing Analysis 5.2 software (Applied Biosystems, USA) was used to interpret the sequence 
of each sample. This program interprets each sequence automatically and uses a base caller to give 
the DNA its sequence based on the electropherogram present. The sequences can then be saved and 
analysed. The procedure for this can be seen in Appendix F.10. 
 
The sequences were transferred and analysed using the DNAStar Seqman II software package 
(Lasergene, USA). Each electropherogram could be viewed in Seqman II and corrections could be 
made if there were errors in base calling. Errors were checked by inspection of the 
electropherograms. It was important to check peak intensities, and ‘pull-ups’ were inspected by 
observing the peak patterns to ensure that the software had called the correct bases.  
 
The sequences needed to be aligned with a reference sequence in order to determine if there were 
any variants present. A reference sequence for each region was obtained from the NCBI Genome 
Browser (NG_007109 and NG_007110 for MLH1 and MSH2, respectively, obtained on 21/07/2011) 
using the RefSeq that was independent of genome builds (NCBI, 2011). The Seqman II programme 
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aligned the sequences with the reference sequences and then highlighted any mismatches. By 
reading through each sequence, it was possible to find variations from the RefSeq sequence.   
 
2.2.4.2. MLPA Data Analysis 
MLPA analysis required a panel to be designed in the GeneMapper software v4.0 (Applied 
Biosystems, USA). This panel needed to be designed so that the software could calculate the relative 
quantities of each amplicon. Since the size of each amplicon in the P003-B2 MLPA kit is known, it 
was possible to input the expected sizes of each amplicon into the panel. The amplicons separate by 
size in the capillaries of the 3130xl Genetic Analyser, allowing the software to determine which 
amplicon was being detected by the 3130xl Genetic Analyser. As the amplicons passed through the 
laser, the intensity of each was detected and captured by the software and recorded in the panel. It 
is the relative intensities of each amplicon from the samples and the control samples that is used to 
determine the allele copy numbers (Schouten et al., 2002). The procedure to retrieve the MLPA data 
can be seen in Appendix F.10. The GeneMapper v4.0 software was used to analyse the raw data and 
determine if the correct size calling occurred for each allele. The data from the GeneMapper v4.0 
software was then exported to await analysis using spread sheets from the National Genetics 
Reference Laboratory. 
 
The National Genetics Reference Laboratory (NGRL) at Manchester provides Excel spread sheets that 
have been preformatted for easier analysis and interpretation of MLPA results (NGRL, 2009). These 
spread sheets are available from their website (www.NGRL.org.uk). The P003-B1 HNPCC spread 
sheet was downloaded to analyse the MLPA data collected. The P003-B2 kit used in this study is an 
updated P003-B1 kit, with two control probes being replaced in the newer kit. The spread sheet was 
formatted to allow easy input of data from the GeneMapper software, thus making it ideal for use in 
this study. The final data is presented as a graph showing the dosage of each exon in the MLPA 
probe mix. 
 
Once all the data from MLPA and Sanger sequencing was collected, it was possible to check the 
reporting history of the variants found using the LOVD database at InSiGHT. 
 
2.2.4.3. Determining Reporting History of Variants 
All variants that were found were checked against one large curated database, The LOVD database 
(v2.0, Build 32b; www.LOVD.nl) at InSiGHT (InSiGHT, 2011). The LOVD database aims to provide a 
freely available and flexible tool for the collection and display of genetic variants (Fokkema et al., 
2011). The LOVD database at InSiGHT is a curated database that has been modified and optimised to 
display the data from MLH1, MSH2 and eight other genes commonly involved in hereditary CRC 
(InSiGHT, 2011).  
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InSiGHT provide a coding reference sequence which allowed for an international standardised 
numbering of nucleotides, allowing for the correct positioning of a variant when identified. The 
numbering in the variant name refers to the nucleotide relative to the ATG start site, where the ‘A’ is 
the first base of the coding sequence (InSiGHT, 2011). Once the variant was correctly named, it could 
be checked against the database to determine if it is novel or has been reported previously. 
 
The LOVD database at InSiGHT contains variants that have been published as well as variants that 
have been directly submitted to the database but not previously published. The database also 
displays information from other, merged databases such as the MMR Gene Unclassified Variants 
Database (Ou et al., 2008) and the Mismatch Repair Genes Variant Database at the Memorial 
University of Newfoundland (Woods et al., 2007). If a variant has already been reported in the 
database, it may be known to be pathogenic or non-pathogenic. This allows variants to be classified 
as novel, pathogenic, non-pathogenic or of unknown significance. The procedure for using and 
evaluating variants on the InSiGHT database can be seen in Appendix F.11. 
 
If a variant was previously reported on the database, it is possible that it would have been submitted 
to the Single Nucleotide Polymorphism database (dbSNP, Build 135) (Sherry et al., 2001). dbSNP is 
the world’s largest database of variations and contains information on variants that have been 
reported. Variants submitted to dbSNP receive a reference SNP number which allows the variant to 
be tracked.  
 
The LOVD database contained links to the UCSC Genome Browser for all previously reported variants 
(Kent et al., 2002a). The UCSC Genome Browser contained information on the variant position and 
the reference SNP number from dbSNP (if available). UCSC also contained the BLAST-like Alignment 
Tool (BLAT), which allowed the variant sequences to be checked to ensure that they had not been 
reported previously on other databases (Kent, 2002b). The BLAT searches were performed by 
inserting the sequence into the BLAT tool and determining whether the sequences had been 
reported previously by giving a percentage match of the queried region (BLAST-Like Alignment Tool 
(BLAT), 2012). 
 
2.2.5. Determining Pathogenicity of Novel Variants 
Six novel variants with an unknown functional significance were detected using the Sanger 
sequencing method. Since these variants had an unknown contribution toward disease, elucidation 
of their potential for pathogenicity was sought. The allele frequencies for each allele were 
determined in a sample of normal controls to elucidate their potential for pathogenicity, using RFLP 
or HRM. If a variant occurs only in one patient, it is suggestive that the variant is possibly pathogenic 
as more common variants are unlikely to be pathogenic (Strachan and Read, 2004). The allele 
frequencies from the control samples were calculated by dividing the number of times a variant 
allele was observed by the total number of alleles in the assay.  
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Bioinformatic analysis was used to determine whether one variant (MSH2 c.-185C>A) may have a 
possible pathogenic effect. This variant was investigated using bioinformatic tools as it is located 
upstream of the transcription start site. Transcription factor binding site prediction, such as that 
found in FASTSNP (fastsnp.ibms.sinica.edu.tw), is a simple and robust method for predicting whether 
a variant will have a functional effect (Yuan et al., 2006). The other variants were located near 
intron/exon boundaries and may create or abolish splice sites. However, in silico tools were unable 
to reliably reproduce results for splice site abolition or creation. 
 
2.2.5.1. Restriction Fragment Length Polymorphism Analysis  
RFLP analysis uses restriction endonucleases to determine whether a restriction site is present, or 
not. This is particularly useful for genotyping as one can design an assay with an appropriate 
restriction endonuclease and determine the genotype of the DNA, depending on whether or not the 
restriction site is present or absent (Strachan and Read, 2004). For this study, the same PCR primers 
for previous PCR reactions were used to amplify the region of interest. Restriction endonucleases 
were then chosen firstly based on whether they had a restriction site at the variant position, and 
secondly whether they were present in the lab or could be ordered. After the restriction enzymes 
were chosen, the PCR products were checked for additional cut sites in the product by searching the 
previously mentioned RefSeq (2.2.4.1) from NCBI (NCBI, 2011). No additional cut sites were 
expected to be present in the PCR products.  
 
RFLP analysis was performed for four of the novel variants detected in this study to determine the 
frequency of the variant in the normal population. Other novel variants were not investigated using 
RFLP as RFLP assays could not be designed due to restriction endonucleases not being available to 
cut at the site of the variant. The novel variants that could not be investigated by RFLP were 
investigated using HRM. The four variants that were investigated using RFLP are listed in Table 2.2. 
 
Table 2.2: Restriction enzymes used to investigate the frequencies of the novel variants 
Gene Variant Restriction 
Enzyme 
Incubation 
Temperature 
Recognition 
Site 
Effect of Variant 
on Recognition 
Site 
MLH1 c.885-1G>A HpyCH4III 37°C ACNGT Abolish 
MSH2 c.1662-10C>T TaqI 65°C* TCGA Abolish 
MSH2 c.1662-43C>T RsaI 37°C GTAC Abolish 
MSH2 c.-185C>A MluI 37°C ACGCGT Create 
*10% efficiency at 37°C 
TaqI (Thermo Fisher Scientific, USA) 
HpyCH4III, RsaI & MluI (New England Biolabs, USA) 
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2.2.5.1.1. RFLP Conditions 
The RFLP analysis was performed using similar conditions for all reactions, which can be seen in 
Table 2.3. The samples were incubated at 37°C. Although TaqI has an incubation temperature of 
65°C, it is still able to digest at 37°C. The RFLP reactions were performed to confirm presence of 
variants in the patient DNA. Each variant were screened in the normal, ethnically matched control 
samples, a no-enzyme control (referred to as a ‘no-cut’ control) to ensure no contamination of 
enzymes, and the patient allele to confirm the presence of the variant. The samples were checked 
using a 3% (w/v) agarose gel at 5V/cm with ethidium bromide and a 1kb+ DNA ladder was used to 
determine the size of the digested fragments.  
Table 2.3: Summary of the RFLP reactions for all enzymes 
Reagent Final Concentration Volume (1X) 
Restriction Enzyme 1U/ul 1ul 
Appropriate Buffer 1X 2.5ul 
ddH2O  11.5ul 
PCR Product  10ul 
Total  25ul 
 
2.2.5.1.2. RFLP for MLH1 Variants 
The MLH1 c.885-1G>A variant was detected in a white patient. The PCR primers for exon 9 of MLH1 
were used to amplify the region around this variant. The amplicon was then digested with HpyCh4III. 
The enzyme will cut the wildtype allele of the PCR product, which is 247bp in size. Therefore, 
following digestion, if the ‘wildtype’ sequence is present, a 77bp fragment and 169bp fragment will 
be present. Figure 2.4 shows the expected fragment lengths for the wildtype and variant sites. 
 
 
 
 
 
 
 
2.2.5.1.3. RFLP Analysis for MSH2 Variants 
The MSH2 c.1662-10C>T novel variant was investigated further as it was found in two black patients. 
The primers for exon 11 of MSH2 were used to amplify the PCR product, which give a product of 
246bp. TaqI was used to investigate this variant as it recognises the wildtype TCGA site. TaqI 
generates two fragments of 80bp and 166bp in wildtype samples. The expected RFLP fragments are 
given in Figure 2.5. 
 
 Size (bp)      1kb+ DNA Ladder     Homozygous G       Heterozygous G/A      Homozygous A 
     300 
     200 
     100 
                                                               
Figure 2.4: Diagram of the expected RFLP analysis using HpyCH4III to screen for the MLH1 
c.885-1G>A variant. HpyCH4III will recognise and cut the wildtype allele.   
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The MSH2 c.1662-43C>T variant was found in one black patient. The PCR primers for exon 11 of 
MSH2 were used to amplify the region surrounding this variant, giving a PCR product size of 246bp. 
This variant was investigated using RsaI, which cuts the wildtype C allele, producing bands of 47bp 
and 199bp. The expected RFLP pattern for each allele can be seen below, in Figure 2.6. 
 
 
 
 
 
 
 
 
The MSH2 c.-185C>A variant was investigated further after it was detected in one black patient. The 
PCR primers for exon one of MSH2 were used to amplify the DNA, giving a PCR product of 535bp in 
size. MluI would cut the DNA if the variant C allele was present, leading to two bands of 35bp and 
500bp. The expected RFLP bands are displayed in Figure 2.7.   
 
2.2.5.2. High Resolution Melt Analysis 
HRM is a technique used to genotype DNA using fluorescent dyes, melt-curve analysis and other 
statistical techniques. HRM uses PCR techniques with a fluorescent, intercalating dye to perform 
real-time PCR. Immediately after the real-time PCR stage, the PCR products are melted and the 
fluorescence is measured. The technique is so sensitive, that a single base pair change in the PCR 
product could alter the melting curve, even in PCR products as large as 300bp (Gundry et al., 2003; 
Wittner et al., 2003). The sensitivity of the technique allows one to determine the genotype of the 
Size (bp)   1kb+ DNA Ladder    Homozygous C   Heterozygous C/T     Homozygous T 
300bp 
200bp 
100bp 
Figure 2.5: Diagram showing the expected RFLP fragments when TaqI is used to 
investigate the MSH2 c.1662-10C>T variant. TaqI will recognise the wildtype allele 
 
300bp 
200bp 
100bp 
Size (bp)   1kb+ DNA Ladder    Homozygous C   Heterozygous C/T     Homozygous T 
Figure 2.6: Diagram showing the expected RFLP fragments when RsaI is used 
to investigate the MSH2 c.1662-43C>T variant. RsaI recognises the wildtype 
GTAC site.  
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sample by comparing the normalised melting curve of a sample with that of a control, as shown in 
Figure 2.8.  
 
 
 
 
 
 
HRM analysis was used to determine the allele frequencies of two novel variants (MSH2 c.367-16T>A 
and MLH1 c.1732-19T>A) in 25 random samples from the ethnically matched populations (described 
500bp 
400bp 
300bp 
200bp 
100bp 
 Size (bp)    1kb+ DNA Ladder    Homozygous A   Heterozygous A/C   Homozygous C 
Figure 2.7: The expected RFLP fragments when MluI is used to investigate the 
MSH2 c.-185C>A variant located within the regulatory region. MluI will cut the 
DNA if the variant is present.  
 
Figure 2.8: The HRM normalised melting curve obtained from control 
samples. The wildtype allele is the top curve and the variant (MLH1 
c.1732-19T>A is the bottom curve. Random samples would be compared 
to these curves to determine allele frequency  
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in Section 2.1.4). HRM was chosen to analyse these variants as the restriction enzymes required to 
investigate these variants were not available in the lab and could not be ordered. Only 25 samples 
were used as the HRM reagents are costly and were limited. The PCR primers used to amplify the 
variants were the same PCR primers used for previous PCR reactions. These gave amplicons sizes of 
284bp (MLH1 c.1732-19T>A) and 391bp (MSH2 c. 367-16T>A).  
 
HRM was performed using the Bioline SensiMix HRM kit (Bioline, USA) in the Roche LightCycler 480 
(Roche, Switzerland) following the manufacturer’s instructions (given in Appendix F.12). This kit 
contains EvaGreen fluorescent dye. SYBR Green is not considered a good dye for HRM as it affects 
the melting of the double stranded DNA; it inhibits PCR and affects the signal intensities as liberated 
dyes redistribute to the double stranded DNA (Gundry et al., 2003). EvaGreen is able to provide 
similar spectra to SYBR Green, but does not have the abovementioned drawbacks.  
 
The normalised melting curve was obtained by performing HRM on two samples with known 
genotypes. The positive control for a heterozygous genotype was the patient sample that was found 
to harbour the variant. The normal homozygote was also a patient sample that was known to be a 
homozygous normal after sequencing. When the HRM analysis was completed, a normalised melting 
curve, which accounts for differences in temperature between wells, for the samples and controls 
was generated by the software, using the information from the fluorescence as the amplicons 
melted.  
 
2.2.5.3. FASTSNP 
The Functional Analysis and Selection Tool for Single Nucleotide Polymorphisms (FASTSNP) is a 
bioinformatics tool that is used to predict whether a particular variant will have a functional effect 
on the protein. The tool analyses non-coding variants, non-synonymous variants and synonymous 
variants (Yuan et al., 2006). 
 
FASTSNP was used to evaluate whether the MSH2 c.-185C>A variant could have a possible functional 
effect with regard to changes in mRNA transcription by altering transcription factor binding sites. 
The 300bp region upstream of the transcription start site was submitted to FASTSNP using the novel 
SNP analysis tool. The position of the variant was given as well as the base change.  
 
Since this is a non-coding region, FASTSNP will analyse the region to determine if the variant alters 
the binding site of any transcription factors, which may affect mRNA transcription. FASTSNP 
analysed the sequence and the variant against the TFSEARCH database to predict transcription 
factor binding affinities. Altering mRNA transcription may lead to a lower or higher expression of 
mRNA, which could affect the functioning of the gene (Strachan and Read, 2004; Yuan et al., 2006). 
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3. Results 
This chapter will describe all the results that were found during this study. Section 3.1 will describe 
the results of the MLPA analysis. Section 3.2 will describe all the variants that were found during 
Sanger sequencing of the exons of MLH1 and MSH2. This will include all the variants that were found 
and their positions in the gene as determined using the InSiGHT coding reference sequence. Section 
3.3 will describe the results of elucidating the pathogenicity of the novel variants that were detected 
using Sanger sequencing. Section 3.4 will characterise the mutation spectrum of the MLH1 and 
MSH2 variants in this cohort. 
 
3.1. MLPA Analysis for MLH1 and MSH2 
MLPA analysis is an important technique to perform as it has been found that more than 6% of 
MSH2 mutations are large deletions and that large deletions also occur in MLH1 (Wijnen et al., 1998; 
Boland and Goel, 2010). Gille et al. (2002) found that 29% of their cohort had mutations that were 
detected using MLPA, 22% of which were found to be pathogenic. MLPA was performed on 19 
patients and five random white samples as controls. The MLPA technique found no large deletions 
or duplications in any of the exons tested in the P003-B2 kit. The MLPA graphs that were generated 
were all similar and an example of the graphs can be seen in Figure 3.1. 
 
 
  
 
 
3.2. Variants detected using Sanger Sequencing 
All 19 exons of MLH1 and all 16 exons of MSH2 were successfully sequenced and produced good 
data. Variants were detected from sequencing the forward primer and these variants were then 
confirmed by sequencing using the reverse primer. The variants present on both electropherograms 
were considered confirmed. The expected mutation from the positive control was detected. An 
additional 21 different variants were detected in the patient samples. All the variants that were 
detected are given in Table 3.1 for MLH1 and Table 3.2 for MSH2.  
 
 
Figure 3.1: The MLPA result generated using the spread sheet from NGRL. Since all patients tested for 
MLPA were found to have no large insertions, deletions or duplications, all the patients MLPA results were 
similar to this one, with each allele being ≈1.0. If one allele was deleted, the bar would have been ≈0.5. If 
both alleles were deleted, the bar would be at 0. If one allele was duplicated, the bar would be ≈1.5, and if 
both alleles were duplicated, it would have been ≈2.0.  
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Table 3.1: Summary of all variants detected in each patient in MLH1. The dbSNP numbers are available from 
NCBI (Database for Single Nucleotide Polymorphisms (dbSNP), 2012) 
 
Patient Number: Green= Amsterdam II Positive, Blue= Bethesda positive 
MA: Mixed Ancestry Patients. Other green blocks are white patients and other blue blocks are black patients 
Novel variants: Orange blocks 
Previously reported pathogenic variants: Red blocks 
 
 
Table 3.2: Summary all variants detected in each patient in MSH2. The dbSNP numbers are available from 
NCBI (dbSNP, 2012) 
Patient Number: Green= Amsterdam II Positive, Blue= Bethesda positive 
MA: Mixed Ancestry Patients. Other green blocks are white patients and other blue blocks are black patients 
Novel variants: Orange blocks 
Previously reported pathogenic variants: Red blocks 
 
Gene Variant 
dbSNP 
Number 
Location 
Patient Number 
1
3
 (M
A
) 
3
2
 
4
2
 
5
2
 
6
1
 
8
1
 
8
6
 
8
9
 
1
3
6
 
1
5
0
 
1
9
0
 
2
5
3
 
1
0
4
 
1
7
5
 (M
A
) 
2
0
5
 
2
3
5
 
2
3
8
 
2
4
7
 
2
6
7
 
2
9
0
 
MLH1 c.381-41A>G rs4647245 Intron 4                  X  X 
MLH1 c.454-51T>C rs4647255 Intron 5             X        
MLH1 c.454-13A>G  Intron 5             X        
MLH1 c.655A>G rs1799977 Exon 8   X  X   X   X        X  
MLH1 c.731_734delGTTA  Exon 9         X            
MLH1 c.885-1G>A  Intron 10      X               
MLH1 c.1039-8T>A rs193922367 Intron 11    X    X         X    
MLH1 c.1039-7delT  Intron 11       X    X     X    X 
MLH1 c.1558+14G>A rs41562513 Intron 13              X       
MLH1 c.1668-19A>G rs9876116 Intron 14   X  X   X   X    X X  X X X 
MLH1 c.1732-19T>A  Intron 15               X      
Gene Variant 
dbSNP 
Number 
Location 
Patient 
1
3
 (M
A
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3
2
 
4
2
 
5
2
 
6
1
 
8
1
 
8
6
 
8
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1
3
6
 
1
5
0
 
1
9
0
 
2
5
3
 
1
0
4
 
1
7
5
 (M
A
) 
2
0
5
 
2
3
5
 
2
3
8
 
2
4
7
 
2
6
7
 
2
9
0
 
MSH2 c.-185C>A  Upstream               X      
MSH2 c.211+9C>G rs2303426 Intron 1   X   X      X   X X X X   
MSH2 c.367-16T>A  Intron 2     X                
MSH2 c.573C>T rs1800151 Exon 3               X      
MSH2 c.942+16_942+29delA13  Intron 5               X      
MSH2 c.1511-9T>A rs12998837 Intron 9      X               
MSH2 c.1661+12G>A rs3732183 Intron 10      X     X    X X X X  X 
MSH2 c.1662-43C>T  Intron 10             X        
MSH2 c.1662-10C>T  Intron 10                X X    
MSH2 c.1811C>A  Exon 12          X           
MSH2 c.2006-6T>C rs2303428 Intron 12           X          
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A total of 22 variants were detected in this study, including the positive control. All the variants were 
checked to determine reporting history (InSiGHT, 2011; BLAT, 2012). Of the 22 variants, 12 had been 
previously reported as non-pathogenic and four were previously reported as pathogenic mutations. 
Six novel variants were detected. All the variants, except the MSH2 pathogenic mutation, c.1811C>A, 
were detected in the heterozygous state. The MSH2 c.1811C>A mutation was detected as a 
homozygote, although previous investigation showed that this is a heterozygous patient. This finding 
is discussed in more detail in Section 4.3.3.1. 
 
3.2.1. Variants Detected in MLH1 
There were 11 variants found in MLH1 (Table 3.1). Of these variants, two were located within exons 
(c.655A>G and c.731_734delGTTA) and the other nine variants were located within introns. The 11 
variants detected in MLH1 were screened through the LOVD at InSiGHT (InSiGHT, 2011). Nine of the 
variants in MLH1 were previously reported and two were novel variants. Seven of the previously 
reported variants were found to be non-pathogenic while two were previously reported as 
pathogenic mutations. 
 
3.2.1.1. Previously Reported Non-Pathogenic Variants in MLH1 
The seven previously reported non-pathogenic variants are summarised in Table 3.3. All of these 
variants have been reported as benign or have a minor effect. The c.655A>G variant (p.Ile219Val) 
was found in five patients in this study (four whites and one black), suggesting that it is a common 
variant in the population of South Africa. The electropherogram for the c.655A>G variant can be 
seen in Figure 3.2. This variant has been observed in other studies (Table 3.3) and is largely 
considered benign. However, Campbell et al. (2009) indicate that this variant may lead to an 
increased risk of CRC in conjunction with the Western diet. The other non-pathogenic variants in 
MLH1 are benign and will not be investigated further. 
 
 
 
 
 
 
 
 
3.2.1.2. Previously Reported Pathogenic Variants in MLH1 
Two of the variants detected in MLH1 (c.454-13A>G and c.731_734delGTTA) were previously 
reported as pathogenic. These variants are summarised in Table 3.4. These two previously reported 
Figure 3.2: The MLH1 c.655A>G variant (p.I219V), which leads to a missense mutation, in 
exon 8. The wildtype DNA sequence is seen on the left while the variant can be seen on 
the right.  
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variants are confirmed as pathogenic mutations, which indicates that patient 104 and patient 136 
have confirmed Lynch Syndrome. The implications of these mutations in discussed in Section 4.1.1. 
 
Table 3.3: Summary of the previously reported non-pathogenic variants in MLH1 that were detected in the 
South African cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.4: Summary of the previously reported pathogenic variants that were detected in MLH1 in the South 
African cohort 
Mutation Location Patient and 
Ethnicity 
References Comment 
c.454-13A>G Intron 5 104, Black Lagerstedt Robinson 
et al., 2007 
Aberrant splicing of exon 
6 (Lagerstedt Robinson et 
al., 2007) 
c.731_734delGTTA  Exon 9 136, White Ramesar et al. 
(InSiGHT, 2011) 
4bp deletion leading to a 
truncated protein 
(InSiGHT, 2011) 
 
Variant Location Reference Comment 
c.381-41A>G Intron 4 Zavodna et al., 2006 Non-pathogenic 
c.454-51T>C Intron 5 Nystrom-Lahti et al., 1996 
Wu et al., 1997 
Fredriksson et al., 2006 
Non-pathogenic 
c.655A>G 
(p.Ile219Val) 
Exon 8 Liu et al., 1995 
Nystrom-Lahti et al., 1996 
Ward et al., 2002 
Fredriksson et al., 2006 
Takahashi et al., 2007 
Capellá et al., 2008  
Christensen et al., 2008 
Campbell et al., 2009 
Associated with 
increased risk of CRC in 
patients with high 
Western diet intake 
(Campbell et al., 2009) 
c.1039-8T>A Intron 11 Wang et al., 1998 Non-pathogenic 
c.1039-7delT Intron 11 Hudler et al., 2004 Non-pathogenic 
c.1558+14G>A Intron 13 Kowalski et al., 1997 
Auclair et al., 2006 
Fredriksson et al., 2006 
Christensen et al., 2008 
Non-pathogenic 
c.1668-19A>G Intron 14 Nystrom-Lahti et al., 1996 
Hudler et al., 2004 
Auclair et al., 2006 
Fredriksson et al., 2006 
Capellá et al., 2008 
Christensen et al., 2008 
Non-pathogenic 
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3.2.1.2.1. The MLH1 c.454-13A>G Splice Mutation 
The MLH1 c.454-13A>G mutation was detected in patient 104 who is a black patient who fulfilled 
the age criterion of the Bethesda guidelines. This mutation was heterozygous in patient 104 and has 
been previously reported to show aberrant splicing of exon 6 in MLH1 (Lagerstedt Robinson et al., 
2007). The electropherogram for this mutation can be seen in Figure 3.3. 
 
 
 
 
 
 
 
 
3.2.1.2.2. The MLH1 c.731_734delGTTA Frameshift Mutation 
The MLH1 c.731_734delGTTA mutation was found and confirmed as a heterozygous 4bp deletion in 
exon 9 of MLH1 in patient 136, a white patient who fulfilled the Amsterdam II criteria. This mutation 
has been reported on the InSiGHT database by Ramesar et al. (unpublished data). However, the 
InSiGHT entry has this variant as c.731_733delGTTA. This nomenclature is not correct as it is a four 
base pair deletion and not a three base pair deletion. This variant will be called as c.731_734delGTTA 
in this study. The variant data from the LOVD is given in Figure 3.4. The mutation has been reported 
as a deletion that leads to a frame shift, which results in a premature stop codon downstream, as 
given in the abbreviated nomenclature, p.fsX. This gives a truncated protein product (InSiGHT, 2011). 
Figure 3.5 shows the electropherograms for this mutation.  
 
 
 
Figure 3.3: The MLH1 c.454-13A>G variant of intron 5 found in Patient 104. The 
wildtype sequence is displayed on the left while the image on the right shows the 
heterozygous variant seen in Patient 104 
Figure 3.4: The variant data that was obtained from LOVD for the MLH1 c.731_734delGTTA variant 
(InSiGHT, 2011). This image shows that the variant is named as c.731_733delGTTA, which is incorrect 
as it is a four base pair deletion 
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3.2.1.3. Novel Variants Detected in MLH1 
Two novel variants were detected in MLH1, which are shown in Table 3.5. These variants had an 
unknown contribution toward disease. Section 3.3 will describe the results of determining the allele 
frequency of each variant and determining the pathogenic status for novel variants in MLH1 and 
MSH2. The electropherograms for c.885-1G>A and c.1732-19T>A can be seen in Figures 3.6 and 3.7, 
respectively. 
 
 
Table 3.5: Summary of the novel variants detected in MLH1 in the South African cohort 
Variant Location Patient Ethnicity Inclusion Criteria 
c.885-1G>A Intron 10 81 White Amsterdam II  
c.1732-19T>A Intron 15 205 Black Revised Bethesda 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: The MLH1 c.731_734delGTTA mutation in exon 9. This sequence was inspected to 
ensure that the correct base calling was made. The reverse primer was used to confirm the 
presence of the mutation and can be seen in this image. 
Reverse primer 
for patient 136 
Figure 3.6: The MLH1 c.885-1G>A novel variant located within the splice acceptor site of 
intron 10. The wildtype DNA sequence is shown on the left. The image on the right shows the 
heterozygous mutation that was found in patient 81.  
51 
 
 
 
 
 
3.2.2. Variants Detected in MSH2 
Eleven variants were detected in MSH2 using the Sanger sequencing technique. Two of these 
variants were found within exons (c.573C>T and c.1811C>A) while one was found upstream in the 
regulatory region (c.-185C>A). The other eight variants were located within the introns of the MSH2 
gene. One of the variants in MSH2 was the known positive control, which was a pathogenic mutation 
(Described in Section 3.2.2.1). A second variant was found to be previously reported as pathogenic. 
Five of the variants detected in MSH2 were previously reported as non-pathogenic while four 
variants were found to be novel. 
 
3.2.2.1. Positive Control  
The c.1811C>A missense mutation (p.Ala604Asp) had previously been detected in exon 12 of MSH2 
in white patient 150, who fulfilled the Amsterdam II criteria. This variant was detected by the 
Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury and has only been 
reported by this group. This variant was characterised as a pathogenic mutation following IHC 
evidence, bioinformatics tools and disease co-segregation analysis using the patient’s sibling, who 
was also affected by colon cancer.  
 
The patient was included to validate the technique of Sanger sequencing. Figure 3.8 shows the 
electropherogram for the c.1811C>A variant that was detected in patient 150. The report by the 
Wessex Regional Genetics Laboratory indicated that the patient carried a heterozygous mutation. 
However, Figure 3.8 shows a homozygous mutation and this is discussed in Section 4.3.3.1.   
 
Figure 3.7: The MLH1 c.1732-19T>A novel variant that was detected in intron 15. The 
wildtype DNA sequence is seen on the left and the variant is seen on the right 
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3.2.2.2. Previously Reported Non-Pathogenic Variants in MSH2 
In MSH2, there were five variants that were previously reported as non-pathogenic. The c.573C>T 
(p.Leu191Leu) variant is located within exon 3 of MSH2 but has been reported as a non-pathogenic 
synonymous mutation (Auclair et al., 2006). The other non-pathogenic variants were reported as 
benign and will not be discussed further in this section but are summarized in Table 3.6. 
 
Table 3.6: Summary of the previously reported non-pathogenic variants in MSH2 in the South African cohort 
Variant Location Reference Comment 
c.211+9C>G Intron 1 Weber et al., 1997 
Wang et al., 2006 
Capellá et al., 2008 
Non-pathogenic 
c.573C>T 
(p.Leu191Leu) 
Exon 3 Farrington et al., 1998 
Auclair et al., 2006 
Non-pathogenic 
synonymous 
substitution 
c.942+16_942+18delA13 Intron 5 Weber et al., 1997 Non-pathogenic 
c.1511-9T>A Intron 9 Borresen et al., 1995 Non-pathogenic 
c.1661+12G>A Intron 10 Wijnen, Fodde and 
Khan, 1994 
Farrington et al., 1998 
Wang et al., 2006 
Tournier et al., 2008 
Park et al., 2008 
Non-pathogenic 
Figure 3.8: The MSH2 c.1811C>A novel variant in exon 12. This missense mutation was 
detected by the Wessex Regional Genetics Laboratory and was included in this study as a 
positive control. The image on the left shows the wildtype DNA sequence and the image on 
the right shows the variant. 
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3.2.2.3. Previously Reported Pathogenic Variants in MSH2  
Only one previously reported pathogenic variant was detected in MSH2 and is summarised in Table 
3.7. The mutation electropherogram can be seen in Figure 3.9. The implications of these pathogenic 
mutations on the families are discussed in Section 4.1.1. 
 
Table 3.7: Summary of the reporting history for the previously reported pathogenic mutation in MSH2 
detected in this study 
Variant Location Patient and 
Ethnicity 
Reference Comment 
c.2006-6T>C Intron 12 190, White Brentnall et al., 1995 
Farrington et al., 1998 
Beiner et al., 2006 
Wang et al., 2006 
Capellá et al., 2008 
Christensen et al., 2008 
Tournier et al., 2008 
Aberrant splicing of 
exon 13 (Brentnall et 
al., 1995; Tournier et 
al., 2008) 
Increased risk of 
endometrial cancer 
(Beiner et al., 2006) 
 
 
 
 
 
 
 
 
3.2.2.4. Novel Variants Detected in MSH2 
Four novel variants were detected in MSH2 in this study. As in 3.2.1.3, these novel variants have an 
unknown contribution toward disease but Section 3.3 will describe the elucidation of their 
pathogenicity. Table 3.8 shows a summary of the novel variants detected in MSH2. The 
electropherograms for each variant can be seen in Figures 3.10-3.13. 
 
Table 3.8: Summary of the novel variants detected in MSH2 in this study 
Variant Location Patient Ethnicity Inclusion Criteria 
c.-185C>A Upstream 205 Black Revised Bethesda  
c.367-16T>A Intron 2 61 White Amsterdam II 
c.1662-43C>T Intron 10 104 Black Revised Bethesda 
c.1662-10C>T Intron 10 235, 238 Black, Black Revised Bethesda (Both) 
 
Figure 3.9: The MSH2 c.2006-6T>C pathogenic variant of intron 12. The wildtype 
DNA sequence for the region is seen on the left. The image on the right shows the 
heterozygous variant  
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Figure 3.11: The MSH2 c.367-16T>A novel variant of intron 2. The image on the left shows 
the wildtype DNA sequence and the image on the right shows the heterozygous variant in 
patient 61.  
Figure 3.10: The MSH2 -185C>A novel variant in the regulatory region. The image 
on the left shows the wildtype DNA sequence and the image on the right shows the 
variant sequence found in patient 205  
Figure 3.12: The MSH2 c.1662-43C>T novel variant located within intron 10. The 
image on the right shows the variant as it was detected in patient 104 and the image 
on the left shows the wildtype DNA sequence. 
Figure 3.13: The MSH2 c.1662-10C>T novel variant located within intron 10. The image on the 
left shows the wildtype DNA sequence. The images in the middle and on the right show the 
variants that were detected in two different black African patients, 235 and 238, respectively. 
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3.2.3. Summary of Variants Detected by Sanger Sequencing 
In summary, 22 variants were detected in MLH1 and MSH2 in this study. Four variants were 
previously reported as pathogenic, one of which was a positive control, and 12 were previously 
reported as non-pathogenic. The other six variants detected are novel variants that have an 
unknown contribution towards disease. The novel variants are given in Table 3.5 (MLH1) and Table 
3.8 (MSH2). Since these variants had an unknown contribution toward disease, it is important to 
investigate these variants further. 
 
3.3. Determining Pathogenicity of the Novel Variants 
The previously reported variants had known functions since they were previously found and their 
contribution toward disease had been determined. This study found six novel variants that had an 
unknown effect and further investigation was undertaken. The allele frequency of the novel variants 
was investigated using ethnically match, random control samples. Four variants were investigated 
using RFLP and two with HRM. The bioinformatic tool FASTSNP was used to investigate the upstream 
MSH2 c.-185C>A variant. 
 
3.3.1. Restriction Fragment Length Polymorphisms 
The allele frequencies for four variants were determined using restriction enzymes. A summary of 
the allele frequencies of each variant from the RFLP assays is given in Table 3.9. Each individual 
variant is described below with regard to their pathogenicity as determined in this study.  
 
Table 3.9: Summary of the allele frequencies that were determined by RFLP for each variant. If variants were 
not detected in controls, the allele frequency would remain as 1.00. The MSH2 c.1662-10C>T was in both the 
heterozygous and homozygous state for the T allele, in control samples 
Gene Variant Ethnic 
Group 
Number 
(Controls) 
Allele Frequency 
A C G T 
MLH1 c.885-1G>A White 45 0.00 - 1.00 - 
MSH2 c.-185C>A Black 45 0.00 1.00 - - 
MSH2 c.1662-43C>T Black 45 - 1.00 - 0.00 
MSH2 c.1662-10C>T Black 45 - 0.66 - 0.34 
 
3.3.1.1. MLH1 c.885-1G>A variant 
The MLH1 c.885-1G>A variant was screened in patient 81 as well as 45 random white patients using 
the HpyCH4III restriction enzyme. The presence of this variant in patient 81 was confirmed using 
RFLP analysis and the variant was not detected in any of the 45 random white samples that were 
screened. Figure 3.14 shows the gel picture of the DNA ladder, patient 81 and the no cut control.  
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The MLH1 c.885-1G>A variant is located on the splice acceptor site of exon 9 in MLH1 and was not 
detected in control samples. Based on this evidence, the MLH1 c.885-1G>A variant is likely to be 
pathogenic. The implication of this finding on the family is discussed further in Section 4.1.1. 
 
 
 
 
 
 
 
 
3.3.1.2. MSH2 c.-185C>A variant 
The MSH2 c.-185C>A variant was investigated using the MluI restriction enzyme after it was 
detected in patient 205. This variant was not detected in any of the random black samples tested 
(Table 3.9). The low allele frequency (C=1.00; A=0.00) shows that the variant is unlikely to be 
polymorphic, and may be pathogenic. The bioinformatics tool FASTSNP was used to determine 
whether this variant may have a putative functional effect (Section 3.3.3. 
 
3.3.1.3. MSH2 c.1662-43C>T variant 
The MSH2 c.1662-43C>T was detected in the black patient 104, who was previously shown to have 
the pathogenic MLH1 c.454-13A>G mutation. This variant in MSH2 was screened using RsaI in 45 
random black samples. This variant was not found in any of the random black samples (Table 3.9). 
This is suggestive that this variant is non-pathogenic. 
 
3.3.1.4. MSH2 c.1662-10C>T variant 
The MSH2 c.1662-10C>T variant was detected in two black individuals (235 and 238) and was 
investigated further using TaqI to determine the allele frequency of this variant. The c.1662-10C>T 
variant was found to be common (C=0.66; T=0.34) in the black population. It must be stated that the 
allele frequency seen here may not reflect homozygotes as the efficiency of TaqI was reduced due to 
the low incubation temperature. However, it is shown that this variant is polymorphic as the enzyme 
has cut a number of random samples. This strongly suggests that this variant is non-pathogenic. 
Figure 3.15 shows the RFLP gel picture that was obtained for patients 235 and 238, which confirmed 
the presence of the variant. 
 
 
Figure 3.14: RFLP analysis with HpyCH4III performed on patient 81. This gel picture 
shows that patient 81 was heterozygous for c.885-1G>A as the presence of two 
alleles is confirmed. The ‘no enzyme control’ was included to ensure no 
contamination was present 
Size (bp)     1kb+ Ladder           Patient 81      No Enzyme Control  
300 
200 
100 
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3.3.2. High Resolution Melt Analysis 
Two novel variants (MLH1 c.1732-19T>A and MSH2 c.367-16T>A) were investigated using the HRM 
technique. RFLP assays could not be designed for these two variants as no restriction enzymes 
corresponded to their positions. HRM was used to determine the allele frequencies of these two 
variants, and the results are summarised in Table 3.10. 
 
3.3.2.1. MLH1 c.1732-19T>A variant 
The MLH1 c.1732-19T>A variant was detected in the black patient 205 and was investigated using 
HRM. Comparing the HRM normalised melting curves of the 25 random black samples with the 
control samples, it was possible to determine the allele frequencies (T=0.94, A=0.06) as three 
heterozygous control samples were found to have this allele. This indicates that this variant may be 
common in the African population. The HRM melting curve with the controls and one heterozygous 
and one homozygous sample can be seen in Figure 3.16. 
 
3.3.2.2. MSH2 c.367-16T>A variant 
The MSH2 c.367A>C variant was detected in the white patient 61 and was investigated using the 
HRM technique. Unfortunately, the control samples did not produce distinct normalised melting 
curves, making analysis of variants impossible. This result is discussed in Section 4.4.2.2 below. There 
are no allele frequency data for this variant, which means that this variant has unknown significance 
in the white population.   
 
 
 
Figure 3.15: RFLP gel picture from using TaqI to investigate the MSH2 
c.1662-10C>T variants in patients 235 and 238.  
100 
200 
300 
400 
1kb+ ladder Patient 235 Patient238 No Enzyme Control Size (bp) 
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Table 3.10: Summary of allele frequencies for the two variants that were investigated using HRM. Three 
heterozygous control samples were detected among the control samples (3/50=0.06) 
Gene Variant Ethnic 
Group 
Number 
(Controls) 
Allele Frequency 
A C G T 
MLH1 c.1732-19T>A Black 25 0.06 - 0.94 - 
MSH2 c.367-16T>A White 25 - - - - 
 
 
 
  
 
 
3.3.3. FASTSNP Analysis 
The MSH2 c.-185C>A was investigated using the FASTSNP bioinformatics tool which would allow for 
the prediction of changes to transcription factoring binding sites. FASTSNP predicts that there would 
be no change to transcription factor binding at the position of the variant. Table 3.11 shows the 
FASTSNP result for the MSH2 c.-185C>A variant, which indicates that this variant may not have a 
functional effect and may not be pathogenic. 
 
The MSH2 c.-185C>A variant was found to have a low frequency in the control samples and FASTSNP 
indicates that this variant has no functional effect. This variant is considered to have an unknown 
contribution toward disease. 
Figure 3.16: The HRM normalised melting curve for the assay of MLH1 
c.1732-19T>A variant. The top curve shows the normalised curve for the 
homozygous control and random samples. The bottom curve shows the 
normalised curve for the heterozygous control and random sample 
 
Homozygous alleles 
Heterozygous alleles 
59 
 
 
Table 3.11: Adaptation of the FASTSNP results for the MSH2 c.-185C>A variant. This tool predicts that neither 
allele will bind transcription factors and as such predicts that there will be no change to transcription factor 
binding. The entry column will name the transcription factors that bind to that particular sequence over the 
allele. Since the entry column does not change, it indicates that the variant has no effect (Yuan et al., 2006) 
Transcription Regulatory (Predicted result of transcription factor binding sites change: No) 
TFSEARCH 
Allele Transcription Factor Binding Sites Entry 
C AGCGTGCGCGGGAAGCTGGGCCGCGTCTGCTTATGATTGGT  
A AGCGTGCGCGGGAAGCTGGGACGCGTCTGCTTATGATTGGT  
 
3.3.4. Summary of Investigation of Pathogenicity for Novel Variants 
Elucidation of the pathogenic status for the six novel variants was undertaken in this study. A 
summary of the determined status is given in Table 3.12. Only the MLH1 c.885-1G>A variant is 
considered to be pathogenic. The MSH2 c.-185C>A variant and the MSH2 c.367-16T>A variant have 
an unknown contribution toward disease while the other three variants are likely to be non-
pathogenic.  
 
Table 3.12: Summary of the pathogenic status for the seven novel variants detected in the South African 
cohort 
Gene Variant Location Status 
MLH1 c.885-1G>A Intron 10 Pathogenic 
MLH1 c.1732-19T>A Intron 15 Non-pathogenic 
MSH2 c.-185C>A Upstream Unknown  
MSH2 c.367-16T>A Intron 2 Unknown 
MSH2 c.1662-10C>T Intron 10 Non-pathogenic 
MSH2 c.1662-43C>T Intron 10 Non-pathogenic 
  
3.4. Characterising the Mutation Spectrum 
In total, 22 variants were detected in the MMR genes MLH1 and MSH2 in a cohort of 20 patients. 11 
of these variants were in MLH1 and 11 were in MSH2. There were six novel variants that have not 
been previously published or reported. In MLH1, two novel variants were detected (c.885-1G>A and 
c.1732-19T>A). In MSH2, there are four novel variants (c.-185C>A, c.367-16T>A, c.1662-43C>T and 
c.1662-10C>T). A positive control with a known mutation in MSH2 c.1811C>A was included in the 
study. Nine of the variants found in this study were present in more than one patient, indicating that 
13 variants were detected in only one individual each.   
 
3.4.1.1. Variants Separated by Ethnicity 
The variants were separated by ethnicity to determine if there were any variants that were more 
common in a specific ethnic group. Any individual that fulfilled the Amsterdam II criteria was 
included in this study, which led to 12 white patients and one mixed ancestry patient (N=13). Due to 
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the paucity of family history, black and mixed ancestry patients were included using the revised 
Bethesda guidelines, which led to six black patients and one mixed ancestry patient being included in 
this study (N=7). This could show which variants are common in the South African white population 
and which are common in the black population of South Africa. The MLH1 c.381-41A>G and MSH2 
c.1662-10C>T variants were in more than one black patient and not in the white or mixed ancestry 
patients. Table 3.13 gives a summary of all the variants detected in this study as well as the ethnic 
group of the patients each variant was detected in.  
 
Table 3.13: Summary of the variants and the ethnic groups they were detected in. All these variants were 
detected as heterozygotes, or were known to be heterozygous in the case of MSH2 c.1811C>A. 
Pathogenic mutations: Red Blocks 
Non-Pathogenic variants: Green Blocks 
Unknown contribution variants: Blue Blocks  
 
A total of 53 variants were detected, making up 22 different variants. The black study cohort (N=7) 
harboured 29 variants (54%) while 24 variants (45%) were observed in the white individuals (N=11) 
and the mixed ancestry individuals (N=2) were found to have one variant (1%). The MLH1 c.1668-
19A>G variant was the most commonly detected variant in the entire cohort (45% of cohort) and 
Gene Variant Observed 
 
 
Ethnicity 
Black 
(N=7) 
White 
(N=11) 
Mixed 
Ancestry 
(N=2) 
MLH1 c.381-41A>G 2 2   
MLH1 c.454-51T>C 1 1   
MLH1 c.454-13A>G 1 1   
MLH1 c.655A>G 5 1 4  
MLH1 c.731-734delGTTA 1  1  
MLH1 c.885-1G>A 1  1  
MLH1 c.1039-8T>A 3 1 2  
MLH1 c.1039-7delT 4 2 2  
MLH1 c.1558+14G>A 1   1 
MLH1 c.1668-19A>G 9 5 4  
MLH1 c.1732-19T>A 1 1   
MSH2 c.-185C>A 1 1   
MSH2 c.211+9C>G 7 4 3  
MSH2 c.367-16T>A 1  1  
MSH2 c.573C>T 1 1   
MSH2 c.942+16_942+23del
A13 
1 1   
MSH2 c.1511-9T>A 1  1  
MSH2 c.1661+12G>A 7 5 2  
MSH2 c.1662-43C>T 1 1   
MSH2 c.1662-10C>T 2 2   
MSH2 c.1811C>A 1  1  
MSH2 c.2006-6T>C 1  1  
Total  53 29 23 1 
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was always detected in patients with the MLH1 c.655A>G variant. The next most commonly 
detected variants were MSH2 c.211+9C>G (35%) and MSH2 c.1661+12G>A (35%).  
 
 Five pathogenic mutations (MSH2 c.1811C>A, MLH1 c.885-1G>A, MLH1 c.454-13A>G, MLH1 
c.731_734delGTTA and MSH2 c.2006-6T>C) have been identified in this cohort, but all are unique to 
one patient (Shown in Table 3.14). Therefore, there does not appear to be any common, disease 
causing mutations in the South African population. However, there are common, non-pathogenic 
variants among both black and white patients. 
 
Table 3.14: Summary of patients and the pathogenic mutations found in this study 
Pt. #= Patient Number 
Age given is Age of Diagnosis 
  
Ethnic 
Group 
Pt. 
# 
Age Location of 
Tumour 
Inclusion Criteria Met Pathogenic Mutations 
MLH1 MSH2 
Black  104 49 Unknown (3rd 
recurrence) 
Revised Bethesda Guidelines c.454-13A>G  
Black  205 28 Sigmoid colon Revised Bethesda Guidelines   
Black  235 21 Rectum Revised Bethesda Guidelines   
Black  238 49 Rectum Revised Bethesda Guidelines   
Black  247 47 Rectum 
(Recurrence) 
Revised Bethesda Guidelines   
Black  267 47 Rectum Revised Bethesda Guidelines   
Black  290 48 Rectum Revised Bethesda Guidelines   
White  32 50 Sigmoid colon Amsterdam II Criteria    
White  42 64 Unspecified 
(colectomy) 
Amsterdam II Criteria    
White  52 37 Upper gastro-
intestinal tract 
Amsterdam II Criteria    
White  61 67 Distal colon Amsterdam II Criteria    
White  81 29 Proximal colon Amsterdam II Criteria  c.885-1G>A  
White  86 40 Transverse 
colon 
(recurrence) 
Amsterdam II Criteria    
White  89 49 Proximal colon Amsterdam II Criteria    
White  136 56 Transverse 
colon 
Amsterdam II Criteria  c.731_734del
GTTA 
 
White  150 44 Sigmoid colon Amsterdam II Criteria  c.1811C>A 
White  190 50 Duodenum Amsterdam II Criteria   c.2006-6T>C 
White  253 28 Rectum Amsterdam II Criteria    
Mixed 
Ancestry 
13 45 Unspecified 
(Colon) 
Amsterdam II Criteria    
Mixed 
Ancestry  
175 41 Rectum Revised Bethesda Guidelines   
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4. Discussion 
This chapter will discuss the above results in relation to the aim of determining the mutation profile 
of HNPCC in the South African population. Section 4.1 will provide a discussion on patient collection 
using the different inclusion criteria and the variant profile that was found in each group. Section 4.1 
will also discuss possibilities as to why some patients that fulfilled the inclusion criteria were not 
found to have mutations. Section 4.2 will discuss the MLPA results and whether MLPA testing is 
necessary in the South African population. Section 4.3 will provide a discussion on the results that 
were found using Sanger sequencing. This will include a discussion on the known and novel variants 
as well as a discussion on the allele frequency analyses. Finally, section 4.4 will discuss the 
limitations of this study and the possible studies that can be undertaken in the future.  
 
4.1. Patients Fulfilling Inclusion Criteria 
All patients that fulfilled the Amsterdam II criteria were included in this study. Since more white 
patients in the DNA bank had extensive family histories, those who were not Amsterdam II positive 
could be excluded. This could have created a sampling bias, as the Amsterdam II criteria are more 
powerful criteria for detecting HNPCC (Lynch et al., 2006). It was found that 27% of Amsterdam II 
criteria positive patients in this study (not including the positive control) harboured pathogenic 
mutations. This is in contrast to the 13% of revised Bethesda patients that harboured pathogenic 
mutations.    
 
The revised Bethesda guidelines were used to select black patients as none of the black patients 
available fulfilled the Amsterdam II criteria.  Figures G.1 to G.3 in Appendix G show the pedigrees for 
three of the black patients (205, 235 and 238). When compared to the Amsterdam II positive 
pedigrees seen in Figure G.4 and G.5, it becomes noticeable that family history is not well known in 
these families. Since the family history among black patients was generally less significant, the 
revised Bethesda guidelines may be the most ideal criteria for selecting black patients for molecular 
diagnostic screening.  
 
The poor family history among the black patients may be attributed to several factors. A major 
factor would be that many black families may have had a diet rich in grains, fruits and vegetables, 
which would have lowered their risk of CRC (Carrera-Bastos et al., 2005). Exposure to the Western 
diet will have increased their risk for CRC (Cunningham et al., 2010). Other factors for the poor 
family history include language barriers, fears of isolation or prejudice and reluctance to follow-up 
after the medical diagnosis (Cronjé et al., 2009). 
 
 
The average age of CRC diagnosis in this study for black patients was 41, whereas the average age 
for white patients was 46. This indicates that black patients who develop CRC are younger than 
white patients. However, the average ages may have been affected by the different inclusion criteria 
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as no black patients were older than 50 years. CRC development under the age of 50 is more 
suggestive of a genetic predisposition (Anderson et al., 2003; Lynch et al., 2006). This is an important 
consideration for future research and molecular diagnostic screening services as it could allow 
improved research and clinical management.  
 
Patient 104 was included in this study as their medical history showed that they had a third 
recurrence of colon cancer prior to the age of 50 and no family history was available. The previously 
reported pathogenic variant MLH1 c.454-13A>G was detected in this individual. The value of using 
the revised Bethesda guidelines has been shown as this family can benefit from targeted screening 
in the future.  
 
This study has demonstrated that both the Amsterdam II criteria and the revised Bethesda 
guidelines may be effective at identifying patients with MMR gene mutations, but a larger cohort 
would be needed to establish truly accurate detection rates.  
 
4.1.1. Clinical Management of HNPCC Patients  
As mentioned in Section 1.6.4, identification of patients with HNPCC and Lynch syndrome is 
important as it allows for improved clinical management of patients and their families through 
predictive testing (Lynch et al., 2006; Boland and Goel, 2010). Patients in this study were found to 
harbour pathogenic mutations (Patients 81, 104, 136, 150 and 190) and will need to be managed in 
order to limit mortality. Since these patients consented to research, their samples will need to be 
screened by the Molecular Diagnostic Division in the Department of Human Genetics to verify the 
mutations and ensure they do not report a false positive back to the patient.  
 
These families will need to be counselled as their increased risk of CRC, and other associated 
cancers, will need to be explained. Since a mutation is known, family members can have targeted 
screening of the mutation to determine their risk status. High risk individuals can opt for 
preventative colectomy or regular screening to detect the cancer early (Etzioni et al., 2003; Lynch et 
al., 2006; Boland and Goel, 2010). 
 
Previous studies on HNPCC in South Africa have largely been conducted in the Western and 
Northern Cape provinces, where the MLH1 c.1528C>T mutation has been characterised in the Mixed 
Ancestry population (Ramesar et al., 2000; Stupart et al., 2009; Wentink et al., 2010; Hitchins et al., 
2011). This group have been able to show the importance of targeted screening and improved 
clinical management in families with a known pathogenic mutation (Goldberg et al., 1998). Improved 
clinical management of HNPCC should be present throughout South Africa and not limited to one or 
two provinces or families. 
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4.2. MLPA Analysis 
The MLPA analysis on this cohort showed that there were no large deletions or duplications 
detected in this study. At first glance, it may seem that MLPA may not be a worthwhile technique to 
perform in the South African population as none of these patients had any large deletions or 
duplications. However, the number of patients used in this study is small and a bigger sample size 
may have resulted in a better indication of the rate of detection of large deletions or duplications.  
 
Gille et al. (2002) performed the MLPA technique on 126 CRC families and they found 17 families 
that contained large exon deletions, of which, two families had complete deletions of MLH1. This 
shows that less than 15% of the families used in this larger study had large deletions that MLPA 
could detect. Boland and Goel (2010) estimate that 33% of all the mutations detected in MSH2 are 
large exon deletions. Considering this information, MLPA should continue to be performed in larger 
cohorts.  
 
The complementary detection strategy of MLPA and sequencing has been effective at detecting 
mutations (Lynch et al., 2006). The MLPA technique should continue to be used in future studies in 
the South African population unless future evidence suggests that large deletions are very rare or 
not present in this population.  
 
4.3. Variants Detected using Sanger Sequencing  
Sanger sequencing was used to detect small insertions, deletions and substitutions within the DNA 
of the patients that were screened in this study. In total, 53 variants were detected among 20 
patients. This number was made up of 22 different variants. One of the variants was a known 
pathogenic mutation in a positive control. 14 variants had been published previously (Tables 3.3, 3.4, 
3.6 and 3.7) while one has been reported in the curated LOVD open database but has not been 
published (InSiGHT, 2011). Six of the variants (two in MLH1 and four in MSH2) detected in this study 
are novel variants, reported for the first time in this study and whose possible functional effects 
were elucidated in this study (Table 3.12).  
 
The novel variants were detected using the forward primer, and then confirmed using the reverse 
primer. This is the methodology that was adopted for this study as it is the method used by the 
Molecular Genetics Laboratory at the NHLS, Braamfontein to detect pathogenic variants. This 
method does not account for PCR synthesis errors which could be carried over into Sanger 
sequencing and may give a false positive result. Mutations thus need to be confirmed on a new PCR 
amplicon. Future studies should be mindful to perform both bidirectional sequencing and repeat the 
entire procedure on a patient found to have a variant. 
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4.3.1. Number of Variants in Study Cohort 
Excluding the positive control, 17 of 19 patients were found to have variants (89%). Of these 
patients, three were found to have previously reported pathogenic mutations and one novel 
pathogenic mutation was found in this study. This shows that four of 19 patients were found to have 
pathogenic mutations (21%). The patients with pathogenic mutations are considered to have Lynch 
syndrome. 
 
This detection rate is higher than some previous similar studies that were performed in Asians and 
Caucasians (Shin et al., 2004; Woods et al., 2010, Wei et al., 2011) but, excluding the known 
mutation, is similar to a number of other studies (Weber et al., 1997; Farrington et al., 1998; Weber 
et al., 1999; Gille et al., 2002; Wang et al., 2006). These detection rates can be seen in Table 4.1. 
These studies screened MLH1 and MSH2 for mutations using sequencing. In some studies, MLPA was 
used to complement sequencing, or was the sole technique for detecting mutations (Gille et al., 
2002; Woods et al., 2010). The similarity in detection rates among similar studies shows that the 
research performed in this study is consistent with other research groups. 
 
Table 4.1: Summary of mutation detection rates from previous studies which were investigating MLH1 and 
MSH2. The studies given below used similar inclusion criteria for their patients, thus making comparisons 
easier 
Study  Population Group Inclusion Criteria Cohort 
Size 
Detection 
Rate 
Weber et al., 
1997 
Caucasian, African 
American 
Amsterdam II, 
Bethesda guidelines 
40 25% 
Farrington et 
al., 1998 
Caucasian Amsterdam II, 
revised Bethesda 
76 30% 
Weber et al., 
1999 
African American Amsterdam I, 
Revised Bethesda 
11 27% 
Gille et al., 
2002 
Caucasian Amsterdam II, 
Bethesda guidelines 
126 22% 
Shin et al., 
2004 
Korean Amsterdam II, 
Revised Bethesda 
164 13% 
Wang et al., 
2006 
Chinese Amsterdam II 31 22% 
Woods et al., 
2010 
Caucasian Amsterdam II, 
Revised Bethesda, 
FAP criteria 
750 2.7% 
Wei et al., 
2011 
Chinese Amsterdam II, 
Bethesda guidelines 
98 11% 
This study White, Black and 
Mixed Ancestry 
Amsterdam II, 
Revised Bethesda 
20 21% 
 
There were 29 variants detected in the seven black patients, with each of these patients having at 
least two variants detected. Patient 205 was found to harbour the most variants, with seven 
variants, while patient 267 was found to have two variants, both in MSH2.  Weber et al. (1999) also 
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found a high percentage (90%) of variants in African American patients and this study is consistent 
with that finding. The high variant rate is not surprising since the African population has been shown 
to have greater genetic diversity than whites and Asians (Campbell and Tishkoff, 2008).  
 
4.3.2. Previously Reported Variants in MLH1 
11 variants were found in MLH1. Seven variants were previously reported as non-pathogenic, two 
were previously reported as pathogenic and two were novel variants. Generally, there is consensus 
as to whether a previously reported variant is pathogenic or benign. However, the MLH1 c.655A>G 
variant will be discussed as some authors suggest a possible role in carcinogenesis, despite being 
described as non-pathogenic by many other studies. The MLH1 c.731_734delGTTA mutation will also 
be discussed as it was previously reported by the South African researcher, Prof. Raj Ramesar. 
 
4.3.2.1. The MLH1 c.655A>G (pIle219Val) variant 
The MLH1 c.655A>G (p.Ile219Val) mutation is a missense mutation that was found in five patients 
(four Amsterdam II positive whites and one Bethesda positive black) in this study. The MLH1 
c.655A>G variant been reported in many other individuals in different populations and has been 
considered benign (Farrington et al., 1998; Ward et al., 2002). However, other studies indicate that 
this variant is not completely benign (Fredriksson et al., 2006; Takahashi et al., 2007 Campbell et al., 
2009). 
 
The MLH1 p.Ile219Val mutation has been linked to prostate cancer and an increased risk of 
ulcerative colitis (Bagnoli et al., 2004; Fredriksson et al., 2006). Furthermore, it has been indicated 
that the p.Ile219Val mutation leads to a lower level of MLH1 protein expression, approximately 60% 
of the wild-type level (Takahashi et al., 2007). Campbell et al. (2009) found that this variant was 
associated with CRC in individuals that reported a high intake of Western diets. Patients who are 
identified with this variant should be informed of the elevated risk of ulcerative colitis and cancer in 
conjunction with a Western diet. These findings also show that a variant should be investigated fully 
to properly determine the role of the variant in carcinogenesis. 
 
4.3.2.2. The MLH1 c.731_734delGTTA variant 
The MLH1 c.731_734delGTTA variant was identified in an Amsterdam II positive family in exon 9 of 
MLH1. The pedigree for this patient is given in Figure G.4 in Appendix G. This mutation leads to a 
non-functional protein, which indicates that it is pathogenic and is likely to be a significant factor in 
the development of CRC in this patient (InSiGHT, 2011).This mutation has been reported on the 
InSiGHT database by Prof. Raj Ramesar, from the University of Cape Town (UCT) in South Africa 
(InSiGHT, 2011).  
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It is not known if this variant was found in the same family or in a different family from that of Prof. 
Ramesar’s. This variant has been detected by two different South African groups, which could imply 
that the same family was tested, or that a possible common/founder mutation exists in South Africa. 
Collaboration with the UCT group will be needed to identify patient pedigrees and to determine 
whether this mutation is localised to a family or is common in the population.  
 
4.3.3. Previously Reported Variants in MSH2 
11 variants were detected in MSH2, one of which was a positive control that was included to 
validate the Sanger sequencing method. The findings from the control sample will be discussed in 
more detail in Section 4.3.3.1. Five previously reported non-pathogenic variants were detected in 
MSH2 in this study while a previously reported pathogenic mutation (MSH2 c.2006-6T>C) was 
detected. This mutation will be discussed as there have been studies which indicate that it is benign 
and others which indicate that it is pathogenic. The synonymous mutation, MSH2 c.573C>T, will be 
discussed briefly to demonstrate the potential role of synonymous mutations in disease. 
 
4.3.3.1. The MSH2 c.1811C>A (p.Ala604Asp) variant 
The MSH2 c.1811C>A missense mutation is located in Exon 12 of the MSH2 gene and was used as a 
positive control. The pedigree for this patient can be seen in Figure G.5. This patient and their sibling 
both showed a loss of staining for MSH2 in IHC and were both affected by CRC. This variant was also 
found in both patients, which implies strongly that this is the pathogenic mutation associated with 
the disease. Both this patient and their sibling were tested by the Wessex Regional Genetics 
Laboratory, Salisbury District Hospital, Salisbury but the sibling was not included in this study.  
 
This mutation was detected as a heterozygote by the Wessex Regional Genetics Laboratory but was 
found to be homozygous in this study (Figure 3.8). As a homozygote for MMR mutations would be 
expected to present with cancer in their childhood, the most likely explanation is that there has 
been allele dropout (Lynch et al., 2006). The single peak seen may be caused by only one allele 
amplifying, which indicates that one primer may not be binding to the template DNA. This may be 
caused by a polymorphism in the primer binding region. This suggests that further research needs to 
be conducted to determine which polymorphisms are present in the South African population, as 
these could alter the results of sequencing data and give false negatives in patients. This could lead 
to high costs in finding pathogenic mutations in other genes, or hamper family management if it is 
assumed that the CRC was sporadic because a pathogenic mutation could not be detected. The 
positive control in this study was unable to validate the sequencing method, but it was able highlight 
the importance of additional research into polymorphisms in the primer binding domains of these 
genes. 
 
4.3.3.2. The MSH2 c.2006-6T>C mutation 
The c.2006-6T>C mutation of MSH2, which is located in intron 12, has also been reported previously 
(Farrington et al., 1998; Wang et al., 2006; Christensen et al., 2008; Tournier et al., 2008). This 
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mutation has also been reported as being non-pathogenic in HNPCC (Wang et al., 2006). However, 
Tournier et al. (2008) performed a functional ex vivo splicing assay using a pCAS vector that was 
transfected into HeLa cell lines. They found that this mutation leads to partial exon 13 skipping in the 
mRNA of MSH2. Beiner et al. (2006) found that this variant was also associated with an increased 
risk of endometrial cancer.  
 
4.3.3.3. The MSH2 c.573C>T (p.Leu191Leu) variant 
The c.573C>T (p.Leu191Leu) variant was found in exon 3 of MSH2 in black patient 205. This variant 
has been reported previously but has been shown to have no effect on the amino acid sequence in 
the MSH2 protein (Auclair et al., 2006). Although this variant is considered to be benign, it has been 
reported that synonymous mutations are not always benign and may play a role in pathogenicity 
(Parmley and Hurst, 2007).  
 
Synonymous mutations can affect gene expression in a number of ways. Codon bias in the 
translation of mRNA has been observed, where the most widely expressed codons correlate with the 
most widely available tRNA species. The codon could be replaced by a less common tRNA species, 
which could affect the rate of mRNA translation. Furthermore, synonymous mutations may also lead 
to changes in mRNA stability, translation and degradation and alternative splicing of exons (Parmley 
and Hurst, 2007). Although this variant has been found to be non-pathogenic, it must be 
remembered that not all synonymous mutations are silent and this variant warrants further 
investigation.  
 
4.4. Determining the Pathogenicity of the Novel Variants 
The six novel variants were investigated further to determine whether they may have possible 
pathogenic effect. The allele frequency for six variants was determined using RFLP or HRM in 
random control samples (Section 3.3). In addition, FASTSNP was used to predict whether the variant 
upstream of the transcription start site in MSH2 had a functional effect. The likely pathogenic status 
of each variant is summarised in Table 3.12. Since these variants have been detected for the first 
time in this study, they will be submitted to dbSNP at the NCBI and they will also be reported to the 
LOVD database. The allele frequencies obtained will also be submitted for these novel variants 
 
4.4.1. The MLH1 c.885-1G>A mutation 
The MLH1 c.885-1G>A variant was suspected of being pathogenic as it is located on the splice 
acceptor site of intron 10. Mutations in the splice acceptor site may abolish splice site recognition by 
the spliceosome, which would lead to aberrant splicing (Venables, 2004). The AG motif in splice 
acceptor sites is highly conserved and is important for correct splicing of the mRNA. Mutations in the 
splice acceptor site frequently leads to pathogenicity by abolishing the splice recognition site, which 
leads to aberrant splicing (Strachan and Read, 2004; Venables, 2004). Furthermore, a pathogenic 
mutation is known to occur at the MLH1 c.885-2 position (Terdiman et al., 2001). 
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RFLP analysis was undertaken to determine the frequency of the variant in the random white 
population. The MLH1 c.885-1G>A variant was confirmed in patient 81 but was not detected in any 
of the random samples, suggesting that the variant is rare in the white population. The evidence for 
this variant strongly suggests that it is pathogenic. The family of patient 81 can be screened for the 
presence of this mutation to determine whether they are at risk of tumourigenesis.  
 
4.4.2. The MLH1 c.1732-19T>A variant 
The MLH1 c.1732-19T>A variant was investigated using the HRM technique and was found in control 
samples. This technique uses the melting temperature to determine which allele is present at a 
particular position since the allele will alter the melting temperature (Gundry et al., 2003). HRM is 
not very specific and other variants within the PCR amplicons may affect the melting temperature of 
the amplicons, particularly in a large PCR product such as that used in this study (Gundry et al., 
2003). Further investigations may be needed to validate the allele frequency findings for this variant 
and determine whether it is truly polymorphic.  
 
4.4.3. The MSH2 c.-185C>A variant 
The MSH2 c.-185C>A variant was investigated using both RFLP and bioinformatic prediction with 
FASTSNP. This variant could affect transcription by increasing or decreasing the affinity for a 
transcription factor in that region, which would ultimately have a functional effect (Strachan and 
Read, 2004). FASTSNP predicted that this variant does not impact the binding affinity of any 
transcription factors for either allele. 
 
The variant allele was found to be absent (C=1.00, A=0.00) in the control population. This shows that 
this variant is probably not polymorphic in the South African population. These results do not 
provide any evidence on the functional effect of this variant. Therefore, this variant is considered to 
have unknown significance and further investigation will be needed to determine whether it is 
pathogenic or non-pathogenic. This will be important research to conduct as it will guide the family 
on future screening programs. 
 
4.4.4. The MSH2 c.367-16T>A variant 
The MSH2 c.367-16T>A variant was investigated using the HRM technique. The HRM results for this 
variant did not produce detectably different normalised melting curves for the known controls, 
which made analysis impossible. HRM is dependent on detecting the melting temperature of PCR 
amplicons, which is measured in real-time.  
 
Unfortunately, PCR product size does affect the HRM analysis. A longer PCR product becomes more 
stable and the effect of a variant on the overall structure will become weaker as the size of the 
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product increases (Gundry et al., 2003). The PCR product used for analysing the MSH2 c.367-16T>A 
variant was approximately 300bp in size, which was too large to yield any meaningful results with 
the HRM technique. However, this does confirm that the PCR product size is an important 
consideration in HRM and this mistake should be avoided in the future. 
 
4.4.5. The MSH2 c.1662-10C>T variant 
The MSH2 c.1662-10C>T variant was detected in two unrelated black individuals. This variant 
appears to be linked to the MSH2 c.211+9C>G variant and the MSH2 c.1661+12G>A variant, which 
are both non-pathogenic and previously reported (Wijnen et al., 1994; Weber et al., 1997). Although 
this evidence is suggestive that the variant is non-pathogenic, it was investigated further using RFLP 
analysis to determine the frequency of the variant. 
 
This variant was found to be polymorphic in the black population of South Africa (C=0.66, T=0.34) 
(Table 3.9). This finding is highly suggestive that this variant is non-pathogenic. Interestingly, this 
variant appears to be very common in the black population of South Africa but has not been 
reported or published previously in other populations, to the best of our knowledge.   
 
4.4.6. The MSH2 c.1662-43C>T variant 
The MSH2 c.1662-43C>T variant was investigated using RFLP analysis in the random black 
population. This variant was not found (C=1.00, T=0.00), which shows that this variant is not likely to 
be polymorphic. This variant was detected in a patient that was found to harbour the previously 
reported pathogenic MLH1 c.454-13A>G mutation. 
 
The low allele frequency may indicate that the variant is pathogenic but it is not a reliable indicator 
of pathogenicity. If an allele is not common, it does not confirm that it is pathogenic. This patient 
was found to have a pathogenic mutation present, and it is improbable that a person carries a 
pathogenic mutation in both genes (Strachan and Read, 2004). 
 
4.4.7. CRC in Patients with No Pathogenic Mutations 
It is important to consider that not all of the variants that were found are pathogenic. Only four of 
the variants found in this study are pathogenic. There are two variants with an unknown 
contribution to disease. These unknown variants may be pathogenic but they may also have no 
functional impact.  There are several reasons for disease progression in patients who were found not 
to have pathogenic mutations, or whose variants are benign.  
 
The first reason is that they may not have had a pathogenic mutation in MLH1 or MSH2, thus the 
pathogenic mutation would not have been detected in this study. Approximately 90% of all 
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mutations detected in HNPCC genes are found in MLH1 and MSH2. Mutations in MSH6 and PMS2 
account for the majority of the remaining 10% (da Silva et al., 2009). The mutation spectrum of 
HNPCC mutations has not been determined in South Africa, therefore it is possible that there are a 
higher proportion of mutations in other MMR genes.  
 
A second reason that could explain why no pathogenic variants were detected in these patients is 
that there may not be mutations in the MMR genes. Approximately 30-50% of cases of suspected 
HNPCC, or families that fulfil the Amsterdam II criteria, do not have confirmed mutations in the 
MMR genes (de la Chapelle, 2004; Umar et al., 2004a; Hitchins et al., 2011). These patients may have 
mutations in other genes involved in CRC, such as BRAF or KRAS. However, it is important to 
remember that these patients may also have sporadic CRC. These patients may have developed 
sporadic CRC through lifestyle factors, including a more Western diet that is high in red meat and 
fats (Cunningham et al., 2010). Further studies and a larger cohort need to be used to determine the 
accurate hereditary CRC rates. 
 
Germ line mutations in the 3’ region of the EPCAM gene have been found to lead to HNPCC 
(Jasperson et al., 2010). Patients with these mutations have been found to have epigenetically 
silenced MSH2 caused by hyper-methylation of the MSH2 promoter region, which leads to loss of 
expression of MSH2, and subsequently CRC (Jasperson et al., 2010). Hyper-methylation of the MLH1 
promoter region has also been shown in cases of HNPCC and recent evidence suggests that 
constitutional epimutations may account for these cases. However, this mechanism of disease is rare 
but investigation in patients who are not found to harbour any MMR gene mutations may detect this 
specific type of mutation (Hitchins and Ward, 2009; Hitchins et al., 2011). 
 
4.4.8. Molecular Diagnostic Screening of HNPCC Patients 
Although pathogenic mutations were found in this study, a cheaper first line screening method 
would be more preferable than full gene sequencing. As was seen in this study, 21% of patients were 
found to have mutations in MLH1 or MSH2. A screening procedure such as MSI testing or IHC should 
be offered to screen patients prior to gene sequencing. Patients who show MSI or loss of staining in 
IHC should be offered full gene sequencing and MLPA (Lynch et al., 2006). 
 
Patients who are found to not have pathogenic mutations in the MLH1 or MSH2 genes may still need 
to be assessed to determine if they have constitutional epimutations, or mutations in other genes 
such as MSH6, PMS2 or EPCAM (Lynch et al., 2006; Hitchens et al., 2011). IHC testing may be 
preferable as it can be used to direct screening in the MMR genes (Lynch et al., 2006).  
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4.5. Characterising the Mutation Spectrum 
Fifty three variants were detected among 20 patients. This number was made up of 22 different 
variants that were detected among 20 patients. No common pathogenic mutations or founder 
mutations in the white or black population of South Africa were identified in this study. However, 
this study only tested 20 individuals, which is not enough to determine the complete mutation 
spectrum. There were a number of other common variants that were detected. 
 
4.5.1. Mutation Spectrum of MLH1 
The variant MLH1 c.1668-19A>G (rs9876116) was detected in nine (five blacks and four whites) 
patients and is a common polymorphism in the South African population (A=0.66, G=0.34), and has 
been reported by other groups (dbSNP, 2012). All the patients that were found to have the MLH1 
c.655A>G (four white patients and one black patient) variant were also found to have the MLH1 
c.1668-19A>G variant, suggesting that these variants co-occur and may be in linkage disequilibrium, 
particularly in the white population. It is possible that an ancestral chromosome carried the MLH1 
c.1668-19A>G variant, and the MLH1 c.655A>G variant arose later on this chromosome. 
 
4.5.2. Mutation Spectrum of MSH2 
The MSH2 c.211+9C>G, MSH2 c.1661+12G>A and MSH2 c.1662-10C>T variants were all present in 
patients 235 and 238. It is possible that these variants may occur on one haplotype in the black 
population. However, the black patients 205 and 247, as well as the white patient 81, had the MSH2 
c.211+9C>G and the MSH2 c.1661+12G>A variants. This suggests that the MSH2 c.1662-10C>T could 
have arisen on this haplotype but it does seem that MSH2 c.211+9C>G and MSH2 c.1661+12G>A are 
in the same haplotype. Unfortunately, the families were not studied so it is challenging to assign a 
haplotype to each patient or be certain that these variants occurred on the same chromosome.   
 
4.5.3. Mutation Spectrum with regard to Ethnicity 
The MLH1 c.381-41A>G variant and the MSH2 c.1662-10C>T variant were only detected in black 
patients. The MLH1 c.381-41A>G variant has been previously reported in the Slovakian population 
(Zavodna et al., 2006). This shows that this variant is not unique to black South Africans. The MSH2 
c.1662-10C>T variant has not been previously reported, yet is thought to be polymorphic among 
black South Africans after RFLP analysis revealed a high allele frequency (Table 3.9). All other 
variants that were detected in more than one patient were present in both black and white patients, 
showing that these variants are not localised to one ethnic group.  
 
4.5.4. Mutation Spectrum of Pathogenic Mutations 
In the four pathogenic mutations found in this study, none are common mutations and there does 
not seem to be any linkage with any other variants. Three of the pathogenic mutations were 
detected in white patients, and the fourth in a black patient. This is not surprising as the white 
patients fulfilled the Amsterdam II criteria, which is more stringent for the detection of HNPCC. 
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These findings show that MMR gene mutations occur in black and white race but more investigation 
is needed to determine the full spectrum of mutations in South Africa. 
 
Determining the mutation spectrum could have significant cost saving benefits for patients. If a 
mutation is known to be common in a specific ethnic group, a diagnostic laboratory could attempt to 
find that mutation first with a targeted screening technique. This is akin to the targeted screening 
offered to family members of a known mutation carrier. If the common mutation is not present, the 
patient can then proceed with general, more expensive screening techniques such as sequencing. 
Unfortunately, a much larger research cohort will be needed to determine the full spectrum of 
mutations. 
 
4.6. Limitations and Future Directions 
This study collected 20 patients for analysis. Two of these patients were of mixed ancestry, seven 
were black and the remaining 11 were whites. As mentioned in Section 4.1, a selection bias was 
created during the selection of patients. White patients that did not fulfil the Amsterdam II criteria 
were excluded. This would increase the probability of mutations being found in white patients as the 
Amsterdam II criteria are more stringent criteria (Lynch et al., 2006). This also indicates that more 
patients included under the revised Bethesda guidelines would be needed to properly ascertain the 
mutation spectrum of the MMR genes in South Africa. 
 
This study hoped to find common pathogenic mutations but none were found in this cohort, 
suggesting that there may not be any common or founder mutations. A mutation in this study was 
previously reported by Prof. Ramesar at UCT, which may be a possible common mutation or a 
mutation in a large family. A larger cohort size would have possibly allowed more common variants 
to be detected. This is particularly needed to determine the mutation spectrum within each ethnic 
group. This study did not focus on a specific ethnic group, which may have a different mutation 
spectrum to another ethnic group. Large numbers of each ethnic group should be included in a 
future study which could determine adequately the mutation spectrum for each ethnic group, which 
may reveal common or founder mutations which could be used in targeted screening. 
 
One of the greatest challenges this study faced was ascertaining patients that fulfilled the inclusion 
criteria. Future efforts could focus on more intense communication or centralising the cancer patient 
database, which would allow for easier research into cancer related topics. A further limitation was 
the high cost of Sanger sequencing and MLPA, although MLPA costs per patient are reduced if more 
patients are present. A high throughput sequencing platform could be utilised to screen more 
patients at a lower cost per patient. This would ensure results are achieved quicker and more cost-
effectively (Shendure and Ji, 2008).  
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The mixed ancestry mutation profile has been studied more extensively at UCT and a common MLH1 
c.1528C>T mutation has been found in the mixed ancestry population in the Western and Northern 
Cape of South Africa (Ramesar et al., 2000; Stupart et al., 2009). However, a wider profile can be 
determined by studying mixed ancestry and black individuals around Gauteng, and eventually all 
nine provinces in South Africa. A larger study, or even a combined study, will also allow possible 
founder mutations or common mutations to be determined, which could allow more effective 
screening of the disease.  
 
This study focused on the screening of MLH1 and MSH2. These genes account for 90% of all MMR 
gene mutations in HNPCC in other populations. However, these genes may not be involved to the 
same extent in HNPCC in South Africa. Screening of MSH6 and PMS2 will need to be performed to 
determine if these genes are mutated in CRC patients. Furthermore, EPCAM has been shown to be 
mutated in cases of HNPCC and should be investigated in the South African population (Jasperson et 
al., 2010). 
 
With regard to mutation detection, Sanger sequencing and MLPA are useful techniques for 
determining mutations in the DNA of a patient. These techniques can determine both small 
mutations and whole exon deletions/duplications. To complement this strategy, extracting mRNA 
could provide valuable insights into the functional effects of variants, especially since so many 
mutations are located within introns (Strachan and Read, 2004).  
 
Collecting the mRNA will allow future researchers to determine if these intronic variants lead to 
aberrant splicing. However, RNA studies are challenging to perform as mRNA is not as stable as DNA, 
with collection, extraction and storage affecting the mRNA. In addition, mRNA extraction should 
follow soon after the blood is drawn to ensure better mRNA quality (Strachan and Read, 2004; 
Marteau et al., 2005). In South Africa, many medical facilities are not equipped to extract mRNA, 
while transportation and storage of samples is very challenging.  
 
Full gene sequencing of the MMR genes is important in determining whether a family has HNPCC. 
However, this technique is expensive and other screening strategies may be important in reducing 
costs. IHC has the ability to determine which protein is not expressed in a tumour and may provide 
direction for gene screening (Lynch et al., 2006). Additionally, IHC testing can be used to screen 
other disorders that affect protein production. IHC testing is currently available at UCT, but this 
service must be provided nationwide.  
 
MSI is also a feature of tumours that are deficient in MMR function. MSI testing has also been shown 
to be a valuable tool in identifying HNPCC since loss of the MMR genes leads to MSI. However, MSI 
also occurs in sporadic CRC, which will yield a false positive for germ line MMR defects (Lynch et al., 
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2006). Setting up MSI testing and IHC testing in local laboratories could potentially improve 
identification and management of HNPCC families. 
 
Future studies that aim to assess the functions of the novel variants, and even the reported variants, 
will be important in determining the precise mutation profile of HNPCC patients in South Africa. 
Other studies have been performed to determine functional effects (Takahashi et al., 2007; Tournier 
et al., 2008) and bioinformatic prediction (Arnold et al., 2009). Either these techniques, or similar 
techniques, can be performed in South Africa. It may be particularly important to establish 
functional assays as the black population could potentially yield a large number of novel variants 
with unknown function due to the genetic diversity of this population (Campbell and Tishkoff, 2008).  
 
Disease co-segregation studies can also be used to determine if a variant is pathogenic. This was 
performed in patient 150 and their sibling, who was also affected with colon cancer. Both siblings 
showed a loss of MSH2 staining in IHC and both had the MSH2 c.1811C>A variant in MSH2, which 
strongly suggests that this variant is pathogenic. This approach can be used when more than one 
family member is affected by a disease (Strachan and Read, 2004).  
 
Determining the population frequencies of these variants and their allele frequencies is another 
study that can be performed. This will provide further information about the diverse African genome 
and could be submitted to dbSNP or the HapMap project. As seen with the MSH2 c.1662-10C>T and 
MLH1 c.1732-19T>A variants, novel variants were found that are polymorphic in South Africa. These 
results will also be submitted to dbSNP. More studies must be conducted in this population to gain 
further insights into African population genetics.  
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5. Conclusion 
HNPCC accounts for approximately 5% of all CRC worldwide (Jasperson et al., 2010). In South Africa, 
the proportion of CRC cases attributed to HNPCC is unknown and the mutation profile is not well 
established. However, it is suspected that a higher proportion of CRC in South Africa is attributed to 
HNPCC (Cronjé et al., 2009). This study aimed to establish the mutation profile of HNPCC in MLH1 
and MSH2 in the South African population as these genes have been implicated in 90% of MMR gene 
mutations. Twenty patients were collected in total, 12 of which fulfilled the Amsterdam II criteria (11 
white, 1 mixed ancestry), and the remaining eight fulfilling the revised Bethesda guidelines (seven 
black, 1 mixed ancestry). The patients were analysed using MLPA and Sanger sequencing to identify 
which variants were present in MLH1 and MSH2. 
 
MLPA did not detect any large deletions or duplications, but this technique should continue to be 
used to screen MLH1 and MSH2. This was a small cohort and there may be large mutations present 
in other patients. Using Sanger sequencing, a total of 22 different variants were detected. Eleven 
variants were detected in MLH1 and the other 11 in MSH2. A known pathogenic mutation in MSH2 
from a positive control was detected. However, this control highlighted that allele drop-out is 
present and this could be the result of polymorphisms in the primer binding regions. The 
polymorphisms need to be investigated as they could lead to false negatives, which could affect the 
mutation detection and clinical management of HNPCC patients. Fifteen previously reported variants 
were detected, of which three were pathogenic. Six novel variants, of unknown pathogenicity, were 
detected and investigated further using RFLP, HRM or FASTSNP. 
 
From the six novel variants, the MLH1 c.885-1G>A variant was thought likely to be pathogenic as it 
was located on a conserved splice acceptor site and was not present in 45 normal samples. Two 
novel variants, MSH2 c.-185C>A and MSH2 c.367-16T>A, had an unknown contribution toward 
disease and would require further experimentation to determine if they are pathogenic. Three novel 
variants were thought likely to be non-pathogenic. 
 
In total, four pathogenic mutations were detected in 19 patients, giving a detection rate of 21%. This 
detection rate is comparable to other similar studies performed in Caucasians, Asians and African 
Americans. The Amsterdam II criteria had a greater predictive value for identifying patients with 
mutations in MLH1 and MSH2 as three of the pathogenic mutations were detected among 
Amsterdam II positive patients. One pathogenic mutation was detected in a Bethesda positive black 
patient. Both the Amsterdam II criteria and the Bethesda guidelines should continue to be used as 
guidelines for choosing CRC patients for genetic testing.  
 
Identification of inherited pathogenic mutations in HNPCC is very important as it can allow for 
improved management of a patient and their family. Family members of a proband can be screened 
for the pathogenic mutation. If a family member is found to be a carrier of a mutation, that person 
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can undergo regular colon screening via colonoscopy, or endometrial screening (Lynch et al, 2006; 
Järvinen et al., 2009). Early detection of cancer is vital to effective treatment (Etzioni, 2003). 
Alternatively, an at-risk family member can opt to have prophylactic colectomy (Lynch et al., 2006). 
 
There were no common pathogenic mutations detected in this study but further research in a larger 
cohort may reveal common pathogenic mutations. Mutations in other genes, such as MSH6 and 
PMS2 may contribute to HNPCC cases in South Africa. Although these genes account for 10% of 
HNPCC cases worldwide, they may account for a higher proportion of HNPCC cases in South Africa 
(Peltomäki, 2005; da Silva et al., 2009). Screening for mutations in MSH6, PMS2 and EPCAM in the 
future will allow for a more complete mutation spectrum to be established.  
 
Establishing a molecular diagnostic service in South Africa for HNPCC testing is vital to improving the 
treatment and management of this disease. Currently, testing can be performed in research 
laboratories or samples must be sent overseas. The general public in South Africa cannot afford to 
send samples overseas, so a local service is necessary. Determining the mutation profile of MMR 
defects in South Africa will be an important step in establishing the molecular diagnostic service. This 
would allow for targeted screening of common or founder mutations as a first line, if they are 
present in the population.  
 
In summary, this study attempted to characterise the mutation spectrum of MLH1 and MSH2 in the 
South African population. A novel pathogenic mutation (MLH1 c.885-1G>A) and four previously 
reported pathogenic mutations (MLH1 c.454-13A>G; MLH1 c.731_734delGTTA; MSH2 c.1811C>A 
and MSH2 c.2006-6T>C) were detected as well as five other novel variants (MLH1 c.1732-19T>A; 
MSH2 c,-185C>A; MSH2 c.367-16T>A; MSH2 c.1662-43C>T and MSH2 c.1662-10C>T). No common 
mutations were detected but future studies with a larger cohort, investigating MLH1, MSH2, MSH6, 
PMS2 and EPCAM, would better determine the mutation profile of these genes in South Africa.   
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Appendix A: Cancer Statistics 
 
Table A.1: Estimated global incidence of cancer for both genders of all ages 
 Cancer Numbers  Crude Rate  ASR   Cumulative Risk   
 All cancers excl. 
non-melanoma 
skin cancer 
12662554   187.6   181.6   18.70   
 Lung 1608055   23.8   23.0   2.78   
 Colorectum 1235108   18.3   17.3   1.97   
 Stomach 988602   14.6   14.1   1.67   
 Liver 749744   11.1   10.8   1.24   
 Oesophagus 481645   7.1   7.0   0.86   
 Bladder 382660   5.7   5.3   0.60   
 Non-Hodgkin 
lymphoma 
356431   5.3   5.1   0.54   
 Leukaemia 350434   5.2   5.0   0.47   
 Kidney 273518   4.1   4.0   0.46   
 Pancreas 278684   4.1   3.9   0.44   
 Lip, oral cavity 263020   3.9   3.8   0.45   
 Brain, nervous 
system 
237913   3.5   3.5   0.35   
 Thyroid 213179   3.2   3.1   0.31  
 Melanoma of skin 199627   3.0   2.8   0.30   
 Larynx 150677   2.2   2.2   0.28   
 Gallbladder 145203   2.2   2.0   0.22   
 Other pharynx 136622   2.0   2.0   0.25   
 Multiple myeloma 102826   1.5   1.4   0.17   
 Nasopharynx 84441   1.3   1.2   0.13   
 Hodgkin 
lymphoma 
67919   1.0   1.0   0.08   
 Kaposi sarcoma 34477   0.5   0.5   0.04   
Crude and age-standardized rate (ASR) per 100,000. 
Cumulative risk [0-74], percent 
Statistics ordered by Cancer name 
Adapted from GLOBOCAN, 2008 and Ferlay et al., 2010 
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Table A.2: Estimated global cancer mortality for both sexes of all ages 
 Cancer Numbers  Crude Rate  ASR   Cumulative Risk   
 All cancers excl. 
non-melanoma 
skin cancer 
7564802   112.1   106.1   11.16   
 Lung 1376579   20.4   19.4   2.30   
 Stomach 737419   10.9   10.3   1.19   
 Liver 695726   10.3   10.0   1.14   
 Colorectum 609051   9.0   8.2   0.88   
 Oesophagus 406533   6.0   5.8   0.70   
 Pancreas 266669   4.0   3.7   0.41   
 Leukaemia 257161   3.8   3.6   0.33   
 Non-Hodgkin 
lymphoma 
191599   2.8   2.7   0.27   
 Brain, nervous 
system 
174880   2.6   2.5   0.27   
 Bladder 150282   2.2   2.0   0.20   
 Lip, oral cavity 127654   1.9   1.9   0.22   
 Kidney 116368   1.7   1.6   0.18   
 Gallbladder 109587   1.6   1.5   0.16   
 Other pharynx 95550   1.4   1.4   0.17   
 Larynx 81892   1.2   1.2   0.15   
 Multiple 
myeloma 
72453   1.1   1.0   0.11   
 Nasopharynx 51609   0.8   0.8   0.08   
 Melanoma of skin 46372   0.7   0.6   0.07   
 Thyroid 35383   0.5   0.5   0.06   
 Hodgkin 
lymphoma 
29902   0.4   0.4   0.04   
 Kaposi sarcoma 29377   0.4   0.4   0.03   
Crude and age-standardised rate (ASR) per 100,000. 
Cumulative risk [0-74], percent 
Statistics ordered by Cancer name 
Adapted from GLOBOCAN, 2008 and Ferlay et al., 2010 
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Figure A.1: Percentage distribution of 10 most common cancers in South Africa by gender, 1998 and 1999, all 
ages (NCR, 2004) 
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Table A.3: Summary rates for top 5 cancers in South Africa by sex 
Pop / 
Sex  
1998 1999 2004 
Cancer ASR LR Cancer ASR LR Cancer ASR LR 
Females Cervix 34.43 26 Breast 
 
33.41 27 Breast 30.07 29 
Breast 32.70 27 Cervix 
 
28.69 31 Cervix 24.40 36 
CRC 5.83 154 CRC 
 
6.61 131 CRC 5.52 150 
Oes 5.95 136 Oes 
 
5.49 143 Uterus 5.77 128 
Ovary 4.91 166 Uterus 
 
5.09 146 Melanoma 3.89 229 
All 136.74 6 All 
 
134.86 6 All 116.10 8 
Males Prostate 37.59 22 
 
Prostate 34.12 24 Prostate 34.37 23 
Lung 15.18 52 Lung 
 
13.56 59 Lung 9.94 79 
Oes 12.56 65 Oes 
 
11.33 73 Oes 7.56 107 
CRC 9.44 92 CRC 
 
9.74 83 CRC 8.61 98 
Bladder 8.63 98 Bladder 
 
8.24 104 Bladder 6.77 121 
All 156.18 4 All 
 
148.87 5 All 128.36 6 
ASR Age standardized rate per 100 000 
ASR excludes Basal Cell Carcinoma of the skin and Squamous Cell Carcinoma of skin 
LR Lifetime risk (0-74 years) of developing a cancer expressed as 1 in X number of people 
Oes= Oesophagus 
Table adapted from NCR, 2004 & NCR, 2011 
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Table A.4: Summary statistics for colorectal cancer, 1998 and 1999 
Pop/Sex N(Obs) N(Adj) Percent Crude ASR 95%LCL 95%UCL Cumrisk LR 
Females, 1998 
Asian 46 47 5.09 8.56 10.45 7.44 13.46 1.29 78 
Black 226 240 25.00 1.4 2.04 1.77 2.30 0.22 455 
Mixed 
Ancestry 
102 109 11.28 5.66 7.99 6.46 9.51 0.92 109 
White 530 564 58.63 22.21 14.99 13.70 16.28 1.73 58 
Males, 1998 
Asian 44 44 3.97 8.22 11.01 7.83 14.19 1.07 94 
Black 271 287 24.48 1.75 3.02 2.65 3.39 0.31 323 
Mixed 
Ancestry 
130 138 11.74 7.52 13.76 11.40 16.12 1.75 58 
White 662 699 59.80 28.34 23.74 21.97 25.51 2.89 35 
Females, 1999 
Asian 35 35 3.31 6.29 7.31 4.87 9.75 1.02 99 
Black 268 284 25.31 1.62 2.31 2.03 2.58 0.26 385 
Mixed 
Ancestry 
125 132 11.8 6.75 9.66 8 11.33 1.13 89 
White 631 668 59.58 26.23 17.52 16.16 18.88 2.09 48 
Males, 1999 
Asian 53 56 4.57 10.33 14.28 10.4 18.16 1.98 51 
Black 278 301 23.97 1.79 2.96 2.6 3.31 0.35 286 
Mixed 
Ancestry 
128 138 11.03 7.42 14.09 11.7 16.48 1.8 56 
White 701 752 60.43 30.46 25.44 23.64 27.23 3.27 31 
Females, 2004 
Asian 46 50 6.73 8.71 9.14 6.58 11.70 1.34 74 
Black 253 272 2.22 1.45 2.10 1.84 2.36 0.25 392 
Mixed 
Ancestry 
133 142 4.08 6.80 9.34 7.76 10.92 1.10 90 
White 516 550 4.66 24.36 14.78 13.48 16.07 1.75 57 
Males, 2004 
Asian 59 68 10.95 12.19 15.61 11.76 19.46 2.09 48 
Black 288 315 3.70 1.73 3.08 2.72 3.44 0.34 292 
Mixed 
Ancestry 
165 179 5.19 8.94 15.69 13.26 18.13 1.72 58 
White 582 633 4.24 29.10 21.49 19.77 23.20 2.60 38 
 
N(Obs): Number of cases observed 
N(Adj): Observed cases adjusted for unknown population group 
Percent: Percentage of all site cancers 
Crude: Number of cases / population per 100 000 
ASR: Age standardised rate per 100 000 (World standard population) 
95%LCL: 95% Lower confidence limit for ASR 
95%UCL: 95% Upper confidence limit for ASR 
Cumrisk: Cumulative lifetime incidence risk (0-74 years) 
LR: Lifetime risk (0-74 years) of developing a cancer expressed as 1 in X number of people 
Adapted from NCR, 2004 and NCR, 2011 
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Appendix B: Solutions  
 
1 Kb+ DNA marker 
11μl ladder 
10μl Ficoll loading dye 
73μl 1x TE 
 
3% Agarose Gel 
12g Agarose powder 
400ml 1 x TBE  
12μl EtBr (10mg/ml)  
 
TE Buffer (10mM Tris-HCl, pH 7.4; 1mM EDTA) 
0.5ml 2M Tris-HCl (pH7.4)  
20μl EDTA (pH 8.0)  
99.48ml dH20 
Autoclaved and stored at room temperature 
 
2M Tris-HCl pH 7.4 
242.2g Tris base  
700ml dH20 
pH adjusted by adding concentrated HCl 
Final volume made to 1l using dH20 
 
0.5 Ethylenediamine Tetre-acetic Acid (EDTA) 
93.05g Na2.EDTA.2H2O 
300ml dH2O 
pH adjusted to 8.0 with 10M NaOH 
Final volume made to 500ml with dH2O 
 
Deoxyribonucleotide triphosphate (dNTP) 10x stock solution (1.25mM) 
125µl of 10mM dNTP (dATP, dGTP, dTTP and dCTP) 
500 µl of ddH2O to make up to 1ml 
Ten aliquots of 100µl made and stored at -20°C 
Concentration in PCR reaction mix is 0.125mM 
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Ethidium Bromide (EtBr) (10mg/ml) 
Available from Sigma-Aldrich as an aqueous solution (10mg/ml) 
Caution: EtBr is a powerful mutagen. Always wear gloves when handling gels or solutions that 
contain EtBr 
 
Ficoll-bromophenol blue loading dye (100ml)  
50g of 50% sucrose crystals  
0.1ml 0.5M EDTA (pH 7.0)  
0.1g 0.1% bromophenol blue dye  
10g 10% Ficoll powder  
Make up to 100ml with ddH2O before aliquot are made into Eppendorf tubes 
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Appendix C: Consent Forms 
 
The National Health Laboratory Service 
 
University of the Witwatersrand, School Of Pathology 
Division Human Genetics 
 
Hospital Street, Johannesburg 2001                                                      PO Box 1038, Johannesburg 2000 
Telephone: +27-11-489-9224/9223/9211                               Telefax: +27-11-489-9226 or +27-11-489-9209 
Prof A Christianson 489-9211/9239        Prof A Krause 489-9219             Prof M Ramsay 489-9214 
Prof H Soodyall  489-9208                       Dr T Lane 489-9221       
 
 
Information Sheet 
 
Study Title 
 
Investigating the Molecular Etiology of Hereditary Non-Polyposis Colorectal Cancer in South Africa 
 
Investigator: Kenneth Davison: MSc. (Med) Research Student 
 
Good day, I am Kenneth Davison and I am part of the Division of Human Genetics, National Health 
Laboratory Service and University of the Witwatersrand and we are conducting research on a type of 
inherited colon cancer called hereditary nonpolyposis colorectal cancer (HNPCC). The study aims to 
look for changes, known as mutations, in the genes of individuals who are affected by HNPCC. This 
will contribute towards the development of a test to diagnose HNPCC in South Africans, which could 
lead to improvements in the treatment and management of people who have, or are at risk of 
having, HNPCC. 
 
Colorectal cancer (CRC) is one of the most common types of cancer worldwide with HNPCC 
accounting for about 5% of all colorectal cancers. Most cases of CRC are sporadic. This means that 
CRC occurs when many mutations, which happen by chance, build up in the cells of the colon. 
However, in about 5% of CRC, a mutation is passed from a parent to their child and is present at 
birth. When one inherits a mutation from their parents, they have an increased risk of developing 
CRC and will probably develop CRC at a younger age. Generally, sporadic CRC is found in individuals 
over the age of 60. When CRC is diagnosed under the age of 50 it is often the result of an inherited 
mutation.    
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The National Health Laboratory Service 
 
University of the Witwatersrand, School Of Pathology 
Division Human Genetics 
 
Hospital Street, Johannesburg 2001                                                      PO Box 1038, Johannesburg 2000 
Telephone: +27-11-489-9224/9223/9211                               Telefax: +27-11-489-9226 or +27-11-489-9209 
Prof A Christianson 489-9211/9239        Prof A Krause 489-9219             Prof M Ramsay 489-9214 
Prof H Soodyall  489-9208                       Dr T Lane 489-9221       
 
It has been shown that there are four major genes involved in HNPCC and when any of these genes 
have a mutation; one has an increased risk of getting CRC. The four major genes are known as MLH1, 
MSH2, MSH6 and PMS2 and these genes are involved in repairing DNA when mutations occur. Their 
job is to repair mutations but when a mutation happens in them, then they are unable to repair the 
DNA properly and this could lead to CRC. HNPCC is a cancer that is found in families, meaning that 
someone in your family either already has the same cancer, or is at a high risk of getting the same 
cancer as yours. It is also possible that you or your family members could be at risk of getting other 
related cancers.  
 
We would like to invite you to participate in this study by allowing us to take about two teaspoons 
(5-10ml) of blood from you. Taking blood is not harmful to you but it does involve slight discomfort 
when the needle goes through the skin. We will extract DNA from the white blood cells and screen 
the four genes for possible disease causing mutations.  
 
If an inherited mutation is identified, it may have important consequences for your other family 
members. If a mutation is found in these genes, it means that other members of your family may be 
at risk of developing CRC. They can take the test which will be developed to see if they also have the 
mutation and if they are at risk. If they are also affected, they will be advised to have regular 
screening of the colon so that the cancer can be caught early. If the cancer is found early, it is easier 
to treat and manage and affected people are much more likely to survive.  
 
 
 
 
 
87 
 
 
The National Health Laboratory Service 
 
University of the Witwatersrand, School Of Pathology 
Division Human Genetics 
 
Hospital Street, Johannesburg 2001                                                      PO Box 1038, Johannesburg 2000 
Telephone: +27-11-489-9224/9223/9211                               Telefax: +27-11-489-9226 or +27-11-489-9209 
Prof A Christianson 489-9211/9239        Prof A Krause 489-9219             Prof M Ramsay 489-9214 
Prof H Soodyall  489-9208                       Dr T Lane 489-9221       
 
There will be no cost to you for the collection of your blood and all your personal information will be 
kept confidential. We would also like to compare your family history to your genetic condition. We 
would also like to keep your DNA for future research related to HNPCC but you have the right to 
choose whether your DNA can be used for future studies or not.  
 
This study might not help you directly. It will not make you better. Your treatment will continue just 
as before. You also have the right to withdraw from the study at any time and your withdrawal will 
not affect present or future treatments. This project will help us to understand more about HNPCC 
which may help your family and other families in the future 
 
If you have any questions about the study, you can contact me or my colleagues at: 
Prof. Amanda Krause: 011 489 9219 
Dr. Robyn Kerr: 011 489 9344 Cell: 083 601 6303 
Mr. Kenneth Davison: 011 489 9225 Cell: 082 579 4056 
Ms. Anisa Keshav (Ethics): 011 717 1234 
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University of the Witwatersrand, School Of Pathology 
Division Human Genetics 
 
Hospital Street, Johannesburg 2001                                                      PO Box 1038, Johannesburg 2000 
Telephone: +27-11-489-9224/9223/9211                               Telefax: +27-11-489-9226 or +27-11-489-9209 
Prof A Christianson 489-9211/9239        Prof A Krause 489-9219             Prof M Ramsay 489-9214 
Prof H Soodyall  489-9208                       Dr T Lane 489-9221       
Consent Form 
 
Investigating the Molecular Etiology of Hereditary Non-Polyposis Colon Cancer in South Africa 
 
Surname: …………………………………. 
 
Personal Name: ………………………………….. 
 
Date of Birth: …………………………….. 
 
1. The research has been explained to me and I understand that the test involves taking a 
sample of blood from myself  
2. The information collected about me will be kept confidential 
3. I understand why the study is being done and that it may have direct benefits for me / my 
child and my extended family. However, there may also be no direct benefits. The study will 
help researchers understand HNPCC so that they can develop treatments and ways to 
prevent HNPCC 
4. I have had sufficient opportunity to ask questions about the research and I have decided to 
participate in the study without coercion 
5. I understand that I do not have to take part in this study. If I choose not to participate it will 
not affect the way I am treated at the hospital / clinic. Similarly, if I choose to withdraw 
from the study at any time, it will not affect any future treatment I will require 
 
My decision for the sample after the study is completed: (Please mark block with an x) 
 I give permission for the researcher to view my clinical notes 
 I give permission for the researcher to receive copies of my histology reports and scans 
 I would like to be notified of positive results 
 If possible, my samples(s) should be stored for future analysis in my interest, only on my 
request 
 My samples(s) can also be used for medical research 
 With my name 
 Without my name (anonymous). This means that I can’t be informed about eventual 
results 
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The National Health Laboratory Service 
 
University of the Witwatersrand, School Of Pathology 
Division Human Genetics 
 
Hospital Street, Johannesburg 2001                                                      PO Box 1038, Johannesburg 2000 
Telephone: +27-11-489-9224/9223/9211                               Telefax: +27-11-489-9226 or +27-11-489-9209 
Prof A Christianson 489-9211/9239        Prof A Krause 489-9219             Prof M Ramsay 489-9214 
Prof H Soodyall  489-9208                       Dr T Lane 489-9221       
 
 
 My samples must be discarded after this study is completed 
 
Signed on           day of                    20         at                     
 
Patient     Name:                                                   Signature:                                                        
 
Witness   Name:                                                   Signature:                       
 
Researcher Name: Mr. K. Davison                   Signature:   
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Appendix D: Ethics Clearance Certificate 
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Appendix E: PCR Primers for MLH1 and MSH2 
 
Table E.1: PCR Primers for MLH1 and PCR Product Sizes. The universal tails on the primers are underlined. The 
sequencing primers are complementary to the universal tails. The PCR product sizes are given. 
MLH1 Single Exon Tailed Primers  
Exon Forward (5’-3’) Reverse (5’-3’) PCR 
Product 
Size 
1 GTAGCGCGACGGCCAGTACTGAGGTGAT
TGGCTGA 
CAGGGCGCAGCGATGACGGCCCGTTAAG
TCGTAGCC 
270 
2 GTAGCGCGACGGCCAGTGTACATTAGAG
TAGTTGCAGAC 
CAGGGCGCAGCGATGACCCAGAACAGAG
AAAGGTCCTGA 
248 
3 GTAGCGCGACGGCCAGTAGAGATTTGGA
AAAATGAGTAAC 
CAGGGCGCAGCGATGACACAATGTCATC
ACAGGAGG 
242 
4 GTAGCGCGACGGCCAGTGTGACCCAGCA
GTGAGTT 
CAGGGCGCAGCGATGACCCTAGGCAAAA
AATACATTT 
228 
5 GTAGCGCGACGGCCAGTGATTTTCTCTTT
TCCCCTT 
CAGGGCGCAGCGATGACCCAATATTTATA
CAAACAAAGCT 
236 
6 GTAGCGCGACGGCCAGTCTTTTGCCAGGA
CATCTT 
CAGGGCGCAGCGATGACCTAGAACACAT
TACTTTGATGAC 
261 
7&8 GTAGCGCGACGGCCAGTAAAAGGGGGCT
CTGACATCT 
CAGGGCGCAGCGATGACATGTGATGGAA
TGATAAACC 
451 
9 GTAGCGCGACGGCCAGTTTCTTTTGTAAT
GTTTGAGTTTTGAG 
CAGGGCGCAGCGATGACCCTGTGAGTGG
ATTTCCCATG 
247 
10 GTAGCGCGACGGCCAGTACCCCTCAGGA
CAGTTTT 
CAGGGCGCAGCGATGACTCTGTTCCTTGT
GAGTCTTG 
220 
11 GTAGCGCGACGGCCAGTCCACATACACCA
TATGTGGGC 
CAGGGCGCAGCGATGACAAGGCCCCAGA
GAAGTAG 
303 
12 CTCCATTTGGGGACCTGTAT  
Needs an internal fwd sequencing 
primer: 
TTTAATACAGACTTTGCTACCAGGAC 
CAGGGCGCAGCGATGACTAAAGAGTAGC
TGTACTTTTCCCAA 
545 
13 GTAGCGCGACGGCCAGTCTGCACTTCCTT
TTCTTCAT 
CAGGGCGCAGCGATGACCCCTATGCATCC
CAGGCA 
228 
14 GTAGCGCGACGGCCAGTCTATTACTTACC
TGTTTTTTGG 
CAGGGCGCAGCGATGACGTAGCTCTGCTT
GTTCACAC 
220 
15 GTAGCGCGACGGCCAGTAACTGGTTGTAT
CTCAAGCATG 
CAGGGCGCAGCGATGACGTGGAGAGCTA
CTATTTTCAG 
227 
16 GTAGCGCGACGGCCAGTCAGGCTTCATTT
GGATGCTCCG 
CAGGGCGCAGCGATGACCAGAAGTATAA
GAATGGCTGTC 
284 
17 GTAGCGCGACGGCCAGTTGACAGCATTAT
TTCTTGTTC 
CAGGGCGCAGCGATGACCATGTACCGAA
ATGCTTAGTA 
210 
18 GTAGCGCGACGGCCAGTTCTGTGATCTCC
GTTTAGAATGA 
CAGGGCGCAGCGATGACGTGCCAGTGTG
CATCACC 
246 
19 GTAGCGCGACGGCCAGTACAGGGAGGCT
TATGACATC 
CAGGGCGCAGCGATGACCACATCCCACA
GTGCATAAA 
266 
 
92 
 
Table E.2: PCR primers for MSH2 and the PCR product sizes. The universal tails on the primers are underlined. 
The sequencing primers are complementary to the universal tails. The PCR product sizes are given. 
MSH2 Single Exon Tailed Primers 
Exon Forward Reverse PCR 
Size 
1 GTAGCGCGACGGCCAGTTAGCTAAAGTC
ACCAGCG 
CAGGGCGCAGCGATGACTCTGAGGCGGGA
AAGGAG 
535 
2 TTTTTCTTCCCAGTCTCG CAGGGCGCAGCGATGACTTTTCTACTCTTA
AAAAAATAAGTA 
329 
3 GTAGCGCGACGGCCAGTGTTCAAGAGTTT
GTTAAATT 
CAGGGCGCAGCGATGACGGAATCTCCTCTA
TCACTAG 
391 
4 GTAGCGCGACGGCCAGTTTCTTATTCCTTT
TCTCATAGTAG 
CAGGGCGCAGCGATGACGAGATAAATATG
ACAGAAATATCC 
344 
5 GTAGCGCGACGGCCAGTTGGATCCAGTG
GTATAGAAAT 
ACCATTCAACATTTTTAACC 265 
6 GTAGCGCGACGGCCAGTAGCTTGCCATTC
TTTCTATT 
CAGGGCGCAGCGATGACATAATCATGTGG
GTAACTGC 
267 
7 GTAGCGCGACGGCCAGTGCTTAGTTGATA
AATTTTAATTT 
CAGGGCGCAGCGATGACATTGTATGAGTT
GAAGGAAAA 
345 
8 GTAGCGCGACGGCCAGTTTTGTATTCTGT
AAAATGAGATC 
CAGGGCGCAGCGATGACAGTGGCCTTTGCT
TTTT 
247 
9 GTAGCGCGACGGCCAGTTTTCTGTCTTTA
CCCATTATT 
CAGGGCGCAGCGATGACCTGGCATCAATAT
TTTGTCT 
283 
10 GTAGCGCGACGGCCAGTAATGGTAGTAG
GTATTTATGGAA 
CAGGGCGCAGCGATGACCACATCATGTTAG
AGCATTTAGGG 
301 
11 GTAGCGCGACGGCCAGTTGTTTCACGTAG
TACACATTGCTT 
CAGGGCGCAGCGATGACCCAGGTGACATT
CAGAACAT 
246 
12 GTAGCGCGACGGCCAGTTTATTATTCAGT
ATTCCTGTGTAC 
CAGGGCGCAGCGATGACAAACGTTACCCCC
ACAAAG 
379 
13 GTAGCGCGACGGCCAGTGCTTTCTGATAT
AATTTGTT 
CAGGGCGCAGCGATGACCAGAGACATACA
TTTCTATCTTCA 
311 
14 GTAGCGCGACGGCCAGTTATGTGATGGG
AAATTTCATG 
CAGGGCGCAGCGATGACTCCCATTACCAAG
TTCTGA 
364 
15 GTAGCGCGACGGCCAGTGCTGTCTCTTCT
CATGCTG 
CAGGGCGCAGCGATGACAACCTTCATCTTA
GTGTCCTG 
332 
16 GTAGCGCGACGGCCAGTGTGTGATATGTT
TAGATGGAAA 
CAGGGCGCAGCGATGACTTACAGACAATA
GCTTATCAATAT 
356 
Underlines: Universal tails for primers 
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Table E.3: DNA Sequence of MLH1. The PCR primer binding sites are shown 
MLH1 Exon DNA Sequence 
1 1   tggctggatg ctaagctaca gctgaaggaa gaacgtgagc acgaggcact gaggtgattg 
61  gctgaaggca cttccgttga gcatctagac gtttccttgg ctcttctggc gccaaaATGT 
121 CGTTCGTGGC AGGGGTTATT CGGCGGCTGG ACGAGACAGT GGTGAACCGC ATCGCGGCGG 
181 GGGAAGTTAT CCAGCGGCCA GCTAATGCTA TCAAAGAGAT GATTGAGAAC TGgtacggag 
241 ggagtcgagc cgggctcact taagggctac gacttaacgg gccgcgtcac tcaatggcgc 
 
2 1   aaacacgtta atgaggcact attgtttgta tttggagttt gttatcattg cttggctcat 
61  attaaaatat gtacattaga gtagttgcag actgataaat tattttctgt ttgatttgcc 
121 agTTTAGATG CAAAATCCAC AAGTATTCAA GTGATTGTTA AAGAGGGAGG CCTGAAGTTG 
181 ATTCAGATCC AAGACAATGG CACCGGGATC AGGgtaagta aaacctcaaa gtagcaggat 
241 gtttgtgcgc ttcatggaag agtcaggacc tttctctgtt ctggaaacta ggcttttgca 
 
3 1   tttcctggat taatcaagaa atggaattca aagagatttg gaaaaatgagt aacatgatt 
61  atttactcat ctttttggta tctaacagAA AGAAGATCTG GATATTGTAT GTGAAAGGTT 
121 CACTACTAGT AAACTGCAGT CCTTTGAGGA TTTAGCCAGT ATTTCTACCT ATGGCTTTCG 
181 AGGTGAGgta agctaaagat tcaagaaatg tgtaaaatat cctcctgtga tgacattgtc 
 
4 1   tggaagcagc agncagataa cctttccctt tggtgaggtg acagtgggtg acccagcagt 
61  gagtttttct ttcagtctat tttcttttct tccttagGCT TTGGCCAGCA TAAGCCATGT 
121 GGCTCATGTT ACTATTACAA CGAAAACAGC TGATGGAAAG TGTGCATACA Ggtatagtgc 
181 tgacttcttt tactcatata tattcattct gaaatgtatt ttttgcctag gtctcagagt 
 
5 1   aaacaggaaa atgataaata attaagataa tatataatat ggctatattt taatctattg 
61  ttgatatgat tttctctttt ccccttggga ttagtatcta tctctctact ggatattaat 
121 ttgttatatt ttctcattag AGCAAGTTAC TCAGATGGAA AACTGAAAGC CCCTCCTAAA 
181 CCATGTGCTG GCAATCAAGG GACCCAGATC ACGgtaagaa tggtacatgg gagagtaaat 
241 tgttgaagct ttgtttgtat aaatattgga ataaaaaata aaattgcttc taagttttca  
 
6 1   agtcagtgct tagaactgtg ctgttggtaa atataattgg attcactatc ttaagacctc 
61  gcttttgcca ggacatcttg ggttttattt tcaagtactt ctatgaattt acaagaaaaa 
121 tcaatcttct gttcagGTGG AGGACCTTTT TTACAACATA GCCACGAGGA GAAAAGCTTT 
181 AAAAAATCCA AGTGAAGAAT ATGGGAAAAT TTTGGAAGTT GTTGGCAGgt acagtccaaa 
241 atctgggagt gggtctctga gatttgtcat caaagtaatg tgttctagtg ctcatacat 
 
7 1   gagatatttt tctttatatg tacctttgtt tagattactc aactccacta atttatttaa 
61  ctaaaagggg gctctgacat ctagtgtgtg tttttggcaa ctcttttctt actcttttgt 
121 ttttcttttc cagGTATTCA GTACACAATG CAGGCATTAG TTTCTCAGTT AAAAAAgtaa 
181 gttcttggtt tatgggggat ggttttgttt tatgaaaaga aaaaagggga tttttaatag 
241 tttgctggtg gagataaggt tatg 
  
8 1   atgtttcagt ctcagccatg agacaataaa tccttgtgtc ttctgctgtt tgtttatcag 
61  CAAGGAGAGA CAGTAGCTGA TGTTAGGACA CTACCCAATG CCTCAACCGT GGACAATATT 
121 CGCTCCATCT TTGGAAATGC TGTTAGTCGg tatgtcgata acctatataa aaaaatcttt 
181 tacatttatt atcttggttt atcattccat cacattattt tggaaccttt caagatatta 
 
9 1   ccttgtgttt ttaaattctg attcttttgt aatgtttgag ttttgagtat tttcaaaagc 
61  ttcagaatct cttttctaat agAGAACTGA TAGAAATTGG ATGTGAGGAT AAAACCCTAG 
121 CCTTCAAAAT GAATGGTTAC ATATCCAATG CAAACTACTC AGTGAAGAAG TGCATCTTCT 
181 TACTCTTCAT CAACCgtaag ttaaaaagaa ccacatggga aatccactca caggaaacac 
 
10 1   gcatatcact acagaaatgt ctttcctgag gtgatttcat gactttgtgt gaatgtacac 
61  ctgtgacctc acccctcagg acagttttga actggttgct ttctttttat tgtttagATC 
121 GTCTGGTAGA ATCAACTTCC TTGAGAAAAG CCATAGAAAC AGTGTATGCA GCCTATTTGC 
181 CCAAAAACAC ACACCCATTC CTGTACCTCA Ggtaatgtag caccaaactc ctcaaccaag 
241 actcacaagg aacagatgtt ctatcaggct ctcctctttg aaagagatga gcatgctaat  
 
11 1   gatcctgagg ttttgaccac tgtgtcatct ggcctcaaat cttctggcca ccacatacac 
61  catatgtggg ctttttctcc ccctcccact atctaaggta attgttctct cttattttcc 
121 tgacagTTTA GAAATCAGTC CCCAGAATGT GGATGTTAAT GTGCACCCCA CAAAGCATGA 
181 AGTTCACTTC CTGCACGAGG AGAGCATCCT GGAGCGGGTG CAGCAGCACA TCGAGAGCAA 
241 GCTCCTGGGC TCCAATTCCT CCAGGATGTA CTTCACCCAG gtcagggcgc ttctcatcca 
301 gctacttctc tggggccttt gaaatgtgcc cggccagacg tgagagccca gatttttgc 
 
12 1   gataattata cctcatacta gcttctttct tagtactgct ccatttgggg acctgtatat 
61  ctatacttct tattctgagt ctctccacta tatatatata tatatatata tatttttttt 
121 tttttttttt tttaatacag ACTTTGCTAC CAGGACTTGC TGGCCCCTCT GGGGAGATGG 
181 TTAAATCCAC AACAAGTCTG ACCTCGTCTT CTACTTCTGG AAGTAGTGAT AAGGTCTATG 
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241 CCCACCAGAT GGTTCGTACA GATTCCCGGG AACAGAAGCT TGATGCATTT CTGCAGCCTC 
301 TGAGCAAACC CCTGTCCAGT CAGCCCCAGG CCATTGTCAC AGAGGATAAG ACAGATATTT 
361 CTAGTGGCAG GGCTAGGCAG CAAGATGAGG AGATGCTTGA ACTCCCAGCC CCTGCTGAAG 
421 TGGCTGCCAA AAATCAGAGC TTGGAGGGGG ATACAACAAA GGGGACTTCA GAAATGTCAG 
481 AGAAGAGAGG ACCTACTTCC AGCAACCCCA Ggtatggcct tttgggaaaa gtacagccta 
541 cctcctttat tctgtaataa aactgccttc taactttggc ttttcatgaa tcacttgca 
 
13 1   aaatgcaacc cacaaaattt ggctaagttt aaaaacaaga ataataatga tctgcacttc 
61  cttttcttca ttgcagAAAG AGACATCGGG AAGATTCTGA TGTGGAAATG GTGGAAGATG 
121 ATTCCCGAAA GGAAATGACT GCAGCTTGTA CCCCCCGGAG AAGGATCATT AACCTCACTA 
181 GTGTTTTGAG TCTCCAGGAA GAAATTAATG AGCAGGGACA TGAGGgtacg taaacgctgt 
241 ggcctgcctg ggatgcatag ggcctcaact gccaaggttt tggaaatgga gaaagcagtc  
 
14 1   tgcctggtgc tttggtcaat gaagtggggt tggtaggatt ctattactta cctgtttttt 
61  ggttttattt tttgttttgc agTTCTCCGG GAGATGTTGC ATAACCACTC CTTCGTGGGC 
121 TGTGTGAATC CTCAGTGGGC CTTGGCACAG CATCAAACCA AGTTATACCT TCTCAACACC 
181 ACCAAGCTTA Ggtaaatcag ctgagtgtgt gaacaagcag agctactaca acaatggtcc 
 
15 1   aaccagattc cacagccagg cagaactatt tctgtctcat ccatgtttca gggattactt 
61  ctcccatttt gtcccaactg gttgtatctc aagcatgaat tcagcttttc cttaaagtca 
121 cttcattttt attttcagTG AAGAACTGTT CTACCAGATA CTCATTTATG ATTTTGCCAA 
181 TTTTGGTGTT CTCAGGTTAT CGgtaagttt agatcctttt cacttctgac atttcaactg 
241 atcgtttctg aaaatagtag ctctccacta ata 
 
16 1   catttatggt ttctcacctg ccattctgat agtggattct tgggaattca ggcttcattt 
61  ggatgctccg ttaaagcttg ctccttcatg ttcttgcttc ttcctagGAG CCAGCACCGC 
121 TCTTTGACCT TGCCATGCTT GCCTTAGATA GTCCAGAGAG TGGCTGGACA GAGGAAGATG 
181 GTCCCAAAGA AGGACTTGCT GAATACATTG TTGAGTTTCT GAAGAAGAAG GCTGAGATGC 
241 TTGCAGACTA TTTCTCTTTG GAAATTGATG AGgtgtgaca gccattctta tacttctgtt 
 
17 1   ggcagatagg agcacaaggc ctgggaaagc actggagaaa tgggatttgt ttaaactatg 
61  acagcattat ttcttgttcc cttgtccttt ttcctgcaag cagGAAGGGA ACCTGATTGG 
121 ATTACCCCTT CTGATTGACA ACTATGTGCC CCCTTTGGAG GGACTGCCTA TCTTCATTCT 
181 TCGACTAGCC ACTGAGgtca gtgatcaagc agatactaag catttcggta catgcatgtg 
 
18 1   attcattccc agcaatattc agcagtccca tttacagttt taacgcctaa agtatcacat 
61  ttcgtttttt agctttaagt agtctgtgat ctccgtttag aatgagaatg tttaaattcg 
121 tacctatttt gaggtattga atttctttgg accagGTGAA TTGGGACGAA GAAAAGGAAT 
181 GTTTTGAAAG CCTCAGTAAA GAATGCGCTA TGTTCTATTC CATCCGGAAG CAGTACATAT 
241 CTGAGGAGTC GACCCTCTCA GGCCAGCAGg tacagtggtg atgcacactg gcaccccagg 
 
19 1   aagccctaga taacaccaag tctttccaga cccagtgcac atcccatcag ccaggacacc 
61  agtgtatgtt gggatgcaaa cagggaggct tatgacatct aatgtgtttt ccagAGTGAA 
121 GTGCCTGGCT CCATTCCAAA CTCCTGGAAG TGGACTGTGG AACACATTGT CTATAAAGCC 
181 TTGCGCTCAC ACATTCTGCC TCCTAAACAT TTCACAGAAG ATGGAAATAT CCTGCAGCTT 
241 GCTAACCTGC CTGATCTATA CAAAGTCTTT GAGAGGTGTT AAatatggtt atttatgcac 
301 tgtgggatgt gttcttcttt ctctgtattc cgatacaaag tgttgtatca aagtgtgat 
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Table E.4: DNA Sequence of MSH2. The PCR primer binding sites are shown 
MSH2 Exon DNA Sequence 
1 1   cagcatgcgc agtagctaaa gtcaccagcg tgcgcgggaa gctgggccgc gtctgcttat 
61  gattggttgc cgcggcagac tcccacccac cgaaacgcag ccctggaagc tgattgggtg 
121 tggtcgccgt ggccggacgc cgctcggggg acgtgggagg ggaGGCGGGA AACAGCTTAG 
181 TGGGTGTGGG GTCGCGCATT TTCTTCAACC AGGAGGTGAG GAGGTTTCGA CATGGCGGTG 
241 CAGCCGAAGG AGACGCTGCA GTTGGAGAGC GCGGCCGAGG TCGGCTTCGT GCGCTTCTTT 
301 CAGGGCATGC CGGAGAAGCC GACCACCACA GTGCGCCTTT TCGACCGGGG CGACTTCTAT 
361 ACGGCGCACG GCGAGGACGC GCTGCTGGCC GCCCGGGAGG TGTTCAAGAC CCAGGGGGTG 
421 ATCAAGTACA TGGGGCCGGC AGgtgagggc cgggacggcg cgtgctgggg agggacccgg 
481 ggccttgtgg cgcggctcct ttcccgcctc agagagtggg cggtgagcag cctctccagt 
 
2 1   aagtccagta agctcttttt tcttcccagt ctcgggtatg tctttatcag cagcatgaag 
61  tccagctaat acagtgcttg aacatgtaat atctcaaatc tgtaatgtac tttttttttt 
121 tttaagGAGC AAAGAATCTG CAGAGTGTTG TGCTTAGTAA AATGAATTTT GAATCTTTTG 
181 TAAAAGATCT TCTTCTGGTT CGTCAGTATA GAGTTGAAGT TTATAAGAAT AGAGCTGGAA 
241 ATAAGGCATC CAAGGAGAAT GATTGGTATT TGGCATATAA GGtaattatc ttccttttta 
301 atttacttat ttttttaaga gtagaaaaat aaaaatgtga agaatttaat tgtgttttta 
 
3 1   attaataagg ttcatagagt ttggattttt cctttttgct tataaaattt taaagtatgt 
61  tcaagagttt gttaaatttt taaaatttta tttttactta ggCTTCTCCT GGCAATCTCT 
121 CTCAGTTTGA AGATATTCTC TTTGGTAACA ATGATATGTC AGCTTCCATT GGTGTTGTGG 
181 GTGTTAAAAT GTCCGCAGTT GATGGCCAGA GACAGGTTGG AGTTGGGTAT GTGGATTCCA 
241 TACAGAGGAA ACTAGGACTG TGTGAATTCC CTGATAATGA TCAGTTCTCC AATCTTGAGG 
301 CTCTCCTCAT CCAGATTGGA CCAAAGGAAT GTGTTTTACC CGGAGGAGAG ACTGCTGGAG 
361 ACATGGGGAA ACTGAGACAG gtaagcaaat tgagtctagt gatagaggag attccaggcc 
 
4 1   aaacatttaa tgtaggtgaa tctgttatca ctatagttat caatgttata attttcattt 
61  ttgcttttct tattcctttt ctcatagtag tttaaactat ttctttcaaa atagATAATT 
121 CAAAGAGGAG GAATTCTGAT CACAGAAAGA AAAAAAGCTG ACTTTTCCAC AAAAGACATT 
181 TATCAGGACC TCAACCGGTT GTTGAAAGGC AAAAAGGGAG AGCAGATGAA TAGTGCTGTA 
241 TTGCCAGAAA TGGAGAATCA Ggtacatgga ttataaatgt gaattacaat atatataatg 
301 taaatatgta atatataata aataatatgt aaactatagt gactttttag aaggatattt 
361 ctgtcatatt tatctcaaaa acctgtgtat caatgatat 
 
5                                                                tggatc 
1   ccagtggtat agaaatcttc gatttttaaa ttcttaattt tagGTTGCAG TTTCATCACT 
61  GTCTGCGGTA ATCAAGTTTT TAGAACTCTT ATCAGATGAT TCCAACTTTG GACAGTTTGA 
121 ACTGACTACT TTTGACTTCA GCCAGTATAT GAAATTGGAT ATTGCAGCAG TCAGAGCCCT 
181 TAACCTTTTT CAGgtaaaaa aaaaaaaaaa aaaaaaaaaa agggttaaaa atgttgaatg 
241 gttaaaaaat gttttcattg acatatactg aagaagctta taaaggagct aaaatatttt 
 
6 1   tcatggcgta gtaangtttt cactaatgag cttgccattc tttctatttt attttttgtt 
61  tactagGGTT CTGTTGAAGA TACCACTGGC TCTCAGTCTC TGGCTGCCTT GCTGAATAAG 
121 TGTAAAACCC CTCAAGGACA AAGACTTGTT AACCAGTGGA TTAAGCAGCC TCTCATGGAT 
181 AAGAACAGAA TAGAGGAGAG gtatgttatt agtttatact ttcgttagtt ttatgtaacc 
241 tgcagttacc cacatgatta taccacttat tgtaatatgc agttttggaa gtatatgtta 
 
7 1   ctgatttagt tgagacttac gtgcttagtt gataaatttt aattttatac taaaatattt 
61  tacattaatt caagttaatt tatttcagAT TGAATTTAGT GGAAGCTTTT GTAGAAGATG 
121 CAGAATTGAG GCAGACTTTA CAAGAAGATT TACTTCGTCG ATTCCCAGAT CTTAACCGAC 
181 TTGCCAAGAA GTTTCAAAGA CAAGCAGCAA ACTTACAAGA TTGTTACCGA CTCTATCAGG 
241 GTATAAATCA ACTACCTAAT GTTATACAGG CTCTGGAAAA ACATGAAGgt aacaagtgat 
301 tttgtttttt tgttttcctt caactcatac aatatatact tggcaatgtg ctgtcctcat 
 
8 1   aaaattttat gatttgtatt ctgtaaaatg agatcttttt atttgtttgt tttactactt 
61  tcttttagGA AAACACCAGA AATTATTGTT GGCAGTTTTT GTGACTCCTC TTACTGATCT 
121 TCGTTCTGAC TTCTCCAAGT TTCAGGAAAT GATAGAAACA ACTTTAGATA TGGATCAGgt 
181 atgcaatata ctttttaatt taagcagtag ttatttttaa aaagcaaagg ccactttaag 
 
9 1   cagtaaaatt taagtgggag gaaatatttg ctttataatt tctgtcttta cccattattt 
61  ataggatttt gtcactttgt tctgtttgca gGTGGAAAAC CATGAATTCC TTGTAAAACC 
121 TTCATTTGAT CCTAATCTCA GTGAATTAAG AGAAATAATG AATGACTTGG AAAAGAAGAT 
181 GCAGTCAACA TTAATAAGTG CAGCCAGAGA TCTTGgtaag aatgggtcat tggaggttgg 
241 aataattctt ttgtctatac actgtataga caaaatattg atgccagaat tattttataa 
 
10 1   tttttcacta tttaaataat tttagaatta cattgaaaaa tggtagtagg tatttatgga 
61  atactttttc ttttcttctt gtttatcaag GCTTGGACCC TGGCAAACAG ATTAAACTGG 
121 ATTCCAGTGC ACAGTTTGGA TATTACTTTC GTGTAACCTG TAAGGAAGAA AAAGTCCTTC 
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181 GTAACAATAA AAACTTTAGT ACTGTAGATA TCCAGAAGAA TGGTGTTAAA TTTACCAACA 
241 Ggtttgcaag tcattattat atttttaacc ctttattaat tccctaaatg ctctaacatg 
301 atgtgaatgt tctatgataa gttttactaa tgtagtcatc aggtaagagt caagctttct 
 
11 1   ttccatttta attatcatta tttggatgtt tcataggata ctttggatat gtttcacgta 
61  gtacacattg cttctagtac acattttaat atttttaata aaactgttat ttcgatttgc 
121 agCAAATTGA CTTCTTTAAA TGAAGAGTAT ACCAAAAATA AAACAGAATA TGAAGAAGCC 
181 CAGGATGCCA TTGTTAAAGA AATTGTCAAT ATTTCTTCAG gtaaacttaa tagaactaat 
241 aatgttctga atgtcacctg gcttttggta acagaagaaa aatcatgata tttgaagtgt 
 
12 1   tttaaaaaag tgtaaattag gaaatgggtt ttgaattccc aaatgggggg attaaatgta 
61  tttttacggc ttatatctgt ttattattca gtattcctgt gtacattttc tgtttttatt 
121 TTTATACAGG CTATGTAGAA CCAATGCAGA CACTCAATGA TGTGTTAGCT CAGCTAGATG 
181 CTGTTGTCAG CTTTGCTCAC GTGTCAAATG GAGCACCTGT TCCATATGTA CGACCAGCCA 
241 TTTTGGAGAA AGGACAAGGA AGAATTATAT TAAAAGCATC CAGGCATGCT TGTGTTGAAG 
301 TTCAAGATGA AATTGCATTT ATTCCTAATG ACGTATACTT TGAAAAAGAT AAACAGATGT 
361 TCCACATCAT TACTGgtaaa aaacctggtt tttgggcttt gtgggggtaa cgttttgttt 
 
13 1   tcagtgtaca gtttaggact aacaatccat ttattagtag cagaaagaag tttaaaatct 
61  tgctttctga tataatttgt tttgtagGCC CCAATATGGG AGGTAAATCA ACATATATTC 
121 GACAAACTGG GGTGATAGTA CTCATGGCCC AAATTGGGTG TTTTGTGCCA TGTGAGTCAG 
181 CAGAAGTGTC CATTGTGGAC TGCATCTTAG CCCGAGTAGG GGCTGGTGAC AGTCAATTGA 
241 AAGGAGTCTC CACGTTCATG GCTGAAATGT TGGAAACTGC TTCTATCCTC AGgtaagtgc 
301 atctcctagt cccttgaaga tagaaatgta tgtctctgtc ctgtgagaag gaaaagtata 
 
14 1   taagatgatc cattatgttt gtggcatatc cttcccaatg tattgtcata attttgtttt 
61  tgtatgtgta tgttaccaca ttttatgtga tgggaaattt catgtaatta tgtgcttcag 
121 GTCTGCAACC AAAGATTCAT TAATAATCAT AGATGAATTG GGAAGAGGAA CTTCTACCTA 
181 CGATGGATTT GGGTTAGCAT GGGCTATATC AGAATACATT GCAACAAAGA TTGGTGCTTT 
241 TTGCATGTTT GCAACCCATT TTCATGAACT TACTGCCTTG GCCAATCAGA TACCAACTGT 
301 TAATAATCTA CATGTCACAG CACTCACCAC TGAAGAGACC TTAACTATGC TTTATCAGGT 
361 GAAGAAAGgt atgtactatt ggagtactct aaattcagaa cttggtaatg ggaaacttac 
 
15 1   cgaggtgaga ggataaatcc attacataaa ttgctgtctc ttctcatgct gtcccctcac 
61  gcttccccaa atttcttata gGTGTCTGTG ATCAAAGTTT TGGGATTCAT GTTGCAGAGC 
121 TTGCTAATTT CCCTAAGCAT GTAATAGAGT GTGCTAAACA GAAAGCCCTG GAACTTGAGG 
181 AGTTTCAGTA TATTGGAGAA TCGCAAGGAT ATGATATCAT GGAACCAGCA GCAAAGAAGT 
241 GCTATCTGGA AAGAGAGgtt tgtcagtttg ttttcatagt ttaacttagc ttctctatta 
301 ttacataaac aggacactaa gatgaaggtt ttttgtcgtc gtttgtttcc ctctgtgttt 
 
16 1   tgtgggagga gtttgagacc accctgggcn ccatagtgag accctcttct ctcaaaatat 
61  gaaaaataaa aaaaaaaatt tttaaatgtg tgatatgttt agatggaaat gnnacaattt 
121 gtcactctct cacatgactt ttagaaaaga tattttaatt actcatggga cattcacatg 
181 tgtttcagca aggtgaaaAA ATTATTCAGG AGTTCCTGTC CAAGGTGAAA CAAATGCCCT 
241 TTACTGAAAT GTCAGAAGAA AACATCACAA TAAAGTTAAA ACAGCTAAAA GCTGAAGTAA 
301 TAGCAAAGAA TAATAGCTTT GTAAATGAAA TCATTTCACG AATAAAAGTT ACTACGTGAa 
361 aaatcccagt aatggaatga aggtaatatt gataagctat tgtctgtaat agttttatat 
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Appendix F: Protocols Used 
 
F.1 MLPA Protocol 
1. Performed using the SALSA P003-B2 MLPA probe mix (MRC-Holland, Holland) 
2. Dilute DNA to 40ng/µl with TE Buffer  
3. Aliquot 5µl to a 0.5ml PCR tube and allow to re-suspend for 45 minutes 
4. Denature DNA at 98°C for 5 minutes 
5. Add the 3µl of the hybridisation mix to (Table F.1) each DNA sample 
 
Table F.1: Hybridisation Mix for MLPA Technique 
Reagent 1x Volume 
SALSA Probe mix 1.5µl 
MLPA Buffer 1.5µl 
Total 3µl  
 
6. Hybridise at 95°C for 1 minute, then 60°C for 18 hours and hold at 54°C 
7. Add Ligation mix (Table F.2) to the 8µl of the hybridised products 
 
Table F.2: Ligation mix for MLPA Technique 
Reagent 1x Volume 
Ligase-65 Buffer A 3µl 
Ligase-65 Buffer B 3µl 
ddH2O 25µl 
Ligase-65 1µl 
Hybridised Product 8 
Total 40µl 
 
8. Ligate at 54°C for 15 minutes, then denature the ligase at 98°C for 5 minutes 
9. Prepare the hot-start PCR reaction mix (Table F.3) 
Table F.3: Pre-PCR reaction mix for MLPA Technique 
Reagent 1x Volume 
MLPA Ligated Products 10µl 
SALSA PCR Buffer 4µl 
ddH2O 26µl 
Total 40µl 
  
10. Heat the pre-PCR reaction mix to 60°C in an Applied Biosystems 2720 Thermal cycler 
(Applied Biosystems, USA) 
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11. Add the polymerase mix (Table F.4) to the ligated products 
Table F.4: Polymerase Mix for MLPA Technique 
Reagent 1x Volume 
SALSA PCR Primers 2µl 
SALSA Enzyme Dilution 
Buffer 
2µl 
ddH2O 5.5µl 
SALSA Polymerase 0.5µl 
Total 10µl 
  
12. Start the PCR using the conditions given in Table F.5: 
 
Table F.5: PCR Conditions for MLPA Technique 
Temperature Time Cycles 
95°C 30 Seconds 
35 Cycles 60°C 30 Seconds 
72°C 1 minute 
72°C 20 minutes  
 
13. Load 1µl of PCR product with 0.5µl Liz-500 marker (Applied Biosystems, USA) and 8.5µl of Hi-
Di Formamide into a 96-well optical plate 
14. Load plate into 3130xl Genetic Analyser and follow Protocol for MLPA on the 3130xl Genetic 
Analyser 
 
F.2 Protocol for MLPA on the 3130xl Genetic Analyser 
Creating a Panel for the MLPA Run 
1. Open GeneMapper v4.0 Software (Applied Biosystems, USA) 
2. Create a new Panel for the P003 MLPA kits: 
a. Click ‘Panel Manager’→ ’File’→ ’New Kit’ 
b. Highlight the new panel in the window on the left 
c. Click ‘File’→ New Panel 
d. Highlight new panel  
e. Click ‘File’→ New Marker 
f. Give the marker a name, size and the dye colour it will be 
g. Then highlight the new marker 
h. Click ‘Bins’→ Add Bin 
i. Highlight bin area→ Give bin a name, location and size range 
j. Repeat until all markers have been named and sized 
3. Then need to ensure that the Panel uses correct analysis method: 
a. Tools→ GeneMapper Manager→ Analysis Methods 
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b. Open the ‘Allele’ tab 
c. Select ‘HNPCC’  as the Bin Set to use 
4. Can  Adjust the peak detection if peaks not called: 
a. Tools→ GeneMapper Manager→ Analysis Methods 
b. Open the ‘Peak Detector’ tab 
c. Select Advanced 
d. Lower the peak intensities value to detect lower peaks 
Preparing the Sample Sheet for the MLPA Run 
1. Open the Foundations Data Collection v3.0 software (Applied Biosystems, USA) 
2. To create a plate record: 
a. GA Instruments→ga3130xl→Plate Manager 
b. Click ‘New’ icon 
c. A new window will open to input information for the run: 
i. Name the plate so it can save results under that name 
ii. Can provide a description of that plate 
iii. Application is set to ‘GeneMapper-ABI-3130XL’ 
iv. Plate type is set to 96 well plate 
v. Owner name and operator are added 
vi. Click ‘OK’ 
3. The sample sheet will open 
4. Add the sample names to the corresponding wells 
5. Select following parameters into the sample sheet: 
a. Sample Type is set to Sample 
b. Priority remains at 100 
c. Size Standard is set to GS500(-250)LIZ 
d. Panel is set to ‘P003’ (Panel created for this particular MLPA kit) 
e. Analysis Method is set to ‘HNPCC P003 MLPA’ (Created for this MLPA kit) 
f. SNP Set, Study and User Defined columns left blank 
g. Results group is Molecular_Genetics 
h. Instrument Protocol is set to ‘MLPA_G5_Dye’ 
i. Save the sample sheet and close 
Preparing the MLPA Run 
1. Place the 96-well plate into the 3130xl Genetic Analyser 
1. Click on ‘Run Scheduler’ icon 
a. GA Instruments→ ga3130xl→3130xl→ Run Scheduler 
2. Update the list to include the newly created sample sheets by clicking ‘Find All’ 
3. Find the name of the sample sheet for the plate 
4. Highlight the name of your plate and then link it to the plate by clicking on the yellow 
onscreen plate that corresponds to your plate (Slot A or B) 
5. Can check you have linked the correct plate and runs by clicking ‘Run View’ 
a. GA Instruments→ ga3130xl→3130xl→ Run Scheduler→ Run View 
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6. To start the run, click the green ‘play’ arrow in the top task bar and confirm that you want to 
start by clicking ‘OK’ 
 
F.3 PCR Reaction and cycling conditions 
 
1. A master mix for the PCR reaction is prepared with all reagents given in Table F.6, except the 
DNA  
2. Appropriate volumes are aliquoted into an Eppendorf tube 
3. 19ul of the reaction mix are aliquoted into a well in strip tubes or a single PCR tube 
4. 1ul of DNA are aliquoted into each tube 
 
 
Table F.6: PCR reaction mix used for amplification of all exons for 1X reaction 
Reagent Volume 
(µl) 
Stock Final 
Buffer 2 10X 1X 
Forward 
Primer 
1 10µM 1µM 
Reverse 
Primer 
1 10µM 1µM 
MgCl2 2 10X 1X 
dNTP 2 10X 1X 
Taq 0.2 5U/µl 1U/µl 
DNA 1  50ng 
ddH2O 10.8   
Total 20   
AmpliTaq Gold polymerase buffer (Applied Biosystems, USA), 
AmpliTaq Gold DNA polymerase (Applied Biosystems, USA) 
MgCl2 (Applied Biosystems, USA 
dNTPs (Invitrogen, USA) 
 
5. The strip tubes /PCR tubes are transferred to an Applied Biosystems 2720 Thermal Cycler 
(Applied Biosystems, USA) 
6. The PCR conditions given in Table F.2 were used for every PCR reaction 
  
Table F.7: PCR conditions for amplification of all reactions 
Step Temperature Time  
Initial 
Denaturation 
95°C 3 minutes  
Denaturation 95°C 1 minute  
35 Cycles Annealing 55°C 1 minute 
Extension 72°C 1 minute 
Final Extension 72°C 5 minutes  
Hold 4°C ∞  
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F.4 Minelute 96 UF PCR Purification Kit Protocol 
The Minelute 96 UF PCR purification kit (Qiagen, Germany) was used to purify higher numbers of 
samples due to the high throughput capabilities of the kit. 
1. Place Minelute 96 UF PCR Purification plate on top of vacuum manifold 
2. Pipette entire PCR sample into the wells of the plate 
3. Apply a vacuum of approximately -800mbar until the wells are completely dry. Switch off 
vacuum source 
4. Add 50µl deionized water to each well, apply vacuum (-800mbar) until the wells are completely 
dry. Switch off vacuum source 
5. Carefully remove plate from the vacuum manifold 
6. Tap the plate on a stack of clean absorbent paper to remove any liquid that might remain on 
bottom of plate 
7. Add 20µl of elution buffer to each well 
8. Dissolve purified DNA by pipetting samples up and down approximately 20 times 
9. Recover purified PCR product by pipetting eluent out of each well and into a new 96 well plate 
or strip tubes 
 
F.5 Nucleospin Extract II Clean-up Protocol: 
The Nucleospin Extract II clean-up kit (Machery-Nagel, Germany) was used for individual samples 
and small batches  
1. Adjust PCR product volume to 50µl with TE buffer 
2. Mix 100µl of NT buffer with the 50µl of PCR product  
3. Place column in collection tube and load entire sample onto column 
4. Centrifuge for 1 minute at 14 000rpm. Discard flow-through and place column back into 
collection tube 
5. Add 600µl NT3 buffer and centrifuge for 1 minute at 14 000rpm. Discard flow-through and 
place column back into collection tube 
6. Centrifuge for 2 minutes at 14 000rpm to quantitatively remove residual NT3 buffer 
7. Incubate samples at 70°C for 5 minutes to evaporate residual ethanol 
8. Place column in clean Eppendorf tube  
9. Add 20µl NE elution buffer and incubate for 1 minute at room temperature 
10. Centrifuge at 14 000rpm for 1 minute, keep flow through and discard column 
 
F.6 Sanger Sequencing 
The Sanger sequencing protocol is given in Section 2. 
The reagents used in the Sanger sequencing protocol are given in Table F.8 and the thermal cycling 
conditions are given in Table F.9. 
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Table F.8: Sanger Sequencing PCR Reaction mix 
Reagent Stock Final Volume (µl) 
Cleaned PCR product   10µl 
BigDye v3.1   4µl 
BigDye Buffer 5x 0.5x 2µl 
Primer 3.3µmol/µl 3.3 µmol 1µl 
ddH2O   3µl 
Total   20µl 
 
 
Table F.9: Cycle Sequencing PCR Protocol 
Temperature Time  Cycles 
96°C 30 seconds 
25 Cycles 50°C 15 seconds 
60°C 4 minutes 
10°C ∞  
 
 
F.7 DyeEx 96 Dye-Terminator Removal Protocol 
The DyeEx 96 Dye-Terminator kit (Qiagen, Germany) was used to purify the Sanger sequencing 
products for large batches 
1. Take DyeEx 96 plate out of bag and remove the tape sheets from the top and bottom of the 
plate 
2. Place DyeEx 96 plate on top of collection plate and centrifuge for 3 minutes at 2 000rpm 
3. Carefully place the DyeEx 96 plate on an appropriate elution plate with a suitable adaptor 
4. Apply the sequencing samples in a volume of 20µl to the gel beds of each well. Ensure not to 
touch the sides of the wells and the gel surface with the pipette tip 
5. Centrifuge for 3 minutes at 2 000rpm 
6. Dry the samples in a concentrator 5301 (Eppendorf, Germany) and proceed according to 
instructions provided for DNA sequencer 
 
F.8 DyeEx 2.0 Dye-Terminator Removal Modified Protocol 
The DyeEx 2.0 Dye-Terminator kit (Qiagen, Germany) was used to purify Sanger sequencing products 
for individual and small batches 
1. Vortex spin column to re-suspend gel and remove bubbles. 
2. Loosen the column cap a quarter turn and snap off bottom closure of spin column. Place 
column into collection tube 
3. Centrifuge for 3 minutes at 3 000rpm. Discard flow-through 
4. Place spin column into clean Eppendorf tube 
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5. Load sequencing products onto gel bed. Take care not to pipette sample onto sides of column 
or touch the gel bed with pipette tip 
6. Centrifuge for 3 minutes at 3000rpm. Discard spin column 
7. Dry sample in a concentrator 5301 (Eppendorf, Germany) and proceed according to 
instructions provided for DNA sequencer  
 
F.9 Protocol for Sanger Sequencing using the 3130xl Genetic Analyser 
Preparing the Sample Sheet 
1. Open Foundation Data Collection v3.0 software 
2. To create a plate record: 
a. GA Instruments→ga3130xl→Plate Manager 
b. Click ‘New’ icon 
c. A new window will open to input information for the run: 
i. Name the plate so it can save results under that name 
ii. Can provide a description of that plate 
iii. Application is set to ‘Sequencing Analysis’ 
iv. Plate type is set to 96 well plate 
v. Owner name and operator are added 
d. Click ‘OK’ 
3. The sample sheet will open 
4. Add the sample names to the corresponding wells 
5. Select following parameters into the sample sheet: 
a. Priority set to 100 
b. Results group is Molecular_Genetics 
c. Instrument protocol is set to UltraSeq36_POP7_Z (This is used for samples smaller than 
500bp) 
d. Analysis protocol is set to 3130POP7_BDTv3-KB-Denovo_v5.2 
 
Starting the Sequencing Run 
7. Place the 96-well plate in the 3130xl Genetic Analyser 
8. Click on ‘Run Scheduler’ icon 
a. GA Instruments→ ga3130xl→3130xl→ Run Scheduler 
9. Update the list to include the newly created sample sheets by clicking ‘Find All’ 
10. Find the name of your plate 
11. Highlight the name of your plate and then link it to the plate by clicking on the yellow 
onscreen plate that is positioned where your plate is (Slot A or B) 
12. Can check you have linked the correct plate and runs by clicking ‘Run View’ 
13. To start the run, click the green arrow in the top task bar and confirm that you want to start 
by clicking ‘OK’ 
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F.10 Retrieval of Data 
Retrieval of Sanger Sequencing Data 
1. Open the Sequencing Analysis v5.2 software 
2. To add sample files to be analysed: 
a. File→ Add Samples 
b. Select folder containing sample files 
c. Click ‘Add Selected Samples’ 
3. The sample manager window will open with all the files selected for analysis 
4. Each BC box is already ticked for base calling. Click the green arrow in task bar to start base 
calling of the ticked samples 
5. To view the electropherogram for a sample: 
a. Tick the box in the ‘Show” column 
b. The electropherogram opens below the sample manager window 
6. Save the analysis: 
a. File→ Save Samples 
7. These saved results can be transferred to other storage media (such as a USB flash memory 
drive) and printed 
 
Retrieval of the MLPA Run 
1. Open the GeneMapper v4.0 Software 
2. A new project is already open 
3. To add sample files to be analysed: 
a. File→ Add Samples to Project 
b. Find the folder with the files 
c. Highlight the folder→ Click ‘Add to list’ 
d. The click ‘Add and Analyse once all files selected into list 
4. The ‘Save Project As’ window opens 
a. Name your project and click the ok button  
5. The sample manager window will open and automatically analyse the samples 
6. The Project will now be analysed automatically 
a. The “SQ” column should show a green square or a yellow triangle to pass analysis 
b. If a red circle is shown: 
i. Highlight the sample row and click ‘Size Match Editor’ (icon with three red 
peaks) 
ii. Adjust the sizes of the peaks as needed to fit the size standard 
iii. If changes made, highlight the sample with changed size standard 
1. Analysis→ Analyse Selected Samples 
7. Highlight sample and click ‘Display plots’ (Icon with different coloured peaks) 
8. Can choose which colour to view 
9. To zoom plots: 
a. Move cursor onto edge of the plots so that magnifying glass appears 
b. Click and drag over the area to zoom into 
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c. Double click to return to full view  
10. For peaks that were not sized: 
a. Click on peak to highlight  
b. Right click and select ‘Add allele call’ 
11. Once all peaks are called, can prepare sheet for export 
a. Return to Project Main screen 
b. Click ‘Genotypes’ Tab 
c. Columns with each peak and size should appear 
d. Click File→ Export 
i. Export the file as a comma delimited file (.csv) 
12. Download the ‘P003-B1 HNPCC’ Spread sheet from www.ngrl.org.uk 
13. Open the exported .csv file 
a. Highlight all the text→ Copy→ Paste into a blank excel spread sheet 
b. The spread sheet should show each sample number, the name of the marker and 
the peak size of that marker 
c. Copy those three columns and paste them into the corresponding marker columns 
in the P003-B1 HNPCC spread sheet 
14. Once all the markers and intensities have been pasted, the spread sheet can display the 
mathematical data as well as neat graphical data 
a. Click on the ‘Results’ tab to view graphical and mathematical data 
 
F.11 Using the LOVD InSiGHT Database 
1. Access www.insight-group.org on your internet browser 
2. Select ‘Mutations’ Tab 
3. Select the Gene database you wish to examine 
4. Takes you to the main page for that gene 
5. To view which variants have been reported: 
a. Click ‘Variants’ tab 
b. Can search for variants by exon number or using the variant nomenclature if you 
know the DNA, RNA or protein change 
c. If variant has been published, you can retrieve the publication 
i. In the ‘Variant Reference’ column 
ii. Click on hyperlinked name to go to PubMed where article abstract can be 
read 
6. To determine the nomenclature of variants found in Sanger sequencing analysis 
a. In main page, click on ‘coding DNA reference sequence’ 
b. Displays the coding DNA sequence as taken from particular transcripts 
c. The sequence provides numbering so that you can determine the position of 
variants 
d. Intron sequences can be seen by clicking on each exon number  
e. Intron sequence also provides numbering to determine the position of variant 
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F.12 High Resolution Melt Procedure 
1. DNA samples are diluted to 50ng/µl with TE buffer 
2. HRM master mix is made up for each variant 
Table F.10: HRM master mix that was used for all HRM reactions 
Reagent Concentration Volume (µl) 
SensiMix HRM 1X 12.5 
EvaGreen dye  1 
Primers 10µM 0.5 
DNA template 50ng/µl 1 
MgCl2  1 
ddH2O  9µl 
Total  25µl 
 
3. Master mix is aliquoted into PCR tubes 
4. Tubes are placed in the Illumina ECO (Illumina, USA) 
5. ECO software program is opened on the PC connected to the Illumina ECO 
6. HRM Analysis protocol is selected 
7. Each tube position is labelled and the control samples are selected as controls 
8. Conditions for the HRM are pre-set but the primer melting temperature must be adjusted 
(55°C for primers in this study).  
9. PCR and HRM are initiated when the ‘play’ button in the ECO software program is pressed. 
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Appendix G: Patient Pedigrees 
 
 
 
Figure G.1: The pedigree for black patient 205. This patient presented with colon cancer at 28 but has no 
known family history of the disease. This patient was found to have seven variants, two of which were not 
previously reported (MLH1 c.1732-19T>A and MSH2 c.-185C>A). The numbers indicate multiple females and 
deceased males 
 
Figure G.2: Pedigree for black patient 235. Family history is does not fulfil the Amsterdam II criteria but 
patient developed rectal neoplasm at age 21. This patient was found to have five variants, four of which are 
known to be non-pathogenic and the fifth is a novel variant (MSH2 c.1662-10C>T). The number ‘3’ indicates 
three females 
 
 
 
  
     
Age of Diagnosis: 28 
Colon Cancer 
3 4 
  
  
  3 
Age of 
diagnosis: 40 
Breast Cancer 
Current age 19 
Age of diagnosis 21 
Invasive rectal 
adenocarcinoma 
     
  
Age of diagnosis 49 
 Colon Cancer 
Age of death 60  
Unknown cause of death 
? Heart Attack 
? Stroke 
Cause of death 
not cancer  
Figure G.3: Pedigree for black African patient 238. Four variant 
were detected in this patient, two of which are novel variants 
not previously reported. 
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Figure G.5: The pedigree for patient 150 where the MSH2 c.1811C>A variant was found. This variant was first 
found by the Wessex Regional Genetics Laboratory who predicted the variant to be pathogenic. In addition, 
SIFT and PolyPhen also predicted this missense mutation to have a deleterious effect. The patient’s sister, who 
also developed colon cancer, was also investigated by the Wessex Regional Genetics Laboratory and found to 
have the same variant. This provides strong evidence that this variant is pathogenic  
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diagnosis 
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Figure G.4: Pedigree for patient 136. This white patient had a prominent family history of colon 
cancer and her mother had pancreatic cancer. The MLH1 c.731_734delGTTA pathogenic mutation was 
found in this patient, which leads frame shift and a truncated protein product. The other family 
members must be screened for the presence of the mutation. 
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Appendix H: Suppliers of Equipment and Reagents 
 
 
Table H.1: Table of Suppliers of Equipment and Reagents 
Equipment Supplier Country 
3130xl Genetic Analyser Applied Biosystems USA 
GeneAmp 2720 Thermal Cycler Applied Biosystems USA 
Foundation Data Collection v3.0 Applied Biosystems USA 
GeneMapper v4.0 Applied Biosystems USA 
Sequence Analysis v5.2 Applied Biosystems USA 
AmpliTaq Gold PCR Mix (Incl. buffer and MgCl2) Applied Biosystems USA 
BigDye Terminator v3.1 Sequencing Kit Applied Biosystems USA 
Hi-Di Formamide Applied Biosystems USA 
dNTP Mix Invitrogen USA 
1kb+ DNA Ladder Invitrogen USA 
DNAStar Seqman II Lasergene USA 
Restriction Enzymes (HpyCH4III, RsaI & Mlul) New England Biolabs USA 
Restriction Enzymes (TaqI) Thermo-Fisher Scientific USA 
Primers Whitehead Scientific RSA 
Primers Inqaba Biotec RSA 
SensiMix HRM Kit Bioline UK 
Agarose Gel Bioline UK 
Vacutec G:Box Syngene UK 
GeneSnap v6.08 Syngene UK 
Ethidium Bromide Sigma-Aldrich UK 
Minelute 96 UF Purification Kit Qiagen Germany 
DyeEx 96 Kit Qiagen Germany 
DyeEx 2.0 Kit Qiagen Germany 
Nucloespin Extract II Column Clean-up Kit Machery-Nagel Germany 
Concentrator 5301 Eppendorf Germany 
LightCycler 480 Roche Switzerland 
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